

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 January 2009 (22.01.2009)

PCT

(10) International Publication Number  
**WO 2009/012357 A2**

(51) International Patent Classification:

A61K 45/00 (2006.01) C12N 5/08 (2006.01)  
A61K 31/56 (2006.01)

(21) International Application Number:

PCT/US2008/070273

(22) International Filing Date: 17 July 2008 (17.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/959,866 17 July 2007 (17.07.2007) US

(71) Applicant (for all designated States except US): THE

GENERAL HOSPITAL CORPORATION [US/US]; 55  
Fruit Street, Boston, Massachusetts 02114 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DONAHOE, Patricia K. [US/US]; 8 Whittier Place, Apartment 16H, Boston, Massachusetts 02114 (US). SZOTEK, Paul P. [US/US]; 805 Gardenbrook Circle, Apartment B, Indianapolis, Indiana 46202 (US). MACLAUGHLIN, David T. [US/US]; 34 Wolf Hill Road, Gloucester, Massachusetts 01930 (US). PREFFER, Frederic [US/US]; 121 Reed Street, Cambridge, Massachusetts 02140 (US). PIERETTI-VANMARCKE, Rafael [VE/US]; 8 Whittier

Place, Apartment 7H, Boston, Massachusetts 02114 (US).  
**DOMBKOWSKI, David Michael** [US/US]; 7 Lamson  
Place, Apartment 3, Cambridge, Massachusetts 02139  
(US).

(74) Agent: RESNICK, David S.; Nixon Peabody, 100 Summer Street, Boston, Massachusetts 02110-2131 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS TO IDENTIFY AND ENRICH FOR POPULATIONS OF OVARIAN CANCER STEM CELLS AND SOMATIC OVARIAN STEM CELLS AND USES THEREOF




FIG. 7A




FIG. 7B

(57) Abstract: The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and/or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and/or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells.

WO 2009/012357 A2



**Published:**

- *without international search report and to be republished upon receipt of that report*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

METHODS TO IDENTIFY AND ENRICH FOR POPULATIONS OF OVARIAN CANCER  
STEM CELLS AND SOMATIC OVARIAN STEM CELLS AND USES THEREOF

CROSS REFERENCED APPLICATIONS

[001] This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application Serial No: 60/959,866 filed on July 17, 2007, the contents of which is incorporated herein by reference.

FIELD OF THE INVENTION

[002] The present invention relates generally to methods and compositions to treat cancer, and more particularly to treating and/or preventing ovarian cancer, in particular where the ovarian cancer comprises ovarian cancer stem cells. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells.

GOVERNMENT SUPPORT

[003] The present application was made with Government support under Grant Numbers CA17393 and HD32112 awarded by the National Institutes for Health (NIH). The Government of the United States has certain rights in the invention.

BACKGROUND

[004] Recently, two human primary cancers, leukemia and breast, and several human cancer cell lines, such as central nervous system, gastrointestinal tumors, and retinoblastoma, were shown to possess "side population" (SP) cells that have been described as cancer stem cells (1-5). Cancer stem cells, like somatic stem cells, are thought to be capable of unlimited self-renewal

and proliferation. Multipotent cancer stem cells may explain the histologic heterogeneity often found in tumors (6-9).

**[005]** In addition, cancer progression and metastasis may involve tumor stem cell escape from innate somatic niche regulators. Quiescent somatic stem cells residing in specific tissue niches until activation by injury or other stimuli have been described in skin and hair follicles, mammary glands, intestines, and other organs (10). The evolving evidence that somatic stem cells contribute to normal tissue repair and regeneration suggests the potential for multipotent somatic stem cells in the ovary responsible for regulated surface epithelial repair after ovulatory rupture and possibly the generation of oocyte nurse cells for folliculogenesis (11). Ovarian somatic stem cells would be expected to divide asymmetrically, yielding both a daughter cell that proceeds to terminal differentiation for epithelial repair and an undifferentiated self-copy. Repeated asymmetric self-renewal sets the stage for somatic stem cells or their immediate progenitors to accrue mutations over time, which might ultimately lead to their transformation into cancer stem cells and malignant progression.

**[006]** Epithelial ovarian cancer, thought to emanate from the surface epithelium of the ovary (12, 13), consists of various histologic subtypes of Mullerian origin (serous, mucinous, and endometrioid), affects >22,000 women in North America per year, and accounts for >16,000 deaths per year with a projected 5 year mortality rate exceeding 70% (14). Aggressive surgical cytoreduction followed by chemotherapy results in complete clinical response in 50–80% of patients with stage III and IV disease. However, the majority of patients will relapse and become drug-resistant (16).

**[007]** Various types of membrane-spanning ATP-binding cassette transporters, such as the multidrug-resistant gene 1 and breast cancer-resistance protein 1 (BCRP1), contribute to the drug resistance of many cancers, by pumping lipophilic drugs out of the cell (17). Within bone marrow, researchers have defined a subset of verapamil-sensitive BCRP1-expressing cells with

the ability to efflux the lipophilic dye Hoechst 33342. This subset has been described as the side population (SP) (18).

**[008]** Like somatic stem cells, cancer stem cells have the properties of self-renewal, heterologous descendent cells, slow cell-cycle times, and, unlike somatic stem cells, enriched tumor formation (8, 24).

**[009]** Ovarian cancer patients initially respond well to surgical cytoreduction and chemotherapy. Chemotherapy alone can yield several logs of tumor cytoreduction but seldom a cure. The majority of patients who respond to primary chemotherapy ultimately develop recurrent, usually drug-resistant, disease that is likely due to the ability of ovarian cancer stem cells to escape these drugs.

**[010]** The ovarian coelomic epithelium covers the ovary as a layer of simple squamous or cuboidal cells. In early embryonic development, the portion of the coelomic epithelium that covers the lateral tip of the urogenital ridge invaginates, while simultaneously undergoing an epithelial to mesenchymal transition (Zhan et al., 2006), giving rise to the mesenchyme of the Mullerian ducts (the anlagen of the oviduct, endometrium, and endocervix). This close embryonic relationship between ovarian coelomic epithelium and Mullerian structures is thought to explain the acquisition of Mullerian architecture and function during neoplastic progression.

**[011]** Folliculogenesis in the adult ovary is characterized by extensive architectural remodeling that culminates in disruption of the coelomic epithelium and extrusion of the ovum at ovulation (Bjersing and Cajander, 1974, 1975; Bukovsky et al., 2004). After disruption, a subsequent series of molecular events initiates and executes repair of the epithelial wound (Clow et al., 2002; Tan and Fleming, 2004) by either non-stem mediated epithelial cell self-duplication or by stem cell mediated asymmetric division. Asymmetric somatic stem cell division has been proposed as a mechanism by which mutations may be accumulated and

perpetuated to future generations (Reya et al., 2001) leading to neoplastic transformation.

Concomitantly, previous studies of the coelomic epithelium implicating cyclic re-epithelialization as the source of accrued mutations leading to ovarian cancer (Murdoch et al., 2001) raise the possibility that an asymmetrically dividing coelomic epithelial somatic stem cell can have the propensity for transformation into an ovarian cancer stem cell.

**[012]** Somatic stem cells are a subset of normal tissue cells that, through asymmetric division, have the ability to self renew and produce lineage committed daughter cells responsible for tissue regeneration and repair (Li and Xie, 2005). Such injury responsive somatic (non-hematopoietic) stem cells and their niches have been described in skin and hair follicle (Blanpain et al., 2004; Fuchs et al., 2004; Lowry et al., 2005; Tumber et al., 2004), mammary gland (Welm et al., 2003; Welm et al., 2002), intestine (Leedham et al., 2005; Li and Xie, 2005; Mills and Gordon, 2001; Spradling et al., 2001; Vidrich et al., 2003; Williams et al., 1992; Wong, 2004), and other tissues (Alvarez-Buylla and Lim, 2004; Berns, 2005; Imitola et al., 2004; Liu et al., 2004). In some tissues, slow cycling somatic stem cells were initially identified by their ability to retain labels for long periods of time, while asymmetrically derived lineage committed daughter cells dilute out the label during rapid proliferation and terminal differentiation (Albert et al., 2001; Braun and Watt, 2004; Kenney et al., 2001; Morris et al., 1986; Morris and Potten, 1994, 1999; Oliver et al., 2004; Tsujimura et al., 2002; Tumber et al., 2004; Watt and Hogan, 2000; Wu and Morris, 2005). These studies, as well as those leading to the recent identification of LRCs in the uterine endometrial stroma and myometrium (Szotek et al., 2007), used BrdU (or 3H-Thymidine) or histone H2Bj-GFP labeling to identify and isolate somatic stem cells which, in turn, permitted the discovery of tissue specific surface markers.

**[013]** Concurrently, Goodell et al. devised another method to isolate previously unidentified stem or progenitor cells by demonstrating that hematopoietic and mammary gland stem cells have the ability to efflux Hoechst 33342 dye through ATP-binding-cassette (ABC) transporters

such as *Abcg2/Bcrp1* (Goodell et al., 1996; Welm et al., 2002). These “side population” (SP) cells have since been correlated with somatic and cancer stem cells from various tissues (Al-Hajj et al., 2003; Behbod and Rosen, 2005; Bhatt et al., 2003; Haraguchi et al., 2005; Jonker et al., 2005; Kondo et al., 2003; Patrawala et al., 2005; Preffer et al., 2002; Smalley and Clarke, 2005; Smalley et al., 2005; Wulf et al., 2001), including our recent identification of SP cells in ovarian cancer populations (Szotek et al., 2006). Thus, label retention and Hoechst dye efflux are two distinct methods based on stem cell functional properties that can be used individually or potentially in combination to identify candidate somatic stem cells without known surface markers and to define a signature stem cell marker profile.

#### SUMMARY OF THE INVENTION

**[014]** In accordance with the present invention, the inventors have discovered a population of ovarian cancer cells that are ovarian cancer stem cells or tumor-initiating cells. The inventors have also discovered that the ovarian cancer stem cells are responsive to Mullerian Inhibiting Substance (MIS). The inventors have also discovered that ovarian cancer stem cells are also more resistant to inhibition by lipophilic chemotherapeutic agents, for example mitoxantrone, daunorubicin, doxorubicin, indolcabazole. The inventors have also discovered that the ovarian cancer stem cells have the ability to efflux lipophilic dyes, for example Hoechst 33342 and are herein termed Hoeschst<sup>LOW</sup> cells. The inventors have further discovered that the ovarian cancer stem cells are positive for the expression of breast cancer-resistance protein 1 (BCRP1).

**[015]** The inventors have also discovered the intrinsic repair capacity of the coelomic epithelium emanates from ovarian somatic stem cells such as coelomic somatic stem/progenitor cells. Using a variety of transgenic and cell based techniques, the inventors have discovered three somatic stem cell label-retaining populations in the ovary. The inventors have demonstrated that these somatic ovarian stem cells exist in defined perivascular microenvironments, and have characterized one somatic ovarian stem cell population, the coelomic epithelial label retaining

cells (LRCs) *in vitro*, and have discovered a functional response by coelomic epithelial LRCs to the estrous cycle *in vivo*.

**[016]** In further experiments, the inventors have validated the presence of ovarian cancer stem cells by comparing them to a normal somatic ovarian stem cell population, for example somatic ovarian stem cells in the coelomic epithelium that the inventors have also discovered. In some instances, the inventors have discovered a method to study and determine how a normal somatic ovarian stem cell population transforms to become stem cells of ovarian cancer pathology, such as ovarian cancer stem cells as disclosed herein. The inventors have discovered a method whereby the somatic ovarian stem cells can be compared with ovarian cancer stem cells. For example, such methods are useful to determine how, when, and where transformation and progression to the ovarian cancer phenotype occurs, as well as identifying agent that are selective for ovarian cancer stem cells as compared to ovarian somatic stem cells. Using traditional and transgenic pulse chase techniques in conjunction with immunohistochemistry, parabiosis and flow cytochemistry, the inventors demonstrate three somatic ovarian cell populations and define their perivascular niche microenvironment and characterize their surface marker profiles.

**[017]** Accordingly, in one embodiment the present invention is related to methods to identify and enrich for a population of somatic ovarian stem cells, for example methods to identify and enrich for populations of coelomic somatic ovarian stem cells, or populations of subcoelomic/stromal somatic ovarian stem cells, or populations of periphilar medullary somatic ovarian stem cells.

**[018]** Another embodiment of the present invention is related to methods to identify and enrich for a population of ovarian cancer stem cells.

[019] Another embodiment of the present invention is related to methods to screen for agents that inhibit the growth and/or kill ovarian cancer stem cells as compared to somatic ovarian stem cells.

[020] In another embodiment, the present invention relates to methods for the treatment of ovarian cancer by targeting ovarian cancer stem cells. In such embodiments, a method to prevent and/or treat a subject with ovarian cancer is provided, where the subject is identified to have ovarian cancer comprising ovarian cancer stem cells, and the subject is administered a pharmaceutical composition comprising MIS or a derivative, fragment, analogue or homologue thereof. In some embodiments, the subject is also administered additional cancer therapies, for example chemotherapies, radiotherapy, immune therapy and other agent. In some embodiments, the subject is also administered a BCRP1 inhibitor, for example verapamil.

[021] In such embodiments, a method to prevent and/or treat a subject with ovarian cancer is provided, where the subject is identified to have ovarian cancer comprising ovarian cancer stem cells, and the subject is administered a pharmaceutical composition comprising a BCRP1 inhibitor, for example verapamil. In some embodiments, the pharmaceutical composition comprising a BCRP1 inhibitor also comprises MIS or a derivative, fragment, analogue or homologue thereof.

[022] In another aspect of the invention, methods to treat ovarian cancers by targeting cancer stem cells are disclosed, the method comprising targeting the ovarian cancer stem cell with agents that are agonists to the MIS receptor type II (MISRII). Examples of agonists of MISRII are MIS protein and derivatives and variants thereof. Other agonists of MISRII are MIS mimetics, for example pyrazoloanthrone and derivatives thereof.

[023] In some embodiments, the methods of the present invention relate to the treatment of ovarian cancers by targeting ovarian cancer stem cells, the method comprising administering a pharmaceutical composition comprising MIS or derivatives or analogues thereof to the subject

with ovarian cancer stem cells. In some embodiments, the pharmaceutical composition administered to the subject comprises additional therapies, for example agents that function as BCRP1 inhibitors. Examples of BCRP1 inhibitors are well known by persons skilled in the art, and one exemplary BCRP1 is a small molecule, for example verapamil. In alternative embodiments, agent that function as BCRP1 inhibitors are nucleic acids, nucleic acid analogues, proteins, peptides, peptidomimetics, antibodies, ribozymes, aptamer etc.

**[024]** In one aspect of the invention, methods to prevent and/or treat a subject for ovarian cancers, wherein the method comprises the steps (i) of identifying the presence of ovarian cancer stem cells in a subject using the methods as disclosed herein, and wherein if the subject is identified to have ovarian cancer stem cells, the subject is administered a pharmaceutical composition comprising MIS or a derivative, homologue, analogue or fragment thereof and/or a pharmaceutical composition comprising an inhibitor of BCRP1.

**[025]** As a non-limiting example, pharmaceutical compositions comprising at least one agent that activates MISRII and/or inhibits the expression or activity of BCRP1 is administered to an ovarian cancer stem cell in an effective amount for the treatment of ovarian cancer, wherein the ovarian cancer comprises ovarian cancer stem cells.

**[026]** In another embodiment, methods for diagnosing a subject at risk of having a recurrent ovarian cancer are disclosed. In some embodiments, the methods comprise assessing the presence of ovarian cancer stem cells in a subject as disclosed herein, for example assessing ovarian cancer cells obtained from a biological sample of a subject for (i) presence of BCRP1 expression and/or (ii) ability to efflux lipophilic dyes (or uptake lipophilic dyes), wherein ovarian cancer cells positive for BCRP1 expression and/or do not retain a lipophilic dye, the subject is identified as being at risk of a recurrent ovarian cancer. In some embodiments, the biological sample is from a biopsy.

[027] In some embodiments, the present invention provides a method for identifying and isolating for ovarian cancer stem cells which comprises contacting a population of ovarian cells with agents reactive for BCRP1 and separating cells positive for the agent reactive for BCRP1 from cells non-reactive to agents for BCRP1, where the cells that are reactive for BCRP1 (i.e cells that express BCRP1) identify ovarian cancer stem cells and can be isolated.

[028] In some embodiments, agents that are reactive to BCRP1 are agents that are reactive to the nucleic acid encoding BCRP1 and/or agents reactive to the protein BCRP1. In some embodiments, the agent is a nucleic acid, nucleic acid analogue, protein or fragment thereof. In some embodiments, the agent is further labeled with a detectable marker, for example a fluorescent marker, or a label that can be used to isolate the agent that is associated, for example interacting with, BCRP1. Such a label is, for example but not limited to metallic beads and streptavidin. In some embodiments, the agent reactive to BCRP1 is a protein or polypeptide, for example but not limited to an antibody with binding affinity for BCRP1, or fragment thereof, for example an anti-BCRP1 antibody, and in some embodiments, a protein agent is a protein binding-partner to BCRP1 or a fragment thereof, for example a BCRP1 ligand or BCRP1 co-factor.

[029] In another aspect, the present invention provides methods for identifying and isolating ovarian cancer stem cells comprising contacting a population of ovarian cells with a lipophilic dye, for example but not limited to Hoeschts 33342, and separating cells that do not incorporate the lipophilic dye or cells that only incorporate a small amount of the dye, from the cells which do incorporate the lipophilic dye, where the cells that do not incorporate the lipophilic dye are identified as ovarian cancer stem cells and can be isolated. In some embodiments, one can identify and isolate ovarian cancer stem cells using both methods as disclosed herein, for example using agents reactive to BCRP1 and using lipophilic dyes, where ovarian cancer stem cells are cells which are positive for BCRP1 expression and do not take up the lipophilic dye.

[030] Method to separate the ovarian cancer cells reactive for agents to BCRP1 and/or lipophilic dyes are well known in the art and can include, for example separation methods such as, but are not limited to fluorescence cell sorting (FACS), flurometry, flow cytometry, microscopy techniques.

[031] In some embodiments, the ovarian cancer stem cells are identified in a population of ovarian cancer cells, for example a population of ovarian cancer cells present in a biological sample. Such biological samples may be a tissue sample, for example a tumor tissue sample or biopsy tissue sample, for example a biopsy of a cancer or tumor, for example ovarian cancer biopsy. In some embodiments, the tissue sample is obtained from a subject, for example a mammalian, for example but not limited to a human subject.

[032] In some embodiments, the population of ovarian cancer cell comprises ovarian cancer cells, ovarian cancer cells, vulvar epidermal carcinoma cells, cervical carcinoma cells, endometrial adenocarcinoma cells and ovarian adenocarcinoma cells. In alternative embodiments, the population of ovarian cells is a population of primary ascite cells, and in some embodiments, the population of ovarian cells is a population of ovarian cancer cell line cells, for example human or rodent ovarian cancer cell lines. Examples of human and mouse ovarian cancer cells are well known by person skilled in the art, for example, human ovarian cancer cells can include but are not limited to IGROV-1, SK-OV3, OVCAR-3 human cancer cell lines. Examples of mouse ovarian cancer cell lines include, for example but are not limited to MOVCAR7 or 4306 ovarian cancer cell lines.

[033] In some embodiments, ovarian cancer stem cells as disclosed herein are further characterized. Such further characterization includes assessment of multi-drug resistance sensitivity, for example ovarian cancer stem cells that are identified as having multi-drug resistance are identified as being ovarian cancer stem cells. In some embodiments, sensitivity to multi-drug resistance can be determined by assessing sensitivity to an agent which inhibits

BCRP1 (herein termed a BCRP1 inhibitor), wherein ovarian cancer cells as disclosed herein that are sensitive to agents BCRP1 inhibitors are identified as ovarian cancer stem cells. In some embodiments, an agent that inhibits BCRP1 is nucleic acid, nucleic acid analogue, small molecule, protein, aptamer, or fragments or variants thereof. In some embodiments, a BCRP1 inhibitor is verapamil or analogues thereof.

**[034]** Another aspect of the present invention relates to method to identify a population of ovarian cancer stem cells in a biological sample, comprising measuring the biological sample for at least one of: (i) BCRP1 expression, or (ii) ability to efflux a lipophilic dye (iii) multi-drug resistance sensitivity, wherein the biological sample comprises ovarian cells and wherein positiveity for at least one of (i), (ii) or (iii) in the biological sample identifies a population of ovarian cancer stem cells.

**[035]** Another aspect of the present invention relates to methods to treating ovarian cancer in a subject by targeting ovarian cancer stem cells. In such an embodiment, method for treating a subject with ovarian cancer are provided, comprising administering to the subject an effective amount of MIS or a homologue or variant or derivative thereof, wherein the subject is identified to have an ovarian cancer comprising ovarian cancer stem cells. In some embodiments, the subject has recurrent ovarian cancer.

**[036]** In some embodiments, the MIS is a functional derivative, analogue or variant thereof. For example, a functional derivative of MIS is a pyrazoloanthrone or derivative or analogue thereof. In alternative embodiments, the MIS is recombinant human MIS. In some embodiments, the effective amount of MIS is an effective amount of a pharmaceutical composition comprising MIS or a variant or derivative thereof. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In additional embodiments, the pharmaceutical composition optionally further comprises a chemotherapeutic agent or an inhibitor of BCRP1.

- [037] In further embodiments, MIS can further comprise a targeting moiety, for example a targeting moiety where the targeting moiety targets BCRP1. As a non-limiting example, such a targeting moiety useful in the methods of the present invention is a binding partner to BCRP1, for example a protein ligand to BCRP1 and/or a co-factor of BCRP1.
- [038] In some embodiments, the administration of MIS is administered more than once, and in further embodiments, the MIS or derivative thereof is administered before, after or at the same time as the additional therapy.
- [039] In some embodiments, the subject is further administered one or more additional therapies, for example but not limited to chemotherapy, radiotherapy, thermotherapy, immunotherapy, hormone therapy, laser therapy and surgery. In some embodiments, the chemotherapy is an agent that inhibits BCRP1. In some embodiments, the agents that inhibit BCRP1 are, for example but not limited to nucleic acids, nucleic acid analogues, small molecule, proteins, aptamer or fragments or derivatives thereof. In some embodiments, a BCRP1 inhibitor is verapamil or a functional derivative, analogue or variant thereof. In alternative embodiments, the chemotherapy is selected from chemotherapeutic agents, for example but not limited to paclitaxel, cisplatin, doxorubicin or analogues thereof.
- [040] In some embodiments, the pharmaceutical composition comprising MIS, and optionally comprising additional agents is administered to the subject via intravenous, intradermal, intramuscular, intraarterial, intralesional, percutaneous, subcutaneous, intratumoral, or by aerosol routes. In some embodiments, the subject is administered prophylactic administration and/or therapeutic administration.
- [041] In some embodiments, the subject to be treated is a mammal, for example a human. In some instances, the subject undergone one or more cancer therapies, for example but not limited to cancer therapies such as surgery, chemotherapy, radiotherapy, thermotherapy, immunotherapy, hormone therapy and laser therapy.

- [042] In another aspect of the present invention, methods to determine if a subject is at risk of having a recurrent ovarian cancer are provided, comprising assessing the presence of ovarian cancer stem cells in a biological sample from the subject, where if the biological sample comprises ovarian cancer stem cells, the subject is identified as being at risk of having a metastasis or recurrent ovarian cancer.
- [043] In another aspect of the present invention, methods to identify agents that reduce the self-renewal capacity of an ovarian cancer stem cell are provided, comprising contacting an ovarian cancer stem cell with an agent, and measuring the proliferation of the ovarian cancer cell, whereby an agent that decreases the proliferation as compared to a reference agent or absence of an agent identifies an agent that inhibits the self-renewal capacity of the ovarian cancer stem cell. In such embodiments, the agent is any agent, for example but not limited to nucleic acids, nucleic acid analogues, small molecule, proteins, aptamers, ribosomes etc. Proliferation assays useful in the methods are commonly known by persons of ordinary skill in the art, for example but not limited to the methyiazoletetrazolium (MTT) proliferation assay.
- [044] In another aspect of the present invention, methods of treating a subject affected with cancer are also provided, the method comprising assessing the presence of ovarian cancer stem cells in a biological sample obtained from the subject, wherein a clinician reviews the results and if the results indicate the presence of ovarian cancer stem cells in the biological sample, the clinician directs the subject to be treated with an effective amount of a pharmaceutical composition comprising MIS or a homologue or variant or derivative thereof, and/or an BCRP1 inhibitor.
- [045] Another aspect of the present invention relates to methods to determine if a subject is at risk of having a recurrent ovarian cancer, the method comprising assessing the presence of ovarian cancer stem cells by the methods as disclosed herein, and if the biological sample is identified to comprise ovarian cancer stem cells, the subject is at risk of having a metastasis or recurrent ovarian cancer. In such embodiments, the subject can be administered an anti-cancer agent or

therapy such as administration of BCRP1 inhibitor or MIS or an analogue or derivative thereof according to the methods as disclosed herein, or any other cancer therapy known by a person of ordinary skill in the art.

**[046]** Another aspect of the present invention relates to methods for identifying and/or isolating and/or enriching for a population of somatic ovarian stem cells, for example somatic coelomic ovarian stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to cytokeratin-8,  $\beta$ -catenin and E-cadherin and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are somatic ovarian stem cells. In some embodiments, such a method can further comprise contacting the population of with agents reactive to EpCam and separating reactive positive cells from non-reactive cells, wherein the non-reactive cells are somatic ovarian stem cells such as somatic coelomic ovarian stem cells. In alternative embodiments, where the cells are reactive to agents selective for EpCam, the reactive positive cells are identified as ovarian cancer stem cells.

**[047]** In further embodiments, the present invention provides methods for isolating or enriching for a population of somatic ovarian stem cells, for example subcoelomic or stromal ovarian stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD44, CD105 and separating reactive positive cells from non-reactive cells are somatic ovarian stem cells such as subcoelomic or stromal ovarian stem cells. In such embodiments, the method can further comprise contacting the population of cells comprising ovarian cells with agents reactive to CD45 or CD 31 and separating reactive positive cells from non-reactive cells, wherein the non-reactive cells are somatic ovarian stem cells, for example somatic subcoelomic or stromal ovarian stem cells.

**[048]** In further embodiments, the present invention further also provides methods for isolating or enriching for a population of somatic ovarian stem cells, for example periphilar medullary ovarian stem cells, the method comprising contacting a population of cells comprising ovarian

cells with agents reactive to cKIT, SF-1, GATA-4, CD44, CD105 and separating reactive positive cells from non-reactive cells are somatic ovarian stem cells such as periphilar medullary ovarian stem cells. In such an embodiment, such a method can further comprise contacting a population of cells comprising ovarian cells with agents reactive to CD45 and/or CD 31 and/or  $\alpha$ SMA and separating reactive positive cells from non-reactive cells, wherein the non-reactive cells are somatic ovarian stem cells, for example the non-reactive cells are somatic periphilar medullary ovarian stem cells.

**[049]** Another aspect of the present invention provides a method for isolating or enriching for a population of ovarian cancer stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to EpCam, cytokeratin-8,  $\beta$ -catenin and E-cadherin and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are ovarian cancer stem cells. In such an embodiment, such a method can further comprise contacting a population of cells comprising ovarian cells with agents reactive to MISRII and/or BCRP1 and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are ovarian cancer stem cells.

**[050]** In some embodiments, the present invention further provides a method to identify agents that reduce the self-renewal capacity of an ovarian cancer stem cell, comprising contacting an ovarian cancer stem cell as identified according the methods as disclosed herein with an agent, and measuring the proliferation of the ovarian cancer cell, whereby an agent that decreases the proliferation as compared to a reference agent or absence of an agent identifies an agent that inhibits the self-renewal capacity of the ovarian cancer stem cell. In some embodiments, the method can further comprise contacting a somatic ovarian stem cell identified according to the methods as disclosed herein with an agent, and measuring the proliferation of the somatic ovarian cell, and comparing the rate of proliferation of the somatic ovarian stem cell in the presence of the agent with the rate of proliferation of an ovarian cancer stem cell in the presence

of the same agent, whereby if the agent decreases the rate of proliferation of the ovarian cancer stem cells as compared to the rate of proliferation of somatic ovarian stem cells identifies an agent that inhibits the self-renewal capacity of the ovarian cancer stem cell.

**[051]** In another embodiment, the present invention further provides a method for identifying agents which kill or decrease the rate of proliferation of ovarian cancer stem cells, the method comprising: (a) culturing a population of ovarian cancer stem cells as identified according to the methods as disclosed herein, (b) culturing a population of somatic ovarian stem cells as identified according to the methods as disclosed herein, (c) adding to the media of the population of ovarian cancer stem cells one or more agents and adding to the media of the population of somatic ovarian stem cells one or more of the same agents; (d) measuring the rate of proliferation of the population of ovarian cancer stem cells and measuring the rate of proliferation of the population of somatic ovarian stem cells; (e) comparing the rate of proliferation of the population of ovarian cancer stem cells with rate of proliferation of the population of somatic ovarian stem cells, wherein an agent which decreases the rate of proliferation of the ovarian cancer stem cells as compared to the rate of proliferation of somatic ovarian stem cells identifies an agent that kills or decreases the rate of proliferation of an ovarian cancer stem cell. In particular embodiments, the population of somatic ovarian stem cell used in such an assay to identify agents that selectively inhibit the ovarian cancer stem cells are coelomic ovarian stem cell population. In some embodiments, agents used in the methods to identify agents that kill or decrease the rate of proliferation of an ovarian cancer stem cell, such an agent is a nucleic acid, nucleic acid analogue, small molecule, protein, peptiomimetic, antibody, peptide, aptamer, ribozyme, and variants and fragments thereof. Further, proliferation assays useful in identifying agents that kill or decrease the rate of proliferation of an ovarian cancer stem cell are the methyiazoletetrazolium (MTT) proliferation assay or the colony forming unit (CFU) assay, as disclosed herein.

[052] In further aspect, the present invention provides a method of treating a subject affected with cancer, the method comprising assessing the presence of ovarian cancer stem cells in a biological sample obtained from the subject, wherein a clinician reviews the results and if the results indicate the presence of ovarian cancer stem cells in the biological sample, the clinician directs the subject to be treated with an effective amount of a pharmaceutical composition comprising MIS or a homologue or variant or derivative thereof, and/or an BCRP1 inhibitor. In some embodiments, the biological sample is a tissue sample, for example a tissue sample such as a cancer or a tumor, and/or a biopsy tissue sample. In some embodiments, the tissue sample comprises ovarian cancer cells, vulvar epidermal carcinoma cells, cervical carcinoma cells, endometrial adenocarcinoma cells and ovarian adenocarcinoma cells. In a particular embodiment, the tissue sample comprises ascite cells.

[053] In some embodiments, where agent is used to identify and/or enrich for a population of somatic ovarian stem cells or a population of ovarian cancer stem cells, the agent can be a nucleic acid or protein or analogues or fragments thereof. For example, an agent can be reactive to an expression product, for example protein and/or gene transcript such as mRNA, or fragments of an expression product, encoded by genes cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFR $\beta$ , NG2, CD31, CD44, CD105, SF-1 or GATA-4. In some embodiment, the gene transcript is selected from the group consisting of RNA, messenger RNA, or genomic DNA. In some embodiments, a nucleic acid agent is DNA, RNA or nucleic acid analogues, such as PNA (peptide nucleic acid), pc-PNA (pseudo-complementary PNA), LNA (locked nucleic acid) and analogues and derivatives thereof. In some embodiments, a protein agent useful in the methods as disclosed herein is an antibody or antibody fragment thereof. In further embodiments, an agent reactive to the genes to identify somatic ovarian stem cell population and/or an ovarian cancer stem cell populations are small molecule agents or aptamer agents or antibody fragment agents.

[054] A further embodiment of the present invention relates to kits to identify or enrich for a population of ovarian cancer stem cells in a biological sample, the kit comprising agents reactive to EpCam, cytokeratin-8,  $\beta$ -catenin and E-cadherin, and can optionally further comprise agents reactive to BCRP1 and/or MIS. Another embodiment provides a kit to identify somatic coelomic ovarian stem cells in a biological sample, the kit comprising agents reactive to EpCam, cytokeratin-8,  $\beta$ -catenin and E-cadherin. Another kit useful according to the present invention is a kit to identify or enrich for a population of subcoelomic/stromal ovarian stem cells in a biological sample, the kit comprising agents reactive to cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD44, CD105, and can optionally comprise an agent reactive to CD45 and/or an agent reactive to CD31. A further embodiment of the present invention relates to a kit to identify or enrich for a population of somatic periphilar medullary ovarian stem cells in a biological sample, the kit comprising agents reactive to cKIT, SF-1, GATA-4, CD44, CD105, and can optionally comprise agents reactive to CD 45 and/or CD31 and/or  $\alpha$ SMA. A further embodiment provides a kit to identify or enrich for a population of ovarian stem cells in a biological sample, the kit comprising at least 3 agents reactive to cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4, MIS or BCRP1. In some embodiments, the kits comprise agent that are nucleic acid agents, nucleic acid analogue agents or protein agents or fragments or analogues thereof. In some embodiments, the protein agents are antibody, anitmer, aptamer or fragments thereof, and in some embodiments, the kits can be in the form of ELISAs and/or protein chip array formats. In alternative embodiments, where the agent is a nucleic acid agent, the kit can be in the format of, for example a microarray chip or nucleic acid binding chip. In some embodiments, the kits as disclosed herein can be used for isolation of the ovarian stem cell of interest.

#### BRIEF DESCRIPTION OF FIGURES

- [055]** Figures 1A-1H show identification of SP cells in established mouse ovarian cancer cell lines. MOVCAR 7 and 4306 cell lines were labeled with Hoechst 33342 dye and analyzed by flow cytometry before (*A* and *B*) and after (*C* and *D*) treatment with verapamil. MOVCAR 7 and 4306 cells were examined for colocalization of Bcrp1 immunoreactivity and Hoechst dye uptake. Hoechst<sup>Low</sup> cells (*E* and *F*; dashed circle and arrows) show Bcrp1 immunoreactivity (*G* and *H*; arrows).
- [056]** Figures 2A-2E shows growth characteristics of mouse SP cells. MOVCAR 7 and 4306 SP (*2A* and *2C*) and NSP (*2B* and *2D*) cells recovered in culture and photographed with an inverted x10 phase-contrast microscope. SP cells from both cell lines form tight colonies after 4 days in culture, whereas NSP cells are scattered and do not proliferate. MOVCAR 7- and 4306-sorted SP cells (*2E* and *2H*) were cultured for 7–10 days, resorted by flow cytometry (*2F* and *2I*), recovered for an additional 7–10 days, and then reanalyzed by flow cytometry (*2G* and *2J*). Each successive sort demonstrated the enrichment of SP cells and the presence of NSP cells.
- [057]** Figures 3A-3F show side population (SP) cells with decreased inhibition by doxorubicin and G<sub>1</sub> cell cycle arrest. MOVCAR 7 cells were sorted for MTT growth-inhibition analysis against doxorubicin and paclitaxel. SP cells showed 30% inhibition (*3A*) by doxorubicin (\*,  $P < 4.2 \times 10^{-4}$ ) and 85% inhibition (*3B*) by paclitaxel (\*,  $P < 6.7 \times 10^{-10}$ ) compared with vehicle-treated controls. NSP cells were inhibited by doxorubicin and paclitaxel by 81% and 88% versus vehicle-treated controls [\*\*,  $P < 3.2 \times 10^{-11}$  (*3A*); \*\*,  $P < 5.1 \times 10^{-10}$  (*3B*)]. (*3A*) NSP cells were significantly more inhibited by doxorubicin than by SP cells (81% versus 30% growth inhibition; \*\*\*,  $P < 1.6 \times 10^{-9}$ ). Cell cycle analysis of three populations was performed as shown in *3C*. Hoechst<sup>High</sup> NSP and Hoechst<sup>Mid</sup> cells (*3D* and *3E*) demonstrate a predominance of S phase, 69.3% (average = 45.3%) and 68.9% (average = 51.5%), respectively, and decreased G<sub>1</sub>-arrested cells, 23% (average = 53%) and 15.9% (average = 39%), compared with Hoechst<sup>Low</sup> SP cells [ $P < 0.0407$  (*3F*)]. Hoechst<sup>Low</sup> SPs demonstrate a predominance of G<sub>1</sub>-arrested cells, 63%

(average = 65.8%), and decreased S phase replicating cells, 33.4% (30.57%). All experiments were performed in triplicate.

**[058]** Figures 4A-4F shows *In vivo* growth characteristics of MOVCAR 7 SP and NSP cells.

MOVCAR 7 cells were sorted for SP and NSP (4A), and nude mice were injected with equal numbers of SP and NSP cells [group I,  $5 \times 10^5$  cells per animal (4B); group II,  $7.5 \times 10^5$  cells per animal (data not shown)]. Measurable tumors were detected in SP-injected group I animals at 10 weeks (three of three) (4B) and SP-injected group II animals at 7 weeks (Table 1) after implantation, whereas group I (zero of three) (4B) and group II NSP-injected animals did not demonstrate tumors at the first appearance of SP tumors. The appearance of NSP tumors was delayed in group I and II NSP tumors until 14 and 11 weeks after injection. Sorting purity analysis (4C and 4D) showed ~93% purity in both SP and NSP sorts, identifying contamination by NSP sorts with SP cells. NSP tumors harvested after euthanization revealed the presence of a verapamil-sensitive SP of similar percentage to that initially injected due to incomplete sorting (4E and 4F).

**[059]** Figures 5A-5G show MOVCAR 7 SP cells respond to MIS *in vitro*. MOVCAR 7 cells express the MISRII by epifluorescent and confocal microscopy (5A-5C). RT-PCR evaluation of SP cells demonstrated the presence of an intact MIS signaling pathway (5D, left to right: SMAD 1, SMAD 5, SMAD 8, MIS type I receptors Alk 2 and Alk 3, and the MISRII). The proliferation of MOVCAR 7 SP and NSP cells were analyzed after the first sort by MTT assay (5E) and demonstrate inhibition of both SP (86%) and NSP (93%) cells by MIS versus vehicle. SP cells were serially sorted two more times, demonstrating that enriched SP cells remain responsive to MIS (F, 93% inhibition; 5G, 94% inhibition). All experiments were performed in triplicate.

**[060]** Figures 6A-6H show human ovarian cancer cell lines and primary ascites from patients have SPs and express the BCRP1 transporter. Human ovarian cancer cell line IGROV-1 had a

verapamil-sensitive SP (6A and 6E), whereas OVCAR-8 did not (6B and 6F). Human serous adenocarcinoma ascites patients 215 and 216 have small verapamil-sensitive SPs (6C, 6D, 6G, and 6H).

**[061]** Figures 7A-7B show 4306 SP cells respond to MIS *in vitro*. The proliferation of 4306 SP and NSP cells was analyzed after the first sort by MTT assay (7A) and demonstrated significant inhibition of SP (37%; \*,  $P < 5.2 \times 10^{-3}$ ), but not NSP, cells by MIS vs. vehicle control. Serially sorted 4306 SP cells were assayed (7B) and demonstrated that enriched SP cells remain responsive to MIS after the second sort (60% inhibition; \*,  $P < 4.5 \times 10^{-5}$ ), but no significant inhibition was demonstrated after the third sort (17% inhibition,  $P = 0.056$ , data not shown). All experiments were performed in triplicate.

**[062]** Figure 8 shows the surface marker profile of human ovarian cancer cell lines and primary ascites cells. No differential staining between SP and NSP cells was observed, and both populations were positive for these markers when staining was observed. OVCAR-3, OVCAR-8, SKOV-3 (dim), IGROV-1, patient 203 (dim), and patient 216 were ESA-positive. OVCAR-3, OVCAR-8, and patient 214 (dim) were positive for CD24. AC-01 and patient 214 demonstrated CD44 staining. No significant *c-kit* staining was observed.

**[063]** Figures 9A-D show coelomic epithelial cells proliferate in a cycle dependent manner. Mice in proestrus were injected with hCG followed by BrdU 2 hours before sacrifice in sequentially timed stages of estrus. Minimal coelomic epithelial BrdU incorporation was observed in the pre-ovulatory period (diestrus + proestrus; panel 9A; n=4) but showed substantial incorporation in the post-ovulatory period (estrus + metestrus; panel 9B; n=4). Quantification over the whole coelomic epithelium demonstrated  $5.2 \pm 3.2\%$  of pre-ovulatory and  $18.9 \pm 1.3\%$  of post-ovulatory cells incorporated BrdU, resulting in a greater than 3 fold increase in incorporation during the post-ovulatory phase (panel 9C,  $p < 0.0011$ ). Assessment of BrdU labeling within the post-ovulatory period at different anatomical sites (panel 9D) showed increased coelomic

epithelial proliferation in association with antral follicles and corpora lutea ( $29.5 \pm 8\%$ ) when compared to the coelomic epithelium overlying primary and secondary follicles ( $2.3 \pm 0.95\%$ ,  $p < 0.0014$ ).

**[064]** Figure 10A-10D show characterization of BrdU and Rosa26-rtTA; tetO-H2Bj-GFP in the ovary. Rosa26-rtTA;tetO-H2Bj-GFP doxycycline responsive mice were engineered as depicted in panel 10A. Panel 10B outlines the pulse-chase schemes used in this study. Animals were pulsed with doxycycline either beginning embryonically (E0-6wk) or beginning as adults and from 8.5wk-10wk with BrdU/IdU. Pulse-chase labeling efficiency of whole bone marrow, Lin<sup>-</sup>Kit<sup>+</sup>Sca-1<sup>+</sup> hematopoietic stem cells, whole ovary, and coelomic/subcoelomic ovary were analyzed and compared (Fig 16 & 16C). Significant variability in initial whole ovary labeling was observed between the labeling techniques (panel 10C,  $p < 0.05$ , \*). After three months chase there was a significant difference in whole ovary label retention when comparing BrdU to the adult and embryonic pulse H2Bj-GFP labeling methods (panel 10C,  $p = 0.016$ , \* &  $p = 0.010$ , \*). There was no significant difference noted at 3 months chase between the two H2Bj-GFP pulse labeling methods (panel 10C,  $p = 0.12$ ). Quantification of coelomic/subcoelomic labeling efficiency demonstrated no significant difference between the two H2Bj pulse times (91% & 88%,  $p = 0.43$ ), while there was a significant difference between both adult and embryonic pulsed H2Bj-GFP techniques and BrdU (panel 10D,  $p = 0.0016$  &  $p = 0.00011$ , \*). Likewise, no significant difference was noted in label retention after three months chase in the H2Bj-GFP animals (panel 10D,  $p = 0.794$ ) while there remained a significant difference in label retention between the H2Bj animals and the BrdU animals (panel 10D,  $p = 0.021$  &  $p = 0.041$ , \*\*).

**[065]** Figures 11A-11F show identification of LRC populations in the ovary. Panel 11A depicts the uniform loss of BrdU/IdU or GFP signal predicted by a self-duplication coelomic repair model (left) and in contrast, the predicted retention of label by a stem cell asymmetric division coelomic repair model (right). Gross inspection of 3 month chase H2Bj-GFP ovaries

demonstrated that GFP LRCs congregated in a perivascular location following the vascular supply (panel 11B & 11C). Label retention in 3 month chase ovaries identified coelomic LRCs, subcoelomic/stromal LRCs, and perihilar medullary LRCs (panel 11D) Panels 11E-F represent higher magnification of identified LRCs by both H2Bj-GFP (left) and BrdU (right) pulse-chase methods. Number of mice (n=) at each timepoint is shown. Panel 11I is a schematic diagram depicting the three identified LRC populations and their relationship to each other, the vasculature, and maturing follicles (CE=coelomic; SC/Str subcoelomic/stromal, and PHM=peri-hilar medullary). (O=Oocyte; GC=Granulosa Cells; T=Theca; BV=Blood Vessel).

**[066]** Figures 12A-12H show phenotypic characterization of ovarian LRCs and their niche.

Parabiosis studies between actin-GFP positive and negative isogenic littermates (panel 12A & 12B) demonstrated no incorporation of GFP into the coelomic epithelium (panel 12C).

Variable co-localization of subcoelomic/stromal LRC markers such as PDGFRb, NG2, CD44, and CD105 with actin-GFP positive cells suggests an extrinsic source of these cells such as the circulation/bone marrow (panels 12C-12H). No co-localization of actin-GFP with c-KIT was observed demonstrating that PHM are not circulatory/bone marrow derived.

**[067]** Figure 13A-13B show LRCs replicate in response to the estrus cycle *in vivo*. Super-physiologic hCG stimulation of BrdU labeled 3 month chase mice demonstrated increased BrdU signal in the coelomic and subcoelomic/stromal LRCs as compared to unstimulated 3 month chase mice (panel 13A & 13B). PF = Primordial Follicle, CL = Corpora Lutea, GFP = H2Bj-GFP, IdU = iodo-deoxy-uridine, A & B = 20x, C & D = 10x, E & F = 40x. Images representative of n=4.

**[068]** Figures 14A-14D show *in vitro* isolation and characterization of coelomic LRCs by colony forming unit (CFU) assay. Rosa26-rtTA; tetO-H2Bj-GFP coelomic epithelium was harvested and plated in proprietary colony forming unit assay media for 14 days. Giemsa staining identified macroscopic and microscopic colony formation (panel 14A & inset). H2Bj-GFP

LRCs were observed to form a three-dimensional sphere-like structure near the center of GFP positive colonies at each pulse-chase interval (panel 14B, 14D, and Figure 20 (see below)).

Panel 14C demonstrates that an average of  $10 \pm 5$  CFUs ( $n=9$ ) are generated per  $1 \times 10^4$  cells plated and that a visually estimated 30% of the colonies are GFP positive. The percentage of GFP+ CFUs (panel 14C) formed at each pulse-chase interval was independent of the percentage of GFP labeled cells per  $1 \times 10^4$  cells plated demonstrating a constant initial labeling efficiency of candidate stem cells and that these cells retain label with prolonged chase. Quantification of signal loss with replication demonstrated an exponential loss of signal as a function of distance from the brightest LRCs (panel 14D, inset) demonstrating asymmetric replication.

**[069]** Figures 15A-15D shows enrichment of coelomic epithelial SP cells by H2B-GFP LRCs.

Rosa26-rtTa; tetO-H2Bj-GFP coelomic epithelial cells were harvested as described and analyzed for the presence of side population. Normal mouse coelomic epithelial cells demonstrate a verapamil-sensitive SP (panel 15A & 15B;  $2.46 \pm 0.27\%$  SD;  $n=6$ ). Wild type coelomic epithelial cells were used to establish a GFP<sup>+</sup> gate of intensity  $\geq 10^2$  and a GFP<sup>Bright</sup> LRC gate of intensity  $\geq 10^3$  (panel 15C).  $56.5 \pm 4.1\%$  SD (panel 15C;  $n=3$ ) of SP cells were H2Bj-GFP<sup>+</sup> and  $67.7 \pm 8.1\%$  SD of H2Bj-GFP<sup>+</sup>/SP<sup>+</sup> cells were H2Bj-GFP<sup>Bright</sup>/LRCs (panel 15D).

**[070]** Figures 16A-16B shows characterization of Lin<sup>-</sup>cKit<sup>+</sup>Sca-1<sup>+</sup> hematopoietic stem cell label retention. Flow cytometry analysis of embryonic pulse H2Bj-GFP bone marrow was used to characterize Rosa26-rtTA; tetO-H2Bj-GFP in hematopoietic stem cells by colocalization with the known hematopoietic stem cell phenotype Lin<sup>-</sup>cKit<sup>+</sup>Sca-1<sup>+</sup>. Whole bone marrow demonstrated a significantly lower labeling efficiency ( $37.6 \pm 12\%$  SE, standard error, panel 16A) as compared to Lin<sup>-</sup>cKit<sup>+</sup>Sca-1<sup>+</sup> hematopoietic stem cells ( $81.36 \pm 7.6\%$ , panel 16B,  $p=0.016$ ). After 2 and 6 month chase periods there was significant enrichment of GFP label retention in Lin<sup>-</sup>Kit<sup>+</sup>Sca-1<sup>+</sup> hematopoietic stem cells ( $9.64 \pm 2.1\%$  &  $2.93 \pm 1.09\%$ , panel 16B)

as compared to the whole bone marrow ( $0.47 \pm .22\%$  &  $0.21 \pm 0.10\%$ , panel 16A,  $p=0.017$  &  $p=0.003$ ). These findings demonstrate the ability of the Rosa26-rtTA;tetO-H2Bj-GFP to identify hematopoietic and thus somatic stem cells.

**[071]** Figures 17A-17I shows ovarian Pulse Labeling Efficiency. To evaluate the ability of the two labeling methods used in this study, the inventors compared the labeling efficiency in the ovary to that of the positive control intestine. By visual inspection (panels 17A-17B, 17D-17E, 17G-17H) and quantification (panels 17C, 17F and 17I) the inventors demonstrated that the pulse labeling efficiency of the ovary (panel 17G-17H & 17I) appears similar and adequate as compared to the known positive control intestine (panels 17A-17B & 17F) for both H2Bj-GFP labeling methods. The BrdU labeling in the ovary appeared to be low in comparison to the intestinal pulse labeling (Figs 17C, 17I). Thus, the inventors chose to move forward with the two H2B-GFP models.

**[072]** Figures 18A-18D show a schematic of a proposed mechanism of coelomic LRC mediated ovulatory wound healing and the role of SC/Str and PHM LRCs in folliculogenesis. Ovulation of the oocyte results in disruption of both the sub-coelomic/stromal and coelomic cells (panel 18A). Reepithelialization of the wound occurs by a combined mechanism of stem cell proliferation and daughter cell migration as depicted in panel 18B. SC/Str and PHM LRCs appear to play a role in folliculogenesis as depicted in panel 18C & 18D. First, during follicular recruitment the SC/Str LRCs proliferate and incorporate/assist in the development of the thecal capillary network. At the same time, as granulosa cells develop previous work has shown that they begin to produce Kit-ligand which has been proposed to play a role in theca cell recruitment (panel 18C). Our observation that the PHM LRCs are c-Kit receptor positive and are observed to proliferate and incorporate in the maturing follicle (panel 18D) suggests that the PHM LRCs may serve as a reservoir for Kit-ligand induced theca cell differentiation and recruitment.

[073] Figure 19 shows a 3D confocal identification of coelomic and subcoelomic LRCs. Three-dimensional reconstruction of 3 month chase Rosa26-rtTA; tetO-H2B-GFP coelomic and subcoelomic LRCs. This movie demonstrated the relationship of these two populations of cells as well as their location within the interfollicular clefts.

[074] Figure 20 shows a 3D confocal reconstruction of *in vitro* CFU isolated coelomic LRC sphere. Three-dimensional reconstruction of 3 month chase Rosa26-rtTA; tetO-H2B-GFP coelomic LRCs isolated by colony forming unit demonstrate a three-dimensional spheroid LRC (bright) population surrounded by proliferating daughter cells that lose the H2B-GFP label.

#### DETAILED DESCRIPTION

[075] As disclosed herein, one aspect of the present invention relates to methods to identify a population of ovarian cancer stem cells present in a biological sample. In another aspect of the present invention, methods to isolate ovarian cancer stem cells are provided. In one embodiment, one method to isolate and identify a population of ovarian cancer stem cells comprises contacting a population of ovarian cells with a agent reactive to breast cancer-resistance protein 1 (BCRP1) and selecting and isolating cells that are reactive with the agent for BCRP1. In another embodiment, the method comprises contacting a population of ovarian cells with a lipophilic dye, for example Hoechst 33342 and selecting for the cells that do not take up the dye.

[076] As disclosed herein, the inventors have discovered a population of ovarian cancer cells that are ovarian cancer stem cells or tumor-initiating cells. The inventors have also discovered that the ovarian cancer stem cells are responsive to Mullerian Inhibiting Substance (MIS). The inventors have also discovered that ovarian cancer stem cells are also more resistant to inhibition by lipophilic chemotherapeutic agents, for example mitoxantrone, daunorubicin, doxorubicin, indolcabazole. The inventors have also discovered that the ovarian cancer stem

cells have the ability to efflux lipophilic dyes, for example Hoechst 33342 and are herein termed Hoechst<sup>LOW</sup> cells. The inventors have further discovered that the ovarian cancer stem cells are positive for the expression of breast cancer-resistance protein 1 (BCRP1). Accordingly, in one embodiment the present invention is related to methods

[077] As disclosed herein, the inventors have discovered that distinct histologic types of genetically engineered mouse ovarian cancer cells (MOVCAR 7 and 4306) have a proportionately large side population (SP), and thus the inventors have discovered a new model to study ovarian cancer stem cell biology. The inventors also discovered a SP in human ovarian cancer cell lines (IGROV-1, SK-OV3, and OVCAR-3) and in patient primary ascites cells. The inventors used the MOVCAR 7 cell line to demonstrate that SP cells can reconstitute colonies *in vitro*, form tumors earlier than non-side population (NSP) cells *in vivo*, and remain responsive to Mullerian Inhibiting Substance (MIS). The inventors have discovered that the SP phenotype is a marker for ovarian cancer stem cells and that MIS can inhibit proliferation of both stem cell and non-stem cancer cells, as compared with the lipophilic chemotherapeutic doxorubicin, which more effectively inhibited the NSP. The inventors discoveries are useful in methods to treat and to develop therapeutic strategies to treat recurrent ovarian cancer, for example recurrent ovarian cancers after treatment with transporter substrates such as anthracyclines, which typically cytoreduce the ovarian cancer but essentially never cure. The inventors discovery of the ovarian cancer stem cell population in subjects is also useful in advancing the development of novel therapeutic strategies in the management of this ovarian cancer.

[078] Accordingly, in another aspect of the invention, the method to treat a subject with ovarian cancer are provided, where the subject is identified to have ovarian cancer comprising ovarian cancer stem cells, and the subject is administered a pharmaceutical composition comprising MIS or a derivative or homologue thereof. In some embodiments, the subject is also

administered additional cancer therapies, for example chemotherapies and other agent. In some embodiments, the subject is also administered a BCRP1 inhibitor, for example verapamil.

**[079]** The inventors have also discovered the intrinsic repair capacity of the coelomic epithelium emanates from ovarian somatic stem cells such as coelomic somatic stem/progenitor cells in the normal ovary. Using a variety of transgenic and cell based techniques, the inventors have discovered three ovarian somatic stem cell populations which are also label-retaining cell (LRC) populations in the ovary. The inventors have demonstrated that these somatic ovarian stem cells exist in defined perivascular microenvironments, and have characterized one somatic ovarian stem cell population, the coelomic epithelial label retaining cells (LRCs) *in vitro*, and have discovered a functional response by coelomic epithelial LRCs to the estrous cycle *in vivo*.

**[080]** Using traditional and transgenic pulse chase techniques in conjunction with immunohistochemistry, parabiosis and flow cytochemistry, the inventors have discovered the surface marker profiles of three somatic ovarian cell populations. The inventors discovered that somatic coelomic ovarian stem cell population was characterized to have positive surface marker profiles for cytokeratin-8,  $\beta$ -catenin and E-cadherin, but negative expression for EpCam. In contrast, the inventors discovered ovarian cancer stem cells have positive surface marker profiles for EpCam as well as positive for cytokeratin-8,  $\beta$ -catenin and E-cadherin, thereby the inventors have discovered a method to identify and distinguish a population of ovarian cancer stem cells from a population of coelomic ovarian stem cells.

**[081]** The inventors further discovered that a subcoelomic or stromal ovarian stem cell population was characterized to have positive surface marker profiles for cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD44, CD105, but negative for the expression CD45 and CD31. The inventors further discovered that a periphilar medullary ovarian stem cell population was characterized to have positive surface marker profiles for cKIT, SF-1, GATA-4, CD44, CD105, but negative for the expression CD45 and/or CD 31 and/or  $\alpha$ SMA.

[082] Accordingly, the inventors have discovered methods to identify, isolate and enrich for three populations of somatic ovarian stem cells; a coelomic ovarian stem cell population, a subcoelomic/stromal ovarian stem cell population and a periphilar medullary ovarian stem cell population, as well as methods to identify, isolate and enrich for populations of ovarian cancer stem cells.

[083] In further experiments, the inventors have validated the presence of ovarian cancer stem cells by comparing them to a normal somatic ovarian stem cell population the inventors the inventors discovered in the coelomic epithelium. In some instances, the inventors have discovered a method to study and determine how a normal somatic ovarian stem cell population transforms to become stem cells of ovarian cancer pathology, such as ovarian cancer stem cells as disclosed herein. The inventors have discovered a method whereby the somatic ovarian stem cells can be compared with ovarian cancer stem cells, for example, such methods are useful to determine how, when, and where transformation and progression to the ovarian cancer phenotype occurs, as well as identifying agent that are selective for ovarian cancer stem cells as compared to ovarian somatic stem cells.

### *Definitions*

[084] For convenience, certain terms employed in the entire application (including the specification, examples, and appended claims) are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[085] The term “Mullerian Inhibiting Substance” and “MIS” are used interchangeably herein and is also known as anti-Müllerian hormone or AMH, refer to compounds and materials which are structurally similar to MIS. Examples of such intended substances are for example, salts, derivatives and aglycone forms of MIS. Additionally, the present invention is intended to

include mutant forms of MIS which have substantially the same biological activity as MIS. Examples of such mutant MIS molecules carrying a deletion, insertion, or alteration in amino acid sequence. MIS can be obtained from any mammalian source or from non-mammalian sources through the use of recombinant DNA technology, or from chemical synthesis of the MIS protein. For reference purposes only, the human MIS nucleic acid corresponds to Accession No: NM\_000479 or RefSeq ID No: KO3474 (GeneID: 268), herein referred to as SEQ ID NO: 15 which are incorporated herein by reference. The amino acid sequence for MIS correspondes to SEQ ID NO: 16, and corresponds to Accesion No: NP\_000470.

**[086]** The term “Mullerian Inhibiting Substance type II receptor” or “MISRII” are used interchangeably herein refer to the type II receptor for MIS. The term MISRII is intended to encompass all MIS receptors substantially homologous to MISRII and functional derivatives of MISRII. MISRII is also known by the alias as AMHR2, and for reference purposes, the nucleic acid sequence of human MISRII corresponds to NM\_020547 and GenBank No: AF172932, and corresponds to SEQ ID NO: 17 and is incorporated herein by reference. The amino acid sequence for MISRII correspondes to SEQ ID NO: 18, and corresponds to Accesion No: NP\_065434.

**[087]** The term “functional derivative” and “mimetic” are used interchangeably, and refers to compounds which possess a biological activity (either functional or structural) that is substantially similar to a biological activity of the entity or molecule for which it’s a functional derivative. The term functional derivative is intended to include the fragments, variants, analogues or chemical derivatives of a molecule.

**[088]** The term “derivative” as used herein refers to peptides which have been chemically modified, for example but not limited to by techniques such as ubiquitination, labeling, pegylation (derivatization with polyethylene glycol) or addition of other molecules.

[089] As used herein, "variant" with reference to a polynucleotide or polypeptide, refers to a polynucleotide or polypeptide that can vary in primary, secondary, or tertiary structure, as compared to a reference polynucleotide or polypeptide, respectively (e.g., as compared to a wild-type polynucleotide or polypeptide). A "variant" of a MIS for example, is meant to refer to a molecule substantially similar in structure and function, i.e. where the function is the ability to bind with MISRII, to either bind to the entire MISRII molecule, or to a fragment thereof. A molecule is said to be "substantially similar" to another molecule if both molecules have substantially similar structures or if both molecules possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if the structure of one of the molecules not found in the other, or if the sequence of amino acid residues is not identical.

[090] For example, a variant of an MIS can contain a mutation or modification that differs from a reference amino acid in NM\_000479 (SEQ ID NO: 16). In some embodiments, a variant can be a different isoform of MIS or can comprise different isomer amino acids. Variants can be naturally-occurring, synthetic, recombinant, or chemically modified polynucleotides or polypeptides isolated or generated using methods well known in the art. Variants can include conservative or non-conservative amino acid changes, as described below. Polynucleotide changes can result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. Variants can also include insertions, deletions or substitutions of amino acids, including insertions and substitutions of amino acids and other molecules) that do not normally occur in the peptide sequence that is the basis of the variant, for example but not limited to insertion of ornithine which do not normally occur in human proteins. The term "conservative substitution," when describing a polypeptide, refers to a change in the amino acid composition of the polypeptide that does not substantially alter the polypeptide's activity. For example, a conservative substitution refers to substituting an amino

acid residue for a different amino acid residue that has similar chemical properties.

Conservative amino acid substitutions include replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine. "Conservative amino acid substitutions" result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine. Thus, a "conservative substitution" of a particular amino acid sequence refers to substitution of those amino acids that are not critical for polypeptide activity or substitution of amino acids with other amino acids having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitution of even critical amino acids does not reduce the activity of the peptide, (i.e. the ability of the peptide to penetrate the BBB). Conservative substitution tables providing functionally similar amino acids are well known in the art. For example, the following six groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W). (See also Creighton, *Proteins*, W. H. Freeman and Company (1984).) In some embodiments, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids can also be considered "conservative substitutions" if the change does not reduce the activity of the peptide (i.e. the ability of, for example MIS to bind and activate MISRII). Insertions or deletions are typically in the range of about 1 to 5 amino acids. The choice of conservative amino acids may be selected based on the location of the amino acid to be substituted in the peptide, for example if the amino acid is on the exterior of the peptide and exposed to solvents, or on the interior and not exposed to solvents. As used herein, the term "nonconservative" refers to substituting an amino acid residue for a different amino acid residue

that has different chemical properties. The nonconservative substitutions include, but are not limited to aspartic acid (D) being replaced with glycine (G); asparagine (N) being replaced with lysine (K); or alanine (A) being replaced with arginine (R).

**[091]** "Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed can be experimentally determined by producing the peptide synthetically while systematically making insertions, deletions, or substitutions of nucleotides in the sequence using recombinant DNA techniques.

**[092]** The term "functional derivative" and "mimetic" are used interchangeably, and refers to a compound which possess a biological activity (either functional or structural) that is substantially similar to a biological activity of the entity or molecule its is a functional derivative of. The term functional derivative is intended to include the fragments, variants, analogues or chemical derivatives of a molecule.

**[093]** A "fragment" of a molecule, is meant to refer to any contiguous polypeptide subset of the molecule. Fragments of, for example MIS which have the same activity as that of MIS encoded by NM\_000479, referred to herein as SEQ ID NO: 15 (i.e. a fragment of an MIS peptide which can bind and activate MISRII as the MIS polypeptide corresponding to SEQ ID NO: 16) and which are soluble (i.e. not membrane bound) are also encompassed for use in the present invention.

**[094]** An "analog" of a molecule such as MIS, for example an analogue of the protein encoded by NM\_000479 (SEQ ID NO: 15) is meant to refer to a molecule similar in function to either the entire molecule or to a fragment thereof of SEQ ID NO: 16. As used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties can improve the molecule's solubility, absorption, biological half life, etc. The moieties can alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties

capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., MackPubl., Easton, PA (1990).

**[095]** As used herein, "homologous", when used to describe a polynucleotide, indicates that two polynucleotides, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or deletions, in at least 70% of the nucleotides, usually from about 75% to 99%, and more preferably at least about 98 to 99% of the nucleotides. The term "homolog" or "homologous" as used herein also refers to homology with respect to structure and/or function. With respect to sequence homology, sequences are homologs if they are at least 50%, at least 60 at least 70%, at least 80%, at least 90%, at least 95% identical, at least 97% identical, or at least 99% identical. The term "substantially homologous" refers to sequences that are at least 90%, at least 95% identical, at least 97% identical or at least 99% identical. Homologous sequences can be the same functional gene in different species.

**[096]** As used herein, the term "substantial similarity" in the context of polypeptide sequences, indicates that the polypeptide comprises a sequence with at least 60% sequence identity to a reference sequence, or 70%, or 80%, or 85% sequence identity to the reference sequence, or most preferably 90% identity over a comparison window of about 10-20 amino acid residues. In the context of amino acid sequences, "substantial similarity" further includes conservative substitutions of amino acids. Thus, a polypeptide is substantially similar to a second polypeptide, for example, where the two peptides differ by one or more conservative substitutions. The term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 65 percent sequence identity, preferably at least 80 or 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity

or higher). Preferably, residue positions which are not identical differ by conservative amino acid substitutions.

**[097]** Determination of homologs of the genes or peptides of the present invention can be easily ascertained by the skilled artisan. The terms "homology" or "identity" or "similarity" are used interchangeably herein and refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology and identity can each be determined by comparing a position in each sequence which can be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g. , similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology/similarity or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. A sequence which is "unrelated" or "non-homologous" shares less than 40% identity, though preferably less than 25% identity with a sequence of the present application.

**[098]** In one embodiment, the term "MIS peptide homolog" refers to an amino acid sequence that has 40% homology to the full length amino acid sequence of the MIS as disclosed herein, for example the MIS peptide such as SEQ ID NO: 16 or a polypeptide encoded by NM\_000479 (SEQ ID NO: 15) as disclosed herein, more preferably at least about 50%, still more preferably, at least about 60% homology, still more preferably, at least about 70% homology, even more preferably, at least about 75% homology, yet more preferably, at least about 80% homology, even more preferably at least about 85% homology, still more preferably, at least about 90% homology, and more preferably, at least about 95% homology. As discussed above, the homology is at least about 50% to 100% and all intervals in between (i.e., 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, etc.).

**[099]** For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

**[0100]** Optimal alignment of sequences for comparison can be conducted, for example, by the local homology algorithm of Smith and Waterman (*Adv. Appl. Math.* 2:482 (1981), which is incorporated by reference herein), by the homology alignment algorithm of Needleman and Wunsch (*J. Mol. Biol.* 48:443-53 (1970), which is incorporated by reference herein), by the search for similarity method of Pearson and Lipman (*Proc. Natl. Acad. Sci. USA* 85:2444-48 (1988), which is incorporated by reference herein), by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection. (See generally Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, 4th ed., John Wiley and Sons, New York (1999)).

**[0101]** One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show the percent sequence identity. It also plots a tree or dendogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (*J. Mol. Evol.* 25:351-60 (1987), which is incorporated by reference herein). The method used is similar to the method described by Higgins and Sharp (*Comput. Appl. Biosci.* 5:151-53 (1989), which is incorporated by reference herein). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar

sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

**[0102]** Another example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described by Altschul et al. (*J. Mol. Biol.* 215:403-410 (1990), which is incorporated by reference herein). (See also Zhang et al., *Nucleic Acid Res.* 26:3986-90 (1998); Altschul et al., *Nucleic Acid Res.* 25:3389-402 (1997), which are incorporated by reference herein). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information internet web site. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length  $W$  in the query sequence, which either match or satisfy some positive-valued threshold score  $T$  when aligned with a word of the same length in a database sequence.  $T$  is referred to as the neighborhood word score threshold (Altschul et al. (1990), *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction is halted when: the cumulative alignment score falls off by the quantity  $X$  from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.

The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-9 (1992), which is incorporated by reference herein) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

**[0103]** The term “analog” as used herein, is intended to include allelic, species and induced variants. Analogs typically differ from naturally occurring peptides at one or a few positions, often by virtue of conservative substitutions. Analogs typically exhibit at least 80 or 90% sequence identity with natural peptides. Some analogs also include unnatural amino acids or modifications of N or C terminal amino acids. Examples of unnatural amino acids are, for example but not limited to; acedisubstituted amino acids, N-alkyl amino acids, lactic acid, 4-hydroxyproline,  $\gamma$ -carboxyglutamate,  $\epsilon$ -N,N,N-trimethyllysine,  $\epsilon$ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine,  $\sigma$ -N-methylarginine. Fragments and analogs can be screened for prophylactic or therapeutic efficacy in transgenic animal models as described below.

**[0104]** The term “substitution” when referring to a peptide, refers to a change in an amino acid for a different entity, for example another amino acid or amino-acid moiety. Substitutions can be conservative or non-conservative substitutions.

**[0105]** As used herein, the term "subject" refers to any living organism which can be administered to the pharmaceutical compositions of the present invention and in which cancer or a proliferative disorder can occur. The term includes, but is not limited to, humans, non-human animals, for example non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses, domestic subjects such as dogs and cats, laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well

as fetuses, whether male or female, are intended to be covered. The term “subject” also includes living organisms susceptible to conditions or disease states as generally disclosed, but not limited to, throughout this specification. Examples of subjects include humans, dogs, cats, cows, goats, and mice, including transgenic species. The term “non-human animals” and “non-human mammals” are used interchangeably herein and includes all vertebrates, e.g., mammals, such as non-human primates, (particularly higher primates), sheep, dog, rodent (e.g. mouse or rat), guinea pig, goat, pig, cat, rabbits, cows, and non-mammals such as chickens, amphibians, reptiles etc. In one embodiment, the subject is human. In another embodiment, the subject is an experimental animal or animal substitute as a disease model.

**[0106]** The term "tissue" is intended to include intact cells, blood, blood preparations such as plasma and serum, bones, joints, muscles, smooth muscles, and organs.

**[0107]** The term “disease” or “disorder” is used interchangeably herein, refers to any alternation in state of the body or of some of the organs, interrupting or disturbing the performance of the functions and/or causing symptoms such as discomfort, dysfunction, distress, or even death to the person afflicted or those in contact with a person. A disease or disorder can also related to a distemper, ailing, ailment, malady, disorder, sickness, illness, complaint, inderdisposion, affection.

**[0108]** The term ‘effective amount’ as used herein refers to the amount of an agent and/or a pharmaceutical composition required to reduce at least one of the symptom of the disease or disorder. For example, an effective amount is the amount of required to reduce a symptom of ovarian cancer by at least 10%. An effective amount is also the amount sufficient to prevent the development of a disease symptom, or to reduce a symptom or reduce the rate if a symptom progression.

**[0109]** The term ‘malignancy’ and ‘cancer’ are used interchangeably herein, refers to diseases that are characterized by uncontrolled, abnormal growth of cells. Cancer cells can spread locally or

through the bloodstream and lymphatic system to other parts of the body. The term is also intended to include any disease of an organ or tissue in mammals characterized by poorly controlled or uncontrolled multiplication of normal or abnormal cells in that tissue and its effect on the body as a whole. Cancer diseases within the scope of the definition comprise benign neoplasms, dysplasias, hyperplasias as well as neoplasms showing metastatic growth or any other transformations like e.g. leukoplakias which often precede a breakout of cancer.

**[0110]** As used herein, the term "treating" includes preventing the progression and/or reducing or reversing at least one adverse effect or symptom of a condition, disease or disorder associated with inappropriate proliferation, for example cancer.

**[0111]** As used herein, the terms "administering" and "introducing" are used interchangeably herein and refer to the placement of the pharmaceutical compositions as disclosed herein into a subject by a method or route which results in at least partial localization of the pharmaceutical compositions at a desired site. The compounds of the present invention can be administered by any appropriate route which results in an effective treatment in the subject.

**[0112]** The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracerebrospinal, and intrasternal injection and infusion. The phrases "systemic administration," "administered systemically", "peripheral administration" and "administered peripherally" as used herein mean the administration of the pharmaceutical compositions of the present invention comprising pyrazoloanthrones and optionally other agents or material other than directly into the central nervous system, such that it enters the animal's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

**[0113]** The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

**[0114]** The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agents from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, or be biologically inert.

**[0115]** The term "agent" refers to any entity which is normally not present or not present at the levels being administered in the cell. Agent may be selected from a group comprising, for example chemicals; small molecules; nucleic acid sequences; nucleic acid analogues; proteins; peptides; peptidomimetics, aptamers; antibodies; or fragments thereof. A nucleic acid sequence may be RNA or DNA, and may be single or double stranded, and can be selected from a group comprising; nucleic acid encoding a protein of interest, oligonucleotides, antisense oligonucleotides, nucleic acid analogues, for example peptide-nucleic acid (PNA), pseudo-complementary PNA (pc-PNA), locked nucleic acid (LNA), etc.. Such nucleic acid sequences include, for example, but not limited to, nucleic acid sequence encoding proteins, for example that act as transcriptional repressors, antisense molecules, ribozymes, small inhibitory nucleic acid sequences, for example but not limited to RNAi, shRNAi, siRNA, micro RNAi (mRNAi), short-temporal RNAi (stRNA), dsRNA antisense oligonucleotides etc. A chemical entity or biological product is preferably, but not necessarily a low molecular weight compound, but may also be a larger compound, or any organic or inorganic molecule, including without limitation

synthetic and naturally-occurring non-proteinaceous entities. In certain embodiments the agent is a small molecule having a chemical moiety. For example, chemical moieties included unsubstituted or substituted alkyl, aromatic, or heterocyclyl moieties including macrolides, leptomycins and related natural products or analogues thereof. Agents can be known to have a desired activity and/or property, or can be selected from a library of diverse compounds. Agents can be, without limitation an oligomer of nucleic acids, amino acids, or carbohydrates including without limitation proteins, oligonucleotides, ribozymes, DNAzymes, glycoproteins, siRNAs, lipoproteins, aptamers, and modifications and combinations thereof. A protein and/or peptide or fragment thereof can be any protein of interest, for example, but not limited to; mutated proteins; therapeutic proteins; truncated proteins, wherein the protein is normally absent or expressed at lower levels in the cell. Proteins can also be selected from a group comprising; mutated proteins, genetically engineered proteins, peptides, synthetic peptides, recombinant proteins, chimeric proteins, antibodies, midibodies, minibodies, triabodies, humanized proteins, humanized antibodies, chimeric antibodies, modified proteins and fragments thereof. The agent may be applied to the media, where it contacts the ovarian cell and induces its effects. Alternatively, the agent may be intracellular within the cell as a result of introduction of the nucleic acid sequence into the cell and its transcription resulting in the production of the nucleic acid and/or protein agent within an ovarian cancer cell.

**[0116]** As used herein, "proliferating" and "proliferation" refers to an increase in the number of cells in a population (growth) by means of cell division. Cell proliferation is generally understood to result from the coordinated activation of multiple signal transduction pathways in response to the environment, including growth factors and other mitogens. Cell proliferation may also be promoted by release from the actions of intra- or extracellular signals and mechanisms that block or negatively affect cell proliferation.

[0117] The term “enriching” is used synonymously with “isolating” cells, means that the yield (fraction) of cells of one type is increased over the fraction of other types of cells as compared to the starting or initial cell population. Preferably, enriching refers to increasing the percentage by about 10%, by about 20%, by about 30%, by about 40%, by about 50% or greater than 50% of one type of cell in a population of cells as compared to the starting population of cells.

[0118] A "marker" as used herein is used to describe the characteristics and/or phenotype of a cell. Markers can be used for selection of cells comprising characteristics of interests. Markers will vary with specific cells. Markers are characteristics, whether morphological, functional or biochemical (enzymatic) characteristics of the cell of a particular to a cell type, or molecules expressed by the cell type. Preferably, such markers are proteins, and more preferably, possess an epitope for antibodies or other binding molecules available in the art. However, a marker may consist of any molecule found on the surface or within a cell including, but not limited to, proteins (peptides and polypeptides), lipids, polysaccharides, nucleic acids and steroids. Examples of morphological marker characteristics or traits include, but are not limited to, shape, size, and nuclear to cytoplasmic ratio. Examples of functional marker characteristics or traits include, but are not limited to, the ability to adhere to particular substrates, ability to incorporate or exclude particular dyes, for example but not limited to exclusions of lipophilic dyes as disclosed herein, ability to migrate under particular conditions, and the ability to differentiate along particular lineages. Markers may be detected by any method available to one of ordinary skill in the art. Markers can also be a protein expressed from a reporter gene, for example a reporter gene expressed by the cell as a result of introduction of the nucleic acid sequence encoding the reporter gene into the cell and its transcription resulting in the production of the reporter protein that can be used as a marker. Such reporter genes that can be used as markers are, for example but not limited to fluorescent proteins enzymes, chromomeric proteins, resistance genes and the like.

**[0119]** The term ‘lineages’ as used herein refers to a term to describe cells with a common ancestry, for example cells that are derived from the same ovarian cancer stem cell.

**[0120]** As used herein, the term “clonal cell line” refers to a cell lineage that can be maintained in culture and has the potential to propagate indefinitely. A clonal cell line can be a stem cell line or be derived from a stem cell, and where the clonal cell line is used in the context of clonal cell line comprising stem cells, the term refers to stem cells which have been cultured under in vitro conditions that allow proliferation without differentiation for months to years. Such clonal stem cell lines can have the potential to differentiate along several lineages of the cells from the original stem cell.

**[0121]** The term "substantially pure", with respect to a particular cell population, refers to a population of cells that is at least about 75%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% pure, with respect to the cells making up a total cell population. Recast, the terms "substantially pure" or "essentially purified", with regard to a preparation of one or more partially and/or terminally differentiated cell types, refer to a population of cells that contain fewer than about 20%, more preferably fewer than about 15%, 10%, 8%, 7%, most preferably fewer than about 5%, 4%, 3%, 2%, 1%, or less than 1%, of cells that are not cardiovascular stem cells or cardiovascular stem cell progeny of the invention.

**[0122]** As used herein, "protein" is a polymer consisting essentially of any of the 20 amino acids. Although "polypeptide" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of these terms in the art overlaps and is varied. The terms "peptide(s)", "protein(s)" and "polypeptide(s)" are used interchangeably herein.

**[0123]** The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

*Isolating and/or Enriching for populations of ovarian cancer stem cells*

**[0124]** As disclosed herein, the inventors have discovered a method to identify, isolate and enrich for ovarian cancer stem cells. One aspect of the present invention provides methods for identification, isolation and enrichment of ovarian cancer stem cells. The inventors have discovered ovarian cancer stem cells are positive for the expression of the Breast cancer resistance protein 1 (BCRP1) gene. Encompassed in the methods of the present invention are methods for identification, isolation and enrichment of ovarian cancer stem cells using agents that are reactive to BCRP1, for example agents reactive to the nucleic acids encoding BCRP1, for example mRNA BCRP1 and in another embodiment, agents are reactive to the expression products of the nucleic acid encoding BCRP1, for example agent reactive to BCRP1 protein or fragments thereof are useful in the methods as disclosed herein. In another embodiment encompasses methods for the identification, isolation and enrichment of populations of ovarian cancer stem cells, the methods comprising using conventional methods of using reporter genes operatively linked to the promoters of BCRP1 or homologues or variants thereof. In such embodiments, when cells express the BCRP1 protein the cells will also express the reporter gene operatively linked to the promoter of BCRP1, and the expression of the reporter gene can be used to isolate, identify and enrich for populations of ovarian cancer stem cells.

**[0125]** BCRP1, is also known in the art as the ABCG2 transporter is shown herein as a marker for stem cell-like Hoechst 33342-excluding SP of ovarian cancer stem cells. Also disclosed herein, BCRP1 can confer ovarian cancer cell drug resistance-associated efflux of many lipophilic chemotherapeutic agents, such as for example mitoxantrone, daunorubicin, doxorubicin, indolcarbazole, and others (22). BCRP1 is known in the art under alias of ATP binding cassette transporter G2, placenta specific MDR, mxr1, abcg2, ATP binding cassette sub family g white member 2, cdw338, mitoxantrone resistance, breast cancer resistance, est157481, BCRP,

mgc102821, BCRP1, BMDP, ABC transporter, MRX, MRX, ABC15, ABCP, ATP binding cassette sub family g member 2, and for references purposes, the human BCRP1 nucleic acid sequence corresponds to RefSeq ID: NM\_004827 and Accession Number AF103796, which correspond to SEQ ID NO: 19 and is incorporated herein by reference. The amino acid sequence for BCRP1 is Accession No: NP\_004818.2 and corresponds to SEQ ID NO: 20.

**[0126]** As disclosed herein, the ovarian cancer stem cells have the ability to efflux lipophilic molecules, for example lipophilic dyes for example but not limited to Hoechst 33342. In another embodiment, methods for the identification, isolation and enrichment of populations of ovarian cancer stem cells comprises contacting a population of cells with a lipophilic dye, for example Hoechst 33342 and selecting for cells that do not take up the dye, or take up only a small amount of dye as compared to other cells. In such an embodiment, cells that do not comprise as much dye as compared to other, such as somatic non-stem cells are ovarian cancer stem cells.

**[0127]** As used herein, the present invention provides methods to enrich a population of ovarian cancer stem cells. In some embodiments, this encompasses enriching a population of ovarian cancer stem cells from a population of cells comprising ovarian cells. As used herein, the term “enriching” or “enrich for” are used interchangeably, and refers to increasing the population of cells of interest, for example ovarian cancer stem cells in a population of cells, for example increasing the percentage of ovarian cancer stem cells by about 10% or about 20% or about 30%, or about 40% or about 50% or about 60% or greater than 60% within the total population cells as compared to the starting population of cells.

### ***Isolating and enriching for populations of somatic ovarian stem cells***

**[0128]** As disclosed herein, the inventors have discovered a method to identify, isolate and enrich for populations of somatic ovarian stem cells, in particular coelomic ovarian stem cell

populations, subcoelomic/stromal ovarian stem cell populations and periphilar medullary ovarian stem cell populations, in addition to methods to identify and isolate ovarian cancer stem cell populations.

**[0129]** The inventors have discovered somatic coelomic ovarian stem cells are positive for the expression of surface marker proteins cytokeratin-8,  $\beta$ -catenin and E-cadherin, but negative expression for the surface marker protein EpCam. In contrast, the inventors also discovered that ovarian cancer stem cells are positive for surface marker protein EpCam, as well as positive for surface marker proteins cytokeratin-8,  $\beta$ -catenin and E-cadherin. Accordingly, the present invention provides methods to identify and enrich for populations of ovarian stem cells that are positive for cytokeratin-8,  $\beta$ -catenin and E-cadherin, which can be further characterized based on their expression profile for EpCam, where negative expression for the Epcam surface marker expression identifies the ovarian stem cell population as somatic coelomic ovarian stem cells, whereas positive expression for the Epcam surface marker identifies the ovarian stem cell population as ovarian cancer stem cells. Thus, in one embodiment, the present invention provides a method to identify, distinguish and enrich for a population of ovarian cancer stem cells from a population of coelomic ovarian stem cells by determining the expression of EpCam in a population of ovarian stem cells that express the surface markers cytokeratin-8,  $\beta$ -catenin and E-cadherin, wherein negative expression for EpCam identifies and can be used to enrich for ovarian stem cell populations such as coelomic ovarian stem cells, whereas positive expression for EpCam identifies and can be used to enrich for populations of ovarian cancer stem cells.

**[0130]** Encompassed in the methods of the present invention are methods for identification, isolation and enrichment of populations of somatic ovarian stem cells, such as coelomic ovarian stem cells using agents that are reactive to cytokeratin-8,  $\beta$ -catenin and E-cadherin and EpCam, for example agents reactive to the nucleic acids encoding cytokeratin-8,  $\beta$ -catenin and E-cadherin and EpCam, for example mRNA cytokeratin-8,  $\beta$ -catenin and E-cadherin and EpCam

and in another embodiment, agents are reactive to the expression products of the nucleic acid encoding cytokeratin-8,  $\beta$ -catenin and E-cadherin and EpCam, for example agent reactive to cytokeratin-8,  $\beta$ -catenin and E-cadherin and EpCam protein or fragments thereof are useful in the methods as disclosed herein.

**[0131]** In another embodiment encompasses methods for the identification, isolation and enrichment as well as distinguishing between ovarian cancer stem cell and coelomic ovarian stem cell populations, the methods comprising using conventional methods of using reporter genes operatively linked to the promoters of EpCam or homologues or variants thereof. In such embodiments, cells that express the surface markers cytokeratin-8,  $\beta$ -catenin and E-cadherin and also express the EpCam surface marker protein, the cells will also express the reporter gene operatively linked to the promoter of EpCam, and the expression of the reporter gene can be used to isolate, identify and enrich for ovarian cancer stem cells, whereas lack of expression of the reporter gene can be used to isolate, identify and enrich for somatic ovarian stem cells such as coelomic ovarian stem cells. In alternative embodiments, a different reporter gene can be expressed when the EpCam is not expressed, which can be used to identify and enrich for a population of somatic ovarian stem cells such as coelomic ovarian stem cells. In some embodiments, a reporter gene is expressed when EpCam is expressed, which can be used to isolate and identify and enrich for a population of ovarian cancer stem cells, and a different reporter gene, such as a different fluorescent reporter gene can be expressed when the EpCam is not expressed, which can be used to identify and enrich for a population of somatic ovarian stem cells such as coelomic ovarian stem cells.

**[0132]** Another aspect of the present invention relates to the discovery and identification of a subcoelomic or stromal ovarian stem cell population that are positive for the expression of surface marker cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD44, CD105, but negative for the expression of surface markers CD45 and CD31. In another embodiment encompasses methods for the

identification, isolation and enrichment of a population of subcoelomic/stromal ovarian stem cells, the methods comprising using conventional methods of using reporter genes operatively linked to the promoters of cKIT and/or  $\alpha$ SMA and/or PDGFRb and/or NG2 and/or CD44 and/or CD105 or homologues or variants thereof. In additional embodiments, a different reporter gene can be expressed when the CD45 and/or CD31 is not expressed, which can be used to identify and enrich for a population of somatic ovarian stem cells such as subcoelomic/stromal ovarian stem cells.

**[0133]** The inventors further discovered that a periphilar medullary ovarian stem cell population was characterized to have positive surface marker profiles for cKIT, SF-1, GATA-4, CD44, CD105, but negative for the expression CD45 and/or CD31 and/or  $\alpha$ SMA. In another embodiment encompasses methods for the identification, isolation and enrichment of a population of periphilar medullary ovarian stem cells, the methods comprising using conventional methods of using reporter genes operatively linked to the promoters of cKIT and/or SF-1 and/or GATA-4 and/or CD44 and/or CD105 or homologues or variants thereof. In additional embodiments, a different reporter gene can be expressed when the CD45 and/or CD31 and/or  $\alpha$ SMA are not expressed, which can be used to identify and enrich for a population of somatic ovarian stem cells such as periphilar medullary ovarian stem cells.

**[0134]** As used herein, the present invention provides methods to enrich a population of somatic ovarian stem cells, such as for example coelomic ovarian stem cells, subcoelomic/stromal ovarian stem cells and periphilar medullary ovarian stem cells. In some embodiments, this encompasses enriching a population of somatic ovarian stem cells from a population of cells comprising ovarian cells. As used herein, the term “enriching” or “enrich for” are used interchangeably, and refers to increasing the population of cells of interest, for example somatic ovarian stem cells in a population of cells, for example increasing the percentage of somatic ovarian stem cells by about 10% or about 20% or about 30%, or about 40% or about 50% or

about 60% or greater than 60% within the total population cells as compared to the starting population of cells.

**[0135]** Method to determine the expression of surface marker proteins as disclosed herein, such as for example but not limited to, BCRP1, cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4 are well known by persons skilled in the art and are encompassed for use in the methods of the present invention. Such methods of measuring gene expression of BCRP1 are well known in the art, and are commonly performed on using DNA or RNA collected from a biological sample of the cells, and can be performed by a variety of techniques known in the art, including but not limited to, PCR, RT-PCR, quantitative RT-PCR (qRT-PCR), hybridization with probes, northern blot analysis, in situ hybridization, microarray analysis, RNA protection assay, SAGE or MPSS. In some embodiments, the probes used to detect the nucleic acid expression of the marker genes can be nucleic acids (such as DNA or RNA) or nucleic acid analogues, for example peptide-nucleic acid (PNA), pseudocomplementary PNA (pcPNA), locked nucleic acid (LNA) or analogues or variants thereof.

**[0136]** In other embodiments, the expression of the markers can be detected at the level of protein expression. The detection of the presence of nucleotide gene expression of the markers, or detection of protein expression can be similarly analyzed using well known techniques in the art, for example but not limited to immunoblotting analysis, western blot analysis, immunohistochemical analysis, ELISA, and mass spectrometry. Determining the activity of the markers, and hence the presence of the markers can be also be done, typically by in vitro assays known by a person skilled in the art, for example Northern blot, RNA protection assay, microarray assay etc of downstream signaling pathways of BCRP1, cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4.. In particular embodiments, qRT-PCR can be conducted as ordinary qRT-PCR or as multiplex

qRT-PCR assay where the assay enables the detection of multiple markers simultaneously, for example BCRP1, MIS receptor Type II (MISR2), cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4, together or separately from the same reaction sample.

[0137] In some embodiments, conventional methods to isolate a particular stem cell of interest involve positive and negative selection using markers of interest. For example, agents can be used to recognize stem cell markers, for instance labeled antibodies that recognize and bind to BCRP1 protein on ovarian cancer stem cells can be used to separate and isolate the ovarian cancer stem cells from non-stem cell ovarian cancer cells using fluorescent activated cell sorting (FACS), panning methods, magnetic particle selection, particle sorter selection and other method known to persons skilled in the art, including density separation (Xu et al. (2002) *Circ. Res.* 91:501; U.S. patent application Ser. No. 20030022367); separation based on physical properties (Doevendans et al. (2000) *J. Mol. Cell. Cardiol.* 32:839-851). Alternatively, genetic selection methods can be used, where an ovarian cancer cell can be genetically modified to express a reporter protein operatively linked to a tissue-specific promoter and/or a specific gene promoter, therefore the expression of the reporter can be used for positive selection methods to isolate and enrich the desired cell, for example ovarian cancer stem cell. For example, a fluorescent reporter protein can be expressed in the desired stem cell by genetic modification to operatively link the marker protein to the promoter expressed in a desired stem cell (Klug et al. (1996) *J. Clin. Invest.* 98:216-224; U.S. Pat. No. 6,737,054). Other means of positive selection include drug selection, for instance such as described by Klug et al, supra, involving enrichment of desired cells by density gradient centrifugation. Negative selection can be performed and selecting and removing cells with undesired markers or characteristics, for example cells that do not express BCRP1 or non-stem cell markers for example fibroblast markers, epithelial cell markers etc.

[0138] One variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorogenic probe (i.e., TaqMan® probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held et al., *Genome Research* 6:986-994 (1996). Methods of real-time quantitative PCR using TaqMan probes are well known in the art. Detailed protocols for real-time quantitative PCR are provided, for example, for RNA in: Gibson et al., 1996, A novel method for real time quantitative RT-PCR. *Genome Res.*, 10:995-1001; and for DNA in: Heid et al., 1996, Real time quantitative PCR. *Genome Res.*, 10:986-994. TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700™ Sequence Detection System™ (Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700™ Sequence Detection System™. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data. 5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (Ct). To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a relatively constant level among different tissues, and is unaffected by

the experimental treatment. RNAs frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and  $\beta$ -actin.

**[0139]** In some embodiments, the systems for real-time PCR uses, for example, Applied Biosystems (Foster City, Calif.) 7700 Prism instrument. Matching primers and fluorescent probes can be designed for genes of interest using, for example, the primer express program provided by Perkin Elmer/Applied Biosystems (Foster City, Calif.). Optimal concentrations of primers and probes can be initially determined by those of ordinary skill in the art, and control (for example, beta-actin) primers and probes may be obtained commercially from, for example, Perkin Elmer/Applied Biosystems (Foster City, Calif.). To quantitate the amount of the specific nucleic acid of interest in a sample, a standard curve is generated using a control. Standard curves may be generated using the Ct values determined in the real-time PCR, which are related to the initial concentration of the nucleic acid of interest used in the assay. Standard dilutions ranging from  $10^{-1}$ - $10^{-6}$  copies of the gene of interest are generally sufficient. In addition, a standard curve is generated for the control sequence. This permits standardization of initial content of the nucleic acid of interest in a tissue sample to the amount of control for comparison purposes.

**[0140]** Other methods for detecting the expression of genes are well known in the art and disclosed in patent application WO2000/04194, incorporated herein by reference. In an exemplary method, the method comprises amplifying a segment of DNA or RNA (generally after converting the RNA to cDNA) spanning one or more known isoforms of BCRP1 gene sequences. This amplified segment is then subjected to a detection method, such as signal detection, for example fluorescence, enzymatic etc. and/or polyacrylamide gel electrophoresis. The analysis of the PCR products by quantitative mean of the test biological sample to a control sample indicates the presence or absence of the marker gene in the cardiovascular stem cell

sample. This analysis may also be performed by established methods such as quantitative RT-PCR (qRT-PCR).

**[0141]** The methods of RNA isolation, RNA reverse transcription (RT) to cDNA (copy DNA) and cDNA or nucleic acid amplification and analysis are routine for one skilled in the art and examples of protocols can be found, for example, in the *Molecular Cloning: A Laboratory Manual (3-Volume Set)* Ed. Joseph Sambrook, David W. Russell, and Joe Sambrook, Cold Spring Harbor Laboratory; 3rd edition (January 15, 2001), ISBN: 0879695773. Particularly useful protocol source for methods used in PCR amplification is *PCR (Basics: From Background to Bench)* by M. J. McPherson, S. G. Møller, R. Beynon, C. Howe, Springer Verlag; 1st edition (October 15, 2000), ISBN: 0387916008. Other methods for detecting expression of the marker genes by analyzing RNA expression comprise methods, for example but not limited to, Northern blot, RNA protection assay, hybridization methodology and microarray assay etc. Such methods are well known in the art and are encompassed for use in this invention.

**[0142]** Primers specific for PCR application can be designed to recognize nucleic acid sequence encoding BCRP1, are well known in the art. For purposes of a non-limiting example, the nucleic acid sequence encoding human BCRP1 can be identified by accession number: NM\_004827 and AF103796 (SEQ ID NO: 19). BCRP1 is also known as aliases; ATP-binding cassette, sub-family G member 2 (ABCG2), EST157481, MXR, BCRP, ABCP and CDw338.

**[0143]** Any suitable immunoassay format known in the art and as described herein can be used to detect the presence of and/or quantify the amount of BCRP1 expression by the ovarian cancer stem cell. In some embodiments, the invention provides methods of screening for the BCRP1 expression by immunohistochemical or immunocytochemical methods, typically termed immunohistochemistry (“IHC”) and immunocytochemistry (“ICC”) techniques. IHC is the application of immunochemistry on samples of tissue, whereas ICC is the application of

immunochemistry to cells or tissue imprints after they have undergone specific cytological preparations such as, for example, liquid-based preparations. Immunochemistry is a family of techniques based on the use of a specific antibody, wherein antibodies are used to specifically recognize and bind to target molecules on the inside or on the surface of cells, for example BCRP1. In some embodiments, the antibody contains a reporter or marker that will catalyze a biochemical reaction, and thereby bring about a change color, upon encountering the targeted molecules. In some instances, signal amplification may be integrated into the particular protocol, wherein a secondary antibody, that includes the marker stain, follows the application of a primary specific antibody. In such embodiments, the marker is an enzyme, and a color change occurs in the presence and after catalysis of a substrate for that enzyme.

**[0144]** Immunohistochemical assays are known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987).

Antibodies, polyclonal or monoclonal, can be purchased from a variety of commercial suppliers, or may be manufactured using well-known methods, e. g., as described in Harlow et al., *Antibodies: A Laboratory Manual*, 2nd Ed; Cold. Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988). In general, examples of antibodies useful in the present invention include anti-BCRP1. Such antibodies are commercially available and can be purchased, for example, from Sigma, US Biologicals, Novus Biologicals, MBL, Millipore, Santa Cruz Biotechnology and other commercially available sources. In some embodiments, any antibodies that recognize BCRP1 can be used by any persons skilled in the art, and from any commercial source. Alternatively, antibodies (monoclonal and polyclonal) can easily be produced by methods known to a person skilled in the art. In alternative embodiments, the antibody can be an antibody fragment, an analogue or variant of an antibody. Anti-BCRP1 antibodies are commercially available, for example but not limited to from Sigma, US Biologicals, Novus Biologicals, Santa Cruz Biotechnology, Molecular Biology Laboratories, Becton and Dickinson and Millipore.

**[0145]** In some embodiments, where BCRP1 is detected by immunohistochemistry, the ovarian cancer cells can be fixed by a suitable fixing agent such as alcohol, acetone, and paraformaldehyde prior to, during or after being reacted with (or probed) with an antibody. Conventional methods for immunohistochemistry are described in Harlow and Lane (Eds) (1988) In "Antibodies A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor, New York; Ausbel et al (Eds) (1987), in Current Protocols In Molecular Biology, John Wiley and Sons (New York, NY). Biological samples appropriate for such detection assays include, but are not limited to, cells, tissue biopsy, whole blood, plasma, serum, sputum, cerebrospinal fluid, breast aspirates, pleural fluid, urine and the like. For direct labeling techniques, a labeled antibody is utilized. For indirect labeling techniques, the sample is further reacted with a labeled substance. Alternatively, immunocytochemistry may be utilized. In general, cells are obtained from a patient and fixed by a suitable fixing agent such as alcohol, acetone, and paraformaldehyde, prior to, during or after being reacted with (or probed) with an antibody. Methods of immunocytological staining of biological samples, including human samples, are known to those of skill in the art and described, for example, in Brauer et al., 2001 (FASEB J, 15, 2689- 2701), Smith Swintosky et al., 1997. Immunological methods of the present invention are advantageous because they require only small quantities of biological material, such as a small quantity of cardiovascular stem cells. Such methods may be done at the cellular level and thereby necessitate a minimum of one cell.

**[0146]** In some embodiments, cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e.g., using radioisotopes, enzymes, fluorescers, chemilumescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e.g., biotin

with horseradish peroxidase-conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e.g. fluorescein, rhodamine, Texas red, etc.) The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods can of qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.

**[0147]** In a different embodiment, antibodies and antibody derivatives or fragments thereof that are used to identify markers on ovarian cancer cells, for example antibodies that recognize BCRP1 protein can bind to at least one epitope or more epitopes and can be detected using analytical techniques, such as by protein dot blots, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), or any other gel system that separates proteins, with subsequent visualization of the marker (such as Western blots), gel filtration, affinity column purification; morphologically, such as fluorescent-activated cell sorting (FACS), staining with dyes that have a specific reaction with a marker molecule (such as ruthenium red and extracellular matrix molecules), specific morphological characteristics; and biochemically, such as assaying for an enzymatic product or intermediate, or the overall composition of a cell, such as the ratio of protein to lipid, or lipid to sugar, or even the ratio of two specific lipids to each other, or polysaccharides. If such a marker is a morphological and/or functional trait or characteristic, suitable methods include visual inspection using, for example, the unaided eye, a stereomicroscope, a dissecting microscope, a confocal microscope, or an electron microscope are encompassed for use in the invention. The invention also contemplates methods of analyzing the progressive or terminal differentiation of a cell employing a single marker, as well as any combination of molecular and/or non-molecular markers.

**[0148]** Various methods can be utilized for quantifying the presence of the BCRP1 protein or nucleic acid expression. For measuring the amount of a molecule that is present, a convenient method is to label a molecule with a detectable moiety, which may be fluorescent, luminescent, radioactive, enzymatically active, etc., particularly a molecule specific for binding to the parameter with high affinity. Fluorescent moieties are readily available for labeling virtually any biomolecule, structure, or cell type. Immunofluorescent moieties can be directed to bind not only to specific proteins but also specific conformations, cleavage products, or site modifications like phosphorylation. Individual peptides and proteins can be engineered to autofluoresce, e.g. by expressing them as green fluorescent protein chimeras inside cells (for a review see Jones et al. (1999) Trends Biotechnol. 17(12):477-81). Thus, antibodies can be genetically modified to provide a fluorescent dye as part of their structure. Depending upon the label chosen, parameters may be measured using other than fluorescent labels, using such immunoassay techniques as radioimmunoassay (RIA) or enzyme linked immunosorbance assay (ELISA), homogeneous enzyme immunoassays, and related non-enzymatic techniques. The quantitation of nucleic acids, especially messenger RNAs, is also of interest as a parameter. These can be measured by hybridization techniques that depend on the sequence of nucleic acid nucleotides. Techniques include polymerase chain reaction methods as well as gene array techniques. See Current Protocols in Molecular Biology, Ausubel et al., eds, John Wiley & Sons, New York, N.Y., 2000; Freeman et al. (1999) Biotechniques 26(1):112-225; Kawamoto et al. (1999) Genome Res 9(12):1305-12; and Chen et al. (1998) Genomics 51(3):313-24, for examples.

**[0149]** Also encompassed for use in this invention, is the isolation and enrichment of a population of ovarian cancer stem cells as disclosed herein by the use of introduced reporter genes that aids with the identification of ovarian cancer stem cells and/or somatic ovarian stem cells as disclosed herein, for example coelomic ovarian stem cell populations, subcoelomic/stromal

ovarian stem cell populations and periphilar medullary ovarian stem cell populations. As an exemplary example only, ovarian cancer stem cells can be genetically engineered to express a construct comprising a reporter gene which can be used for selection and identification purposes. For example, the ovarian cell is genetically modified to comprise a reporter gene, for example but not limited to a fluorescent protein, enzyme or resistance gene, which is operatively linked to a BCRP1 promoter or fragment thereof. In such an embodiment, when the cell expresses the gene to which the reporter of interest is operatively linked, for example when the cell expresses BCRP1, it will express the reporter gene, for example the enzyme, fluorescent protein or resistance gene. Cells that express the reporter gene can be readily detected and in some embodiments positively selected for cells comprising the reporter gene or the gene product of the reporter gene. Other reporter genes that can be used include fluorescent proteins, luciferase, alkaline phosphatase, lacZ, or CAT.

**[0150]** In another embodiment encompasses methods for the identification, isolation and enrichment as well as distinguishing between ovarian cancer stem cells and coelomic ovarian stem cells, the methods comprising using conventional methods of using reporter genes operatively linked to the promoters of EpCam or homologues or variants thereof. In such embodiments, cells that express the surface markers cytokeratin-8,  $\beta$ -catenin and E-cadherin and also express the EpCam surface marker protein, the cells will also express the reporter gene operatively linked to the promoter of EpCam, and the expression of the reporter gene can be used to isolate, identify and enrich for a population of ovarian cancer stem cells, whereas lack of expression of the reporter gene can be used to isolate, identify and enrich for a population of somatic ovarian stem cells such as coelomic ovarian stem cells. In alternative embodiments, a different reporter gene can be expressed when the EpCam is not expressed, which can be used to identify and enrich for somatic ovarian stem cells such as coelomic ovarian stem cells. In some embodiments, a reporter gene is expressed when EpCam is expressed which can be used

to isolate, identify and enrich a population of ovarian cancer stem cells, and a different reporter gene such as a different fluorescent reporter gene can be expressed when the EpCam is not expressed, which can be used to identify and enrich for somatic ovarian stem cells such as coelomic ovarian stem cells, thus enabling enrichment of populations of somatic ovarian stem cells and ovarian cancer stem cells within different or the same starting population of cells.

**[0151]** In some embodiments, the cells expressing these reporters could be easily purified by FACS, antibody affinity capture, magnetic separation, or a combination thereof. The purified or substantially pure reporter-expressing cells can be used for genomic analysis by techniques such as microarray hybridization, SAGE, MPSS, or proteomic analysis to identify more markers that characterize the ovarian cancer stem cells. These methods can be used to identify genes expressed by ovarian cancer stem cells and genes important in the self-renewal property of ovarian cancer stem cells. In other embodiments, the reporter gene can be a fluorescent protein, for examples but not limited to; green fluorescent protein (GFP); green fluorescent-like protein (GFP-like); yellow fluorescent protein (YFP); blue fluorescent protein (BFP); enhanced green fluorescent protein (EGFP); enhanced blue fluorescent protein (EBFP); cyan fluorescent protein (CFP); enhanced cyan fluorescent protein (ECFP); red fluorescent protein (dsRED); and modifications and fragments thereof.

**[0152]** In some embodiments, methods to remove unwanted cells are encompassed, by removing unwanted cells by negative selection. For example, unwanted antibody-labeled cells are removed by methods known in the art, such as labeling a cell population with an antibody or a cocktail of antibodies, to a cell surface protein and separation by FACS or magnetic colloids. In an alternative embodiment, the reporter gene may be used to negatively select non-desired cells, for example a reporter gene is expressed by cells not expressing BCRP1 and the reporter gene encodes a cytotoxic protein in cells that are not desired. In such an embodiment, the reporter


gene is operatively linked to a regulatory sequence of a gene normally expressed in the cells with undesirable phenotype.

### *Methods of treatment*


[0153] The present invention relates generally to a method of preventing and/or treating ovarian cancer in a subject, where the ovarian cancer comprises ovarian cancer stem cells as identified by the methods as disclosed herein. In some embodiments, the methods of the present invention comprise administration of an effective amount of MIS or a derivative or fragment thereof to a subject with ovarian cancer, where cancer comprises ovarian cancer stem cells. For example, an effective amount of MIS or a homologue or variant or analogue thereof is administered to a subject with ovarian cancer, wherein the subject is identified to have ovarian cancer comprising ovarian cancer stem cells using the methods as disclosed herein. In some embodiments, administration of MIS to a subject is a MIS protein, for example as disclosed in U.S. Patents 5,661,125 and 6,673,352 which are specifically incorporated herein in their entirety by reference. Accordingly, by using the methods of the present invention, one can treat and/or prevent the progression or occurrence of ovarian cancer in a subject wherein the ovarian cancer comprises ovarian cancer stem cells. In some embodiments, the cancer is recurrent ovarian cancer. In some embodiments, where the subject is identified as having ovarian cancer comprising ovarian cancer stem cells, the subject is administered a pharmaceutical composition comprising a BCRP1 inhibitor, for example a verapamil. In some embodiments, where the subject is identified as having ovarian cancer comprising ovarian cancer stem cells, the subject is administered a pharmaceutical composition comprising a BCRP1 inhibitor and/or MIS or a derivative or fragment or variant thereof.

[0154] Inhibitors of BCRP1 are commonly known by one of ordinary skill in the art, for example but not limited to verapamil, Reserpine, CI1033, GF120918, FTC, ko138, P-gp and analogues


and derivatives thereof, as disclosed in Allen et al, Mol Cancer Therapeutics, 2002; 1:427-434, which is incorporated herein in its entirety by reference. The chemical structures of GF120918, FTC (Fumitremorgin) and ko138 are as follows:



GF120918



Fumitremorgin C



Ko134

**[0155]** In some embodiments, the MIS is a MIS protein, for example recombinant human MIS (rhMIS). In such embodiments, MIS or rhMIS can be prepared and administered, in any form, by any method known by persons of ordinary skill in the art, for example as disclosed in International Patent Application WO92/18152 and European Patent EP584287 and also disclosed in patent Applications WO94/00133 and EP221761, which are incorporated herein in their entirety by reference.

**[0156]** In certain embodiments, the endogenous compounds are isolated and/or purified or substantially purified by one or more purification methods described herein or known by those skilled in the art. Generally, the purities are at least 90%, in particular 95% and often greater than 99%.

**[0157]** As used herein, the term ovarian cancer is used to refer to, for example cervical cancer and ovarian cancer. In some embodiments, the ovarian cancer is vulvar epidermal carcinoma, cervical carcinoma, endometrial adenocarcinoma or ovarian adenocarcinoma.

**[0158]** In another embodiment, the methods as disclosed herein also contemplates the administration of MIS to a subject identified with ovarian cancer comprising cancer stem cells in conjunction with other therapies such as conventional chemotherapy, radiotherapy, hormone therapy, immunotherapy, thermotherapy and surgery directed against solid tumors and for control of establishment of metastases. The administration of the compounds described herein is typically conducted prior to and/or at the same time and/or after such additional therapies, although it is also encompassed within the present invention to administer a pharmaceutical composition comprising, for example MIS or a variant or derivative thereof, and/or an inhibitor of BCRP1 at the same time or at times where the ovarian tumor tissue will be responding to a toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. In addition, the pharmaceutical compositions of the invention for the treatment of ovarian cancer comprising ovarian cancer stem cells can be administered prophylactically and/or before the development of a tumor, if the subject has been identified as to have a risk of developing cancer, for example to subjects that are positive for biomarkers of ovarian cancer cells or tumors. Insofar as the present methods apply to inhibition of ovarian cancer stem cells, the methods can also apply to inhibition of ovarian cancer tissue growth, to inhibition of ovarian cancer metastases formation, and to regression of established ovarian cancer tumors.

**[0159]** The effective amount may vary depending upon criteria such as the age, weight, physical condition, past medical history, and sensitivity of the recipient. The effective amount will also vary depending on whether administration is oral, intravenous, intramuscular, subcutaneous, local, or by direct application to the tumor. In the case of direct tumor application, it is preferable that a final serum concentration of at least 0.1 nM, preferably about 0.1-1.0 nM, of MIS be achieved. Effective individual dosage through the additionally named means of administration can be readily determined by methods well known to those of ordinary skill in

the art. For example, using the size ratio calculation as detailed above, one of ordinary skill in the art can determine optimal dosage levels for any means of administration. In treating a patient, it is preferable to achieve a serum level of at least 10 ng/ml of MIS.

**[0160]** Compositions containing MIS or its functional derivatives may be administered orally, intravenously, intramuscularly, subcutaneously, or locally. Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved by the use of polymers to complex or adsorb MIS or its functional derivatives. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, and protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release.

**[0161]** Another possible method to control the duration of action by controlled release preparations is to incorporate MIS into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinyl acetate copolymers. Alternatively, instead of incorporating MIS into these polymeric particles, it is possible to entrap MIS in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly(methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such teachings are disclosed in Remington's Pharmaceutical Sciences, supra (1980).

**[0162]** Pharmaceutical compositions which include the proteolytically cleaved MIS protein fragments of this invention can also include chemotherapeutic agents which are known to inhibit tumor growth in a human or animal. The chemotherapeutic agent included in this composition can be directed to any specific neoplastic disease. Such agents are described in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press,

New York, N.Y., 1985. It is preferred, however, that the chemotherapeutic agent inhibits the growth of the tumors of this invention.

**[0163]** In some embodiments the subject identified to have ovarian cancer comprising ovarian cancer stem cells can be administered other therapies, for example but not limited to chemotherapeutic agents. In some embodiments, the chemotherapeutic agent is a BCRP1 protein inhibitor, for example but not limited to verapamil.

**[0164]** In alternative embodiments, the subject is administered other chemotherapeutic agents, for example paclitaxel, chemotherapeutic agents are paclitaxel, cisplatin, doxorubicin, rapamycin. Also included as chemotherapeutic agents in the pharmaceutical compositions of this invention are nitrogen mustards such as cyclophosphamide, ifosfamide, and melphalan; ethylenimines and methylmelamines such as hexamethylmelamine and thiotepa; pyrimidine analogs such as fluorouracil and fluorodeoxyuridine; vinca alkaloids such as vinblastine; epipodophyllotoxins such as etoposide and teniposide; antibiotics such as actinomycin D, doxorubicin, bleomycin, and mithramycin; biological response modifiers such as interferon; platinum coordination complexes such as cisplatin and carboplatin; estrogens such as diethylstilbestrol and ethinyl estradiol; antiandrogens such as flutamine; and gonadotropin releasing hormone analogs such as leuprolide. Other compounds such as decarbazine, nitrosoureas, methotrexate, diticene, and procarbazine are also effective. Of course, other chemotherapeutic agents which are known to those of ordinary skill in the art can readily be substituted as this list should not be considered exhaustive or limiting.

**[0165]** It is to be understood that the use of the term "equivalent effective amount" does not necessarily mean an equivalent weight or volume quantity, but represents the quantity of MIS that offers an equal inhibition to tumor growth. This may have to be evaluated on a patient by patient case, but can be determined, for example, by comparing quantities that achieve equal size reduction ratios as defined above. Typically, chemotherapeutic agents which can be

combined with MIS for treatment of the tumors of this invention will be effective between about 0.001 and 10.0 mg/kg body weight of the patient. Administration of the combination of MIS and chemotherapeutic agent can be accomplished in the same manner as administration of the MIS alone.

**[0166]** In some embodiments, the methods as disclosed herein provide for the parenteral and oral administration of the compounds of the present invention, in combination with other pharmaceutical compositions to subjects in need of such treatment. Parenteral administration includes, but is not limited to, intravenous (IV), intramuscular (IM), subcutaneous (SC), intraperitoneal (IP), intranasal, and inhalant routes. In the method of the present invention, the resolvins and/or protectins or analogs thereof are preferably administered orally. IV, IM, SC, and IP administration may be by bolus or infusion, and may also be by slow release implantable device, including, but not limited to pumps, slow release formulations, and mechanical devices. The formulation, route and method of administration, and dosage will depend on the disorder to be treated and the medical history of the subject. In general, a dose that is administered by subcutaneous injection will be greater than the therapeutically-equivalent dose given intravenously or intramuscularly.

**[0167]** The methods as disclose herein for treating ovarian cancer comprising ovarian cancer stem cells comprising contacting a tissue in which tumor is occurring, or is at risk for occurring, with the compositions of the present invention comprising a therapeutically effective amount of MIS or derivatives or analogues thereof.

**[0168]** In some embodiments, the subject treated by the methods of the present invention in its many embodiments is a human subject, although it is to be understood that the principles of the invention indicate that the invention is effective with respect to all mammals. In this context, a mammal is understood to include any mammalian species in which treatment of diseases

associated with cancer or a proliferative-related disorder is desirable, particularly agricultural and domestic mammalian species, as well as transgenic animals.

***Administration of Pharmaceutical compositions***

**[0169]** A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

**[0170]** After formulation with an appropriate pharmaceutically acceptable carrier in a desired dosage, the pharmaceutical compositions of this invention can be administered to a subject. The pharmaceutical compositions of this invention can be administered to a subject using any suitable means. In general, suitable means of administration include, but are not limited to, topical, oral, parenteral (e.g., intravenous, subcutaneous or intramuscular), rectal, intracisternal, intravaginal, intraperitoneal, ocular, or nasal routes.

**[0171]** The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

**[0172]** The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

[0173] In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.

[0174] The pharmaceutical compositions of the invention include a "therapeutically effective amount" or a "prophylactically effective amount" of one or more of the compounds of the present invention, or derivatives thereof. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, e.g., a diminishment or prevention of effects associated with ovarian cancer, wherein the cancer comprises ovarian cancer stem cells. A therapeutically effective amount of MIS of the present invention or derivatives thereof may vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the therapeutic compound to elicit a desired response in the subject. A therapeutically effective amount is also one in which any toxic or detrimental effects of the therapeutic agent are outweighed by the therapeutically beneficial effects.

[0175] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to, or at an earlier stage of disease, the prophylactically effective amount may be less than the therapeutically effective amount. A prophylactically or therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the beneficial effects.

[0176] Dosage regimens may be adjusted to provide the optimum desired response (e.g. a therapeutic or prophylactic response). For example, a single bolus may be administered, several

divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigency of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the patient.

**[0177]** The term “dosage unit” as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in subjects.

**[0178]** The therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in other subjects. Generally, the therapeutically effective amount is sufficient to reduce or inhibit cell proliferation in a subject suffering from a proliferative disorder, for example cancer. In some embodiments, the therapeutically effective amount is sufficient to eliminate the proliferative cells, for example eliminate the cancer cells and/or tumor in a subject suffering cancer and/or a proliferative disease.

**[0179]** The efficacy and toxicity of the compound can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose is effective in 50% of

the population) and LD50 (the dose is lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred.

**[0180]** These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.

**[0181]** Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject.

**[0182]** The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

**[0183]** Pharmaceutical Compositions

[0184] In another embodiment of the invention, pharmaceutical compositions containing one or more compounds of this invention are disclosed. For purpose of administration, in some embodiments MIS or derivatives, fragments or variants or analogues thereof and/or inhibitors of BCRP1 are formulated as a pharmaceutical composition. Pharmaceutical compositions of the present invention comprise a compound of this invention and a pharmaceutically acceptable carrier, wherein the compound is present in the composition in an amount which is effective to treat the condition of interest.

[0185] Pharmaceutically acceptable carriers are familiar to those skilled in the art. For compositions formulated as liquid solutions, acceptable carriers include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a compound of this invention, diluents, dispersing and surface active agents, binders, and lubricants. One skilled in this art may further formulate the compounds of this invention in an appropriate manner, and in accordance with accepted practices, such as those disclosed in *Remington's Pharmaceutical Sciences*, Gennaro, Ed., Mack Publishing Co., Easton, Pa. 1990.

[0186] While it is possible to administered MIS and derivatives and fragments alone and/or inhibitors of BCRP1 alone, it is preferable to administer MIS and/or inhibitors of BCRP1 as pharmaceutical compositions.

[0187] Formulations of the invention can be prepared by a number or means known to persons skilled in the art. In some embodiments the formulations can be prepared by combining (i) MIS and derivatives fragments, variants and analogues thereof, and/or inhibitors of BCRP1 in an amount sufficient to provide a plurality of therapeutically effective doses; (ii) the water addition in an amount effective to stabilize each of the formulations; (iii) the propellant in an amount sufficient to propel a plurality of doses from an aerosol canister; and (iv) any further optional components e.g. ethanol as a co-solvent; and dispersing the components. The components can

be dispersed using a conventional mixer or homogenizer, by shaking, or by ultrasonic energy. Bulk formulation can be transferred to smaller individual aerosol vials by using valve to valve transfer methods, pressure filling or by using conventional cold-fill methods. It is not required that a stabilizer used in a suspension aerosol formulation be soluble in the propellant. Those that are not sufficiently soluble can be coated onto the drug particles in an appropriate amount and the coated particles can then be incorporated in a formulation as described above.

**[0188]** The compositions of the present invention can be in any form. These forms include, but are not limited to, solutions, suspensions, dispersions, ointments (including oral ointments), creams, pastes, gels, powders (including tooth powders), toothpastes, lozenges, salve, chewing gum, mouth sprays, pastilles, sachets, mouthwashes, aerosols, tablets, capsules, transdermal patches, that comprise one or more of the compounds of the present invention, and/or their derivatives thereof for oral or subcutaneous administration..

**[0189]** In certain embodiments, the compounds of the present invention, for MIS or derivatives or variants thereof are administered to a subject as a pharmaceutical composition with a pharmaceutically acceptable carrier. In certain embodiments, these pharmaceutical compositions optionally further comprise one or more additional therapeutic agents. In certain embodiments, the additional therapeutic agent or agents are anti-cancer agents. In some embodiments, the therapeutic agents are chemotherapeutic agents, for example but not limited to, cisplatin, paxicital etc. In some embodiments, the therapeutic agents are radiotherapeutic agents. Examples of chemotherapeutic agents in the pharmaceutical compositions of this invention are, for example nitrogen mustards such as cyclophosphamide, ifosfamide, and melphalan; ethylenimines and methylmelamines such as hexamethylmelamine and thiotepa; pyrimidine analogs such as fluorouracil and fluorodeoxyuridine; vinca alkaloids such as vinblastine; epipodophyllotoxins such as etoposide and teniposide; antibiotics such as actinomycin D, doxorubicin, bleomycin, and mithramycin; biological response modifiers such

as interferon, platinum coordination complexes such as cisplatin and carboplatin; estrogens such as diethylstilbestrol and ethinyl estradiol; antiandrogens such as flutamine; and gonadotropin releasing hormone analogs such as leuprolide. Other compounds such as decarbazine, nitrosoureas, methotrexate, diticene, and procarbazine are also effective and encompassed for use in the methods of the present invention. Of course, other chemotherapeutic agents which are known to those of ordinary skill in the art can readily be substituted as this list should not be considered exhaustive or limiting.

**[0190]** In some embodiments the pharmaceutical composition comprises MIS and/or derivatives thereof, alone or in any plurality of combinations. In other embodiments, the pharmaceutical compositions optionally further comprise one or more additional therapeutic agents including but not limited to paxicital, paxicital derivatives, cisplatin and cisplatin derivative, and interferons.

**[0191]** In some embodiments, the methods of the present invention are directed to use of MIS and variants and derivatives thereof with other therapeutic agents, for example chemotherapy agents, wherein the chemotherapy agents, for example verapamil.

**[0192]** The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it can perform its intended function. The term "pharmaceutically acceptable carriers" is intended to include all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and

not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.

**[0193]** In certain embodiments, the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts, esters, amides, and prodrugs as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use of the compounds of the invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention.

**[0194]** These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations

including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example, Berge S. M., et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19 which is incorporated herein by reference).

**[0195]** The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. The term is further intended to include lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl and propyl esters.

**[0196]** As used herein, "pharmaceutically acceptable salts or prodrugs" are salts or prodrugs that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subject without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. These compounds include the zwitterionic forms, where possible, of compounds of the invention.

**[0197]** The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylanunonium, tetraethyl ammonium, methyl amine, dimethyl amine, trimethylamine,

triethylamine, ethylamine, and the like (see, e.g., Berge S. M., et al. (1977) *J. Pharm. Sci.* 66, 1, which is incorporated herein by reference).

**[0198]** The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the compounds of the invention, for example MIS and/or BCRP inhibitor as disclosed herein, by hydrolysis in blood. A thorough discussion is provided in T. Higachi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in *Bioreversible Carriers in: Drug Design*, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference. As used herein, a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound. The prodrug may be designed to alter the metabolic stability or the transport characteristics of a compound, to mask side effects or toxicity, to improve the flavor of a compound or to alter other characteristics or properties of a compound. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, once a pharmaceutically active compound is identified, those of skill in the pharmaceutical art generally can design prodrugs of the compound (see, e.g., Nogrady (1985) *Medicinal Chemistry A Biochemical Approach*, Oxford University Press, N.Y., pages 388-392). Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Suitable examples of prodrugs include methyl, ethyl and glycerol esters of the corresponding acid.

**[0199]** In other embodiments of the present invention, MIS and derivatives thereof and/or BCRP inhibitors are conjugated or covalently attached to another targeting agent to increase the specificity of MIS and derivatives thereof and/or BCRP inhibitors targeting the cell, for example an ovarian cancer stem cell. Targeting agents can include, for example without limitation, antibodies, cytokines and receptor ligands. In some embodiments, the targeting agent

is overexpressed on the cells to be targeted, for example the cancer cells as compared to normal cells. In alternative embodiments, the MIS and derivatives thereof and/or BCRP inhibitors can be conjugated or covalently attached to compounds that elicit an immune response, such as for example but without limitation, cytokines.

**[0200]** In some embodiments, MIS and derivatives thereof of the present invention can be conjugated to, by covalent linkage or any other means, to another agent, for example chemotherapy agents for example BCRP1 inhibitors. In some embodiments, MIS and derivatives thereof, and/or BCRP inhibitors of the present invention can be conjugated to a targeting moiety, for example an ovarian cancer cell targeting moiety to target the MIS and/or BCRP inhibitors to ovarian cancer stem cell. Such targeting moieties and methods are well known by persons of ordinary skill in the art and are encompassed for use in the methods of the present invention. In some embodiments, the targeting moiety is a moiety that interacts with BCRP1 present on the exterior of ovarian cancer stem cells. In some embodiments, the conjugation may be a permanent or reversible conjugation.

**[0201]** Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

**[0202]** Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfate, sodium sulfite and the like; oil- soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

**[0203]** Formulations of the present invention include those suitable for intravenous, oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration. The

formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

**[0204]** Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

**[0205]** Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.

**[0206]** In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption

accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

**[0207]** A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

**[0208]** The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a

certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. In one aspect, a solution of resolvin and/or protectin or precursor or analog thereof can be administered as eye drops for ocular neovascularization or ear drops to treat otitis.

**[0209]** Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.

**[0210]** In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

**[0211]** Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

**[0212]** In some instances, pharmaceutical compositions comprising the resolvins and protectins of the invention for the administration of angiogenesis may be in a formulation suitable for rectal or vaginal administration, for example as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or

carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore release the active compound. Suitable carriers and formulations for such administration are known in the art.

**[0213]** Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

**[0214]** The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

**[0215]** Transdermal patches have the added advantage of providing controlled delivery of the compounds (resolvins and/or protectins and/or precursors or analogues thereof) of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.

**[0216]** Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions,

suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[0217] Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0218] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[0219] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

**[0220]** Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide- polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

**[0221]** Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of ordinary skill in the art.

**[0222]** Remington's Pharmaceutical sciences Ed. Germany, Merk Publishing, Easton, PA, 1 995 (the contents of which are hereby incorporated by reference), discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; malt; gelatin; talc; excipients such as cocoa butter and: suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide;; water; isotonic saline; Ringer's solution, ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium sulfate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

*Uses of the ovarian cancer stem cells*

**[0223]** In some embodiments, ovarian cancer stem cells and somatic ovarian stem cells as disclosed herein can be isolated and enriched using the methods as disclosed herein, for example purified by FACS, antibody affinity capture, magnetic separation, or a combination thereof using the surface markers as disclosed herein, such as, but not limited to, BCRP1 expression, cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1, GATA-4 and MISRII expression and/or lipophilic dye exclusion. The purified or substantially pure ovarian cancer stem cells and/or somatic ovarian stem cells can be used for genomic analysis by techniques such as microarray hybridization, SAGE, MPSS, or proteomic analysis to identify more markers that characterize the ovarian cancer stem cell populations and/or somatic ovarian stem cell populations.

**[0224]** One aspect of the present invention relates to an assay to identify agents that reduce the self-renewal capacity of an ovarian cancer stem cell as compared to somatic ovarian stem cells such as coelomic ovarian stem cell populations and/or subcoelomic/stromal ovarian stem cell populations and periphilar medullary ovarian stem cell populations. In some embodiments, the assay involves contacting an ovarian cancer stem cell with an agent, and measuring the proliferation of the ovarian cancer cell, whereby an agent that decreases the proliferation as compared to a reference agent or absence of an agent identifies an agent that inhibits the self-renewal capacity of the ovarian cancer stem cell. Such an agent can be used for development of therapies for the treatment of ovarian cancer. In some embodiments, the assay can encompass comparing the results of the rate of proliferation of a somatic ovarian stem population, for example a coelomic ovarian stem cell population in the presence of the same agent, where an agent useful for selection as a therapy for the treatment of ovarian cancer in a subject is an agent that inhibits the self-renewal capacity of a population of ovarian cancer stems to a greater

extent, for example greater than 10%, or greater than about 20%, or greater than 30% as compared to the ability of the agent to inhibit the self-renewal capacity of a population of somatic ovarian stem cells, for example a coelomic ovarian stem cell population.

[0225] Also encompassed in the present invention is use of the ovarian cancer stem cells and somatic ovarian stem cells as disclosed herein in assays to identify agents which kill and/or decrease the rate of proliferation of ovarian cancer stem cells. In some embodiments, such an assay can comprising both a population of ovarian cancer stem cells and a population of somatic ovarian stem cells, for example coelomic ovarian stem cell and/or subcoelomic/stromal ovarian stem cells and/or periphilar medullary ovarian stem cells, but preferably coelomic ovarian stem cells and adding to the media of the population of ovarian cancer stem cells and to the population of somatic ovarian stem cells one or more of the same agents. Once can measure and compare the rate of proliferation of the population of ovarian cancer stem cells and the population of somatic ovarian stem cells using the methods as disclosed herein, for example the MTT assay or CFU assay, and an agent identified to decrease the rate of proliferation and/or attenuate proliferation by about 10%, or about 20% or about 30% or greater than 30% and/or kill about 10% or about 20% or about 30% or greater than 30% of the population of ovarian cancer stem cells as compared to a population of somatic ovarian stem cells identifies an agent that is useful for a therapy for the treatment of ovarian cancer. Effectively, the assay as disclosed herein can be used to identify agents that selectively inhibit the ovarian cancer stem cells as compared to coelomic ovarian stem cell population. Agents useful in such an embodiment can be any agent as disclosed herein under the term "agent" in the definitions section, and can be for example nucleic acid agents, such as RNAi agents (RNA interference agents), nucleic acid analogues, small molecules, proteins, peptiomimetics, antibodies, peptides, aptamers, ribozymes, and variants, analogues and fragments thereof.

**[0226]** In further embodiments, the ovarian cancer stem cells and somatic ovarian stem cells identified using the methods as disclosed herein can be used in assay to for the study and understanding of signalling pathways of cancer stem cells. The use of ovarian cancer stem cell and somatic ovarian stem cells of the present invention is useful to aid the development of therapeutic applications for ovarian cancers. The use of such ovarian cancer stem cells identified using the methods as disclosed herein enable the study of ovarian cancers. For example, the ovarian cancer stem cells can be used for generating animal models of ovarian cancer as described in the Examples herein, which can be used for an assay to test for therapeutic agents that inhibit the proliferation of ovarian cancer stem cells. Such a model is also useful in aiding the understanding of ovarian cancer stem cells in the development of ovarian cancer.

**[0227]** The ovarian cancer stem cells can be used to identify additional markers that characterize them as ovarian cancer stem cells as compared to non-stem ovarian cancer cells and/or somatic ovarian stem cells, such as coelomic ovarian stem cell populations and/or subcoelomic/stromal ovarian stem cell populations and periphilar medullary ovarian stem cell populations. Such markers can be cell-surface markers or surface markers or other markers, for example mRNA or protein markers intracellular within the cell. Such markers can be used as additional agents in the diagnosis of ovarian cancer stem cells in subjects with ovarian cancers.

**[0228]** In further embodiments, the ovarian cancer stem cells and somatic ovarian stem cells as disclosed herein can be used to prepare antibodies that are specific markers of ovarian cancer stem cells and somatic ovarian stem cells as disclosed herein. Polyclonal antibodies can be prepared by injecting a vertebrate animal with cells of this invention in an immunogenic form. Production of monoclonal antibodies is described in such standard references as U.S. Pat. Nos. 4,491,632, 4,472,500 and 4,444,887, and Methods in Enzymology 73B:3 (1981). Specific antibody molecules can also be produced by contacting a library of immunocompetent cells or

viral particles with the target antigen, and growing out positively selected clones. See Marks et al., *New Eng. J. Med.* 335:730, 1996, and McGuinness et al., *Nature Biotechnol.* 14:1449, 1996.

A further alternative is reassembly of random DNA fragments into antibody encoding regions, as described in EP patent application 1,094,108 A.

**[0229]** The antibodies in turn can be used as diagnostic applications to identify a subject with ovarian cancer comprising ovarian cancer stem cells, or alternatively, antibodies can be used as therapeutic agents to prevent the proliferation and/or kill the ovarian cancer stem cells.

**[0230]** In another embodiment, the ovarian cancer stem cells and somatic ovarian stem cells as disclosed herein can be used to prepare a cDNA library of relatively uncontaminated with cDNAs that are preferentially expressed in ovarian cancer stem cells as compared to somatic ovarian stem cells and/or non-stem cells ovarian cancer cells. For example, ovarian cancer stem cells and/or somatic ovarian stem cells are collected and then mRNA is prepared from the pellet by standard techniques (Sambrook et al., *supra*). After reverse transcribing the cDNA, the preparation can be subtracted with cDNA from, for example non-stem cell ovarian cancer cells or non-cancer ovarian cells in a subtraction cDNA library procedure. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, hybridization to a microarray, in situ hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA. One of skill in the art can readily use these methods to determine differences in the molecular size or amount of mRNA transcripts between two samples.

**[0231]** Any suitable method for detecting and comparing mRNA expression levels in a sample can be used in connection with the methods of the invention. For example, mRNA expression levels in a sample can be determined by generation of a library of expressed sequence tags (ESTs) from a sample. Enumeration of the relative representation of ESTs within the library can be used to approximate the relative representation of a gene transcript within the starting sample.

The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein.

**[0232]** Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (Velculescu et al., *Science* (1995) 270:484). In short, SAGE involves the isolation of short unique sequence tags from a specific location within each transcript. The sequence tags are concatenated, cloned, and sequenced. The frequency of particular transcripts within the starting sample is reflected by the number of times the associated sequence tag is encountered with the sequence population.

**[0233]** Gene expression in a test sample can also be analyzed using differential display (DD) methodology. In DD, fragments defined by specific sequence delimiters (e.g., restriction enzyme sites) are used as unique identifiers of genes, coupled with information about fragment length or fragment location within the expressed gene. The relative representation of an expressed gene with a sample can then be estimated based on the relative representation of the fragment associated with that gene within the pool of all possible fragments. Methods and compositions for carrying out DD are well known in the art, see, e.g., U.S. Pat. No. 5,776,683; and U.S. Pat. No. 5,807,680. Alternatively, gene expression in a sample using hybridization analysis, which is based on the specificity of nucleotide interactions. Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density

formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e.g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.

**[0234]** Hybridization to arrays may be performed, where the arrays can be produced according to any suitable methods known in the art. For example, methods of producing large arrays of oligonucleotides are described in U.S. Pat. No. 5,134,854, and U.S. Pat. No. 5,445,934 using light-directed synthesis techniques. Using a computer controlled system, a heterogeneous array of monomers is converted, through simultaneous coupling at a number of reaction sites, into a heterogeneous array of polymers. Alternatively, microarrays are generated by deposition of pre-synthesized oligonucleotides onto a solid substrate, for example as described in PCT published application no. WO 95/35505. Methods for collection of data from hybridization of samples with an array are also well known in the art. For example, the polynucleotides of the cell samples can be generated using a detectable fluorescent label, and hybridization of the polynucleotides in the samples detected by scanning the microarrays for the presence of the detectable label. Methods and devices for detecting fluorescently marked targets on devices are known in the art. Generally, such detection devices include a microscope and light source for directing light at a substrate. A photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate. A confocal detection device that can be used in the subject methods is described in U.S. Pat. No. 5,631,734. A scanning laser microscope is described in Shalon et al., *Genome Res.* (1996) 6:639. A scan, using the appropriate excitation line, is performed for each fluorophore used. The digital images generated from the scan are then combined for subsequent analysis. For any particular array element, the ratio of the fluorescent signal from one sample is compared to the fluorescent signal from another sample, and the relative signal intensity determined. Methods for analyzing the data collected from hybridization to arrays are well known in the art. For example, where

detection of hybridization involves a fluorescent label, data analysis can include the steps of determining fluorescent intensity as a function of substrate position from the data collected, removing outliers, i.e. data deviating from a predetermined statistical distribution, and calculating the relative binding affinity of the targets from the remaining data. The resulting data can be displayed as an image with the intensity in each region varying according to the binding affinity between targets and probes. Pattern matching can be performed manually, or can be performed using a computer program. Methods for preparation of substrate matrices (e.g., arrays), design of oligonucleotides for use with such matrices, labeling of probes, hybridization conditions, scanning of hybridized matrices, and analysis of patterns generated, including comparison analysis, are described in, for example, U.S. Pat. No. 5,800,992. General methods in molecular and cellular biochemistry can also be found in such standard textbooks as *Molecular Cloning: A Laboratory Manual*, 3rd Ed. (Sambrook et al., Harbor Laboratory Press 2001); *Short Protocols in Molecular Biology*, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999); *Protein Methods* (Bollag et al., John Wiley & Sons 1996); *Nonviral Vectors for Gene Therapy* (Wagner et al. eds., Academic Press 1999); *Viral Vectors* (Kapliff & Loewy eds., Academic Press 1995); *Immunology Methods Manual* (I. Lefkovits ed., Academic Press 1997); and *Cell and Tissue Culture: Laboratory Procedures in Biotechnology* (Doyle & Griffiths, John Wiley & Sons 1998). Reagents, cloning vectors, and kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, Sigma-Aldrich, and ClonTech.

**[0235]** Having generally described this invention, the same will become more readily understood by reference to the following specific examples which are included herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

## EXAMPLES

[0236] The examples presented herein relate to the methods of prevention and/or treatment of ovarian cancer, for example in subjects that have ovarian cancer comprising ovarian cancer stem cells. Methods as disclosed herein provide treatment of ovarian cancer by targeting ovarian cancer stem cells, in particular by targeting ovarian cancer stem cells with MIS or derivatives or variants thereof and/or inhibitors of BCRP1. Throughout this application, various publications are referenced. The disclosures of all of the publications and those references cited within those publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. The following examples are not intended to limit the scope of the claims to the invention, but are rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods which occur to the skilled artisan are intended to fall within the scope of the present invention.

#### [0237] METHODS

[0238] *Flow Cytometry.* Flow cytometry was performed in the Department of Pathology and Center for Regenerative Medicine Flow Cytometry Laboratory according to their published protocols (36). Mouse and human ovarian cancer SP sorting and immunophenotyping were performed as described in *Supporting Methods*, which is published as supporting information on the PNAS web site. When testing SPs for multidrug resistance-like BCRP1 sensitivity, verapamil (25–50 µg/ml; Sigma) was also added.

[0239] For cell cycle analysis, MOVCAR 7 cells were harvested, sorted for Hoechst<sup>High</sup> NSP, Hoechst<sup>Mid</sup>, and Hoechst<sup>Low</sup> SP cells, and fixed with 70% ethanol for 24 h. Cells were washed in PBS, stained with 20 µg/ml propidium iodide and 1 mg/ml RNase (Type IIA; Sigma), and collected on a Life Sciences Research flow cytometer configured with CELLQUEST PRO software (BD Biosciences, Franklin Lakes, NJ).

**[0240]** *Side population sorting.* Mouse and human ovarian cancer single cell suspensions were stained with 5 µg/ml of the DNA intercalating Hoechst 33342 dye for 90 min at 37°C, washed, and resuspended in PBS containing 2% FCS and 1 mM HEPES. Before cell sorting, 2 µg/ml propidium iodide (Sigma) was added to exclude nonviable cells demonstrating uptake. SP cells were identified and electronically gated on a Digital Vantage cell sorter (Becton Dickinson) after excitation of the Hoechst dye with 150 mW of 350 nm UV light. SP fluorescence emissions were directed toward a 610-nm dichroic filter and captured simultaneously through both a blue (450-nm) band-pass and a red (675-nm) long-pass filter on a linearly amplified fluorescence scale.

**[0241]** *Surface marker antibodies.* Immunophenotyping of mouse and human cells was performed with titrated fluorescein isothiocyanate (FITC), phycoerythrin (PE), or allophycocyanin mAb conjugates of CD24 (binds P-selectin), CD31 (PECAM-1, endothelial cells), CD34 [sialomucin; hematopoietic stem cells (HSCs), adhesion], CD45 (leukocyte common antigen), CD44 (HCAM; binds hyaluronic acid), CD90 (Thy1.1; HSC, neuron, myofibroblast differentiation), *c-kit* (CD117; HSCs, mast cells), Sca-1 (Ly-6A/E; hematopoietic progenitors, mast cells), and CD105 (endoglin; endothelial, type III receptor for TGF-β) purchased from Becton Dickinson. Human cancer cells were also analyzed for the presence of epithelial-specific antigen (ESA/EpCAM, epithelial breast cancer progenitor cells), Lab Vision Corporation Clone 323/A3.

**[0242]** *Cell Lines and Culture.* Mouse ovarian cancer cell lines, MOVCAR 7 and 8, were developed by D.C. by using the MISRII promoter to drive the SV40 T antigen (19). The OVCAR 3 and OVCAR 8 human ovarian cancer cell lines were developed by Thomas Hamilton (Fox Chase Cancer Center) (37). The 4306 cell line was developed by D.M.D. from conditional LSL-K-ras<sup>G12D/+</sup>/Pten<sup>loxP/loxP</sup> mice after infection of ovarian surface epithelium with adenovirus expressing Cre recombinase. These mice developed invasive endometrioid ovarian cancers 7 weeks after infection, and the 4306 cell line was established from ascites cells (20). IGROV-1

and SK-OV-3 were obtained from American Type Culture Collection (ATCC). Cell lines were maintained in 4% female FBS (MIS-free) and DMEM with added L-glutamine, 1% penicillin/streptomycin, and 1% insulin-transferrin-selenium (ITS; GIBCO) at 37°C, 5% CO<sub>2</sub>, in T175 flasks within a humidified chamber. All cells recovered from sorting were grown in the same media.

**[0243]** *Human Primary Ascites Cell Isolation.* Primary ascites cells were analyzed from five stage III ovarian cancer patients and one (AC-01) patient with recurrent ascites, who ranged in age from 54 to 71 years (mean, 62.2 years). The study was approved by the Human Studies Committee of Massachusetts General Hospital (Protocol No. FWA0003136), and consent was obtained from each patient on the Gynecology Oncology Service at the time of outpatient paracentesis or before surgery. Ascites harvested at laparotomy or ultrasound-guided paracentesis were placed on ice, centrifuged to isolate the cellular component, and resuspended in media. Erythrocytes were lysed, and cells were cultured in RPMI with 10% female FBS, 1% penicillin/streptomycin, and 1% fungizone. Cells were analyzed by flow cytometry within 96 h for the presence of an SP and surface markers.

**[0244]** *Immunostaining of Cultured Cells.* Anti-MISR<sub>II</sub> rabbit polyclonal antibodies (153p/MISR<sub>II</sub>) were developed for Western blot analysis in the Pediatric Surgical Research Laboratories (35). Immunofluorescence was performed on MOV<sub>CAR</sub> 7 and 4306 cells by using 153p as described (25). Images were obtained by using either epifluorescent (Nikon Eclipse E400 microscope, SPOT camera, and SPOT ADVANCE software) or confocal microscopy (Leica TCS NT confocal microscope, CONFOCAL software Version 2.5 Build 1227, and krypton 568-nm laser; Leica, Deerfield, IL).

**[0245]** For BCRP<sub>1</sub> immunostaining, cells were double-labeled in suspension with Hoechst 33342 and BCRP<sub>1</sub> antibody as described in ref 5. Briefly, for BCRP<sub>1</sub> immunostaining, cells were double-labeled in suspension with Hoechst 33342 and BCRP antibody (Seigel, G. M.,

Campbell, L. M., Narayan, M. & Gonzalez-Fernandez, F. (2005) *Mol. Vis.* 11, 729-737). Cells ( $2 \times 10^6$ ) were centrifuged for 5 min, resuspended in 4-ml DMEM with 2% FCS, stained with Hoechst 33342 dye (Molecular Probes) at 5 $\mu$ g/ml, incubated at 37°C for 90 min, washed twice in PBS, resuspended in 200  $\mu$ l PBS plus 1% FCS, then divided into two tubes. One tube received BCRP1 antibody (1:20, Clone BX-34; Abcam, Inc., Cambridge, MA), and the other received isotype control antibody. Samples were incubated for 1 h at room temperature, washed twice in PBS, resuspended in 100  $\mu$ l of Alexa Fluor 555 conjugated anti-rat IgG (Molecular Probes) at a dilution of 1:800, incubated for 1 h at room temperature, washed twice, centrifuged, resuspended in 20 $\mu$ l PBS plus 1% FCS, pipetted onto a slide, and coverslipped for microscopic viewing.

**[0246]** *Reverse Transcriptase PCR.* Total RNA from MOVCAR 7 and 4306 SP and NSP cells was extracted by using the Qiagen (Valencia, CA) RNeasy Mini Kit (catalog no. 74104) according to the manufacturer's instructions, and 0.5  $\mu$ g of RNA was reverse transcribed into cDNA by using Superscript II reverse transcriptase as directed by the manufacturer (Invitrogen). All RT-PCRs were run for 30 cycles with an annealing temperature of 57°C and separated on 2% agarose gels. Mouse PCR primers are as in Table 5.

**[0247]** **Table 5.** Mouse PCR Primers

| <b>Protein</b> | <b>Forward Primer</b>                   | <b>Reverse Primer</b>                     |
|----------------|---|---|
| <b>Bcrp1</b>   | CCATAGCCACAGGCCAAAGT<br>(SEQ ID NO:1)   | GGGCCACATGATTCTTCCAC (SEQ<br>ID NO:2)     |
| <b>MisrII</b>  | GCTGGTTTTTGCTGGTTTATGC<br>(SEQ ID NO:3) | TTTGGGGATACTTGTGCTGCCG<br>(SEQ ID NO:4)   |
| <b>Smad1</b>   | TGAACTGAAGCCTCTGGAATGC<br>(SEQ ID NO:5) | TCGTAAGCAACTGCCTGAACATC<br>(SEQ ID NO:6)  |
| <b>Smad5</b>   | AACCTGAGCCACAATGAACCG<br>(SEQ ID NO:7)  | TCTGAACAAAGATGCTGCTGTCAC<br>(SEQ ID NO:8) |
| <b>Smad8</b>   | CAGCACTGGTGTCTGTGCTA<br>C (SEQ ID NO:9) | CCATCTGAGTGAGCACCTTATCC<br>(SEQ ID NO:10) |

| Protein | Forward Primer                                | Reverse Primer                          |
|---------|---|---|
| Alk 2   | TTATACAATGGTCGATGGAGC<br>(SEQ ID NO:11)       | TTCAGGCGCTCTTGATTGC<br>(SEQ ID NO:12)   |
| Alk 3   | ATGACTCAGCTATACACTTACAT<br>CAG (SEQ ID NO:13) | CAGGTCTTTCAGTGATTCTCC<br>(SEQ ID NO:14) |

**[0248]** *Growth Inhibition by MIS in Vitro.* MTT assay was used to assess proliferation inhibition.

MOVCAR 7 and 4306 cells were harvested, sorted for SPs and NSPs, and plated in the inner wells of 96-well plates at 1,000 cells per well in 200  $\mu$ l of medium per well. Twenty-four hours after plating, each set of 10 wells of SP or NSP cells was treated with 10  $\mu$ g/ml recombinant human MIS (25), 4 nM paclitaxel (6 mg/ml; NovaPlus, Irving, TX), a 4-nM doxorubicin hydrochloride injection (2 mg/ml; NovaPlus), or media alone. At day 5 or 7 of incubation, cell viability was quantified by measuring mitochondrial activity (38) on an ELISA plate reader at an absorbance of 550 nm to generate an OD proportional to the relative abundance of live cells in a given well.

**[0249]** *Growth of MOVCAR 7 SP Cells in Vivo.* MOVCAR 7 SP and NSP cells were sorted and injected into T and B cell-deficient 6-week-old female Swiss nude mice in equal numbers (first experiment,  $5.0 \times 10^5$ ; second experiment,  $7.5 \times 10^5$ ) into the dorsal fat pad between the scapulae. Mice were housed in the Edwin L. Steele Laboratory for Tumor Biology under American Association for Laboratory Animal Science guidelines with the approval of the MGH Animal Care and Use Committee (protocol no. 2005N000384).

**[0250]** *Purification of Recombinant Human MIS.* The human MIS gene was transfected into CHO cells, amplified, purified, and maintained in a dedicated facility in the Pediatric Surgical Research Laboratories for use in this study as described in ref.39. MIS levels were measured by using human MIS-specific ELISA (40). MIS was purified by a combination of lectin affinity chromatography and FPLC anion-exchange chromatography (39). The MIS purified by this method causes regression in the organ culture bioassay for MIS (41, 42).

**[0251]** *Transgenic mice and H2Bj-GFP label and chase.* H2Bj-GFP (Tumbar et al., 2004) mice purchased from Jackson Laboratories (JAX® GEMM® Strains, Stock Tg(tetO-HIST1H2BJ/GFP)47Efu/J, Stock Number 005104) were crossed with M2-Rosa26-rtTA mice, generously provided by Konrad Hochedlinger, MGH (Beard et al., 2006) for nearly ubiquitous expression of H2Bj-GFP in the presence of doxycycline and managed as previously described (Brennand et al., 2007). To induce expression of H2Bj-GFP, embryonic mice were pulsed by doxycycline (2 mg/ml, 5% sucrose water, ad libitum through the dams or directly) from E0 to P42. Alternatively, adult animals were pulsed with doxycycline from 6 to 10 weeks of age. In some instances, both pre-pubertal and post-pubertal animals received BrdU (5-bromo-2'-deoxyuridine, Roche, 1 mg/ml) or IdU (5-iodo-2'-deoxyuridine, Sigma; 1 mg/ml) i.p. over the last six to ten consecutive days of the pulse period to co-localize H2Bj-GFP LRCs with BrdU/IdU LRCs. At the end of the pulse period, withdrawal of the doxycycline resulted in suppression of H2Bj-GFP transgene expression. Bone marrow analysis for co-localization of H2Bj-GFP with known hematopoietic stem cell surface markers was used as a positive control and detailed in flow cytometry methods. Transgenic mice not receiving doxycycline served as a negative control as detailed in the quantification methods. Pre-pubertal pulsed bone marrow and ovaries were harvested at pulse day 42 ("sexually mature", n=3), chase 1 week (n=2), 2 weeks (n=2), 1 month (n=3), 2 months (n=3), 3 months (n=4), and 6 months (n=1), and evaluated for GFP expression. Post-pubertal pulsed bone marrow and ovaries were harvested at pulse 1 month (n=3), chase 1 month (n=3), and chase 2 months (n=3). In some instances mice were injected with BrdU or CldU (2'-chloro-2'-deoxyuridine; Sigma; 1 mg/ml) 2h prior to sacrifice to correlate mitotic cells with H2Bj-GFP LRCs.

**[0252]** *BrdU/IdU Labeling and hCG Stimulation.* BrdU & IdU pulse-chase experiments were repeated at least three times with similar results using postpubertal (20-25 g) virgin female CD1 mice from Charles River Laboratories (Wilmington MA) or post-pubertal pulsed M2-Rosa26-

rtTA;H2BJj-GFP mice. Animals were injected daily with 250  $\mu$ l of 1 mg/ml BrdU or IdU i.p. for 7 or 10 days during the pulse period. On day seven or ten, 1-2 mice were sacrificed to visualize the initial BrdU labeling in the ovary as compared to intestinal controls. During the chase period, one to two mice were sacrificed at various time points for a chase period up to 14 weeks. During BrdU chase week 11 (pulse-chase experiment #1) and 12 (pulse-chase experiment #2), ten animals in proestrus by vaginal cytology were injected with 10 IU hCG i.p. and subsequently followed for 5 days to capture each stage of a complete estrous cycle.

**[0253]** *Immunofluorescence.* Immunofluorescence and BrdU detection were performed as previously described in detail (Szotek et al., 2007). In brief, tissues were fixed, gelatin embedded, sectioned, blocked, and stained. Primary Antibodies were as follows: BrdU-Alexa 488 (1:20), BrdU-Alexa 555 (1:20), BrdU-Alexa 647 (1:20), GFP-Alexa 488 (1:200; Molecular Probes), Troma-1 (1:50), CD105 (1:10), Connexin 32 (1:10; Iowa Studies Hybridoma Bank, Iowa City, Iowa); c-Kit receptor (1:100, R & D Systems, Minneapolis MN);  $\alpha$ -SMA (1:5000),  $\beta$ -Catenin (1:1500, Sigma, St. Louis MO), Gata-4 (1:100, Santa Cruz Biotechnology, Santa Cruz CA); EpCAM, CD31 (PECAM), CD45, GR-1-PE, Mac-1-PE, Ter119-PE, pan-NK-PE, CD90, CD34 (all 1:50, Becton Dickinson), VASA/MVH (1:1000, generous gift from T. Noche, Mitsubishi Kagaku Institute of Life Sciences, Tokyo, Japan), NG2 (1:350, Chemicon), PDGFRb (1:25, E-Bioscience), and CD44 (1:25, Caltag) diluted in 1% BSA /PBS and incubated in a humidified chamber for 1 h. Secondary antibodies were as follows: AlexaFluor 488 donkey-anti-(goat, rabbit, rat), AlexaFluor 555 donkey-anti-(goat, rabbit, rat), and AlexaFluor 647 donkey-anti-(goat, rabbit, rat) (1:1000, Molecular Probes) diluted in 1% BSA/PBS and incubated for 1 h at RT in a humidified chamber. Nuclei were counterstained with 4',6'-diamidino-2-phenylindole- (DAPI 1:20,000) impregnated Vectashield (Vector Labs, Burlingame CA) mounting media for microscopy, using a Nikon 80i microscope with epifluorescence attachments. Images were captured using the SPOT RT-KE Camera and Spot

Advance Software (Diagnostic Instruments, Sterling Heights MI). Confocal images and in vitro live cell images were captured on the BD Pathway imaging system and analyzed using BD Attovision software.

**[0254]** *Quantification of labeling.* Quantification of BrdU and H2Bj labeled nuclei was performed either by flow cytometry (bone marrow) or by image acquisition as described above (all images with camera settings: Exp. 500ms; Gamma = 0.95; Gain = 4) and analysis using ImageJ software (NIH) with the nucleus counting plugin. The quantification analysis was standardized using Adobe PhotoShop software to set a threshold level of 60 (determined by images of transgenic mice not receiving doxycycline as a baseline control for “leaky” GFP) on each greyscale image. The ImageJ nucleus counting plugin was set to count particle sizes from 4-500 pixels with K-means clustering to obtain the nuclei count data. Grayscale images were evaluated from at least three images per animal and three animals per time-point.

Quantification of in vitro intensity was performed on the BD Pathway imager using BD Attovision software. Cell nuclei were electronically gated as regions of interest and individual nuclei intensity was determined. The nucleus of greatest intensity was designated as the point from which loss of signal was measured and sequential elliptical rings of equal numbers of cells were established to estimate the loss of signal intensity. All experiments were performed in triplicate.

**[0255]** *Parabiosis.* Parabiosis and ovarian germ cell/stromal chemoablation (cytoxan/busulfan) experiments were performed exactly as previously described (Eggan et al., 2006; Johnson et al., 2005; Wagers et al., 2002; Wright et al., 2001) in accordance with the guidelines established by the Joslin Diabetes Center IACUC for the humane care and use of animals. C57BL/6 wild type isogenic littermates were parabiosed at 4-8 weeks of age to either C57BL/Ka- $\beta$ -actin/eGFP (n=6 pairs; JAX GEMM Strain: STOCK Tg(ACTB-EGFP)D4Nagy/J; stock # 003116) or ubiquitin-GFP (n=4 pairs; JAX GEMM Strain: C57BL/6-Tg(UBC-GFP)30Scha/j; stock #

004353) mice purchased from Jackson Laboratories. ACTB-EGFP animals were euthenized after 2 months and UBC-GFP animals after 5 weeks of parabiosis. Blood was analyzed for chimerism by flow cytometry. Ovaries were harvested and prepared for immunofluorescence as described herein.

**[0256]** *Irradiation and actin-GFP Bone Marrow transplantation.*  $\beta$ -actin-GFP transgenic mice were purchased from Jackson Laboratories (JAX GEMM Strain: STOCK Tg(ACTB-EGFP)D4Nagy/J; stock # 003116) and nucleated marrow cells were harvested by crushing murine long bones in PBS/2%FCS using a mortar and pestle. 1-4 million nucleated marrow cells were injected intravenously into C57BL/6 mice (n=4) conditioned with 9.5Gy within 24 hours of transplantation. 4 weeks post transplant peripheral blood was harvested and engraftment confirmed by CBC analysis (Hemavet 850, Drew Scientific) and flow cytometry to detect GFP, after RBC lysis. Mice were sacrificed 8 weeks after bone marrow transplant.

**[0257]** *Flow Cytometry.* To validate the ability of doxycycline induced GFP expression in M2-Rosa26-rtTA; tetO-H2Bj-GFP mice to identify slow cycling label retaining stem cells, we analyzed the bone marrow for co-localization with the known hematopoietic stem cell (HSC) phenotype of Lin<sup>-</sup>/c-Kit<sup>+</sup>/Sca-1<sup>+</sup> (Morrison et al., 1995; Morrison and Weissman, 1994; Orlic et al., 1993) over the course of the chase. GFP expression in whole bone marrow and the Lin<sup>-</sup>/c-Kit<sup>+</sup>/Sca-1<sup>+</sup> fraction was assessed in the control mice receiving no doxycycline (GFP negative gate) and in embryonic (E0-P42) doxycycline pulsed mice, at the end of the pulse and following 1 week, 2 weeks, 1 month, 2 months and 6 months of chase (no doxycycline).

**[0258]** Bone marrow was harvested by crushing femoral bone shafts in PBS with heat inactivated 2% FBS. Cells were stained with lineage-specific biotinylated antibodies (CD3, CD8, CD4, GR-1, Mac-1, Ter119, and B220), Sca1 PE-conjugated, and cKit APC-conjugated (all BD Pharmingen, San Jose, CA) for 20 minutes at 4 C. Cells were washed twice and then stained with streptavidin PerCp-conjugated (BD Pharmingen) antibody for 20 minutes at 4 C. Cells

were washed and re-suspended in PBS for immediate analysis or fixed with 2% paraformaldehyde for analysis within 24 hours. Flow cytometric analysis was performed using a FACScalibur (BD Biosciences) flow cytometer. Live cells were gated based on forward-scatter (FSC) and side-scatter (SSC) parameters. Wild type bone marrow was analyzed to set the GFP<sup>High</sup>/low/- threshold gates. At least  $2.5 \times 10^5$  events were collected. Data was analyzed on FloJo version 8.1.1 analysis software.

**[0259]** To determine if H2Bj label retention co-localizes with and enriches for the SP phenotype (as determined by Hoechst 33342 exclusion), ovaries were dissected, cleared of their bursa, and enzymatically digested at 37 C in 0.2% (b/w) collagenase type II (Gibco/BRL type II in DMEM) for 30-45 min. followed by collagenase inactivation with F12+20% FBS and transfer of the ovaries to a 6 well plate for mild trituration to disperse the more superficial coelomic and subcoelomic/stromal cells. The ovaries were removed and the remaining media collected, centrifuged, and the cells resuspended in PBS, filtered through a 70  $\mu$ m mesh (BD Falcon), centrifuged again, and resuspended in 2 ml ammonium chloride (ACK) RBC lysis solution on ice for 3 min. After addition of 10 ml HBSS+2% FBS, the cells were centrifuged, then resuspended in DMEM+2% FCS, and counted.

**[0260]** Cell sorting and analysis of GFP and SP cells was performed in the Flow Cytometry Laboratory of the Department of Pathology and the Center for Regenerative Medicine according to their published protocols (Preffer et al., 2002) and as previously described (Szotek et al., 2006). Single cell suspensions were stained with 5  $\mu$ g/ml of the A-T intercalating Hoechst 33342 dye for 90 min at 37 C, washed, and resuspended in PBS containing 2% fetal calf serum for analysis of GFP and SP co-localization using the LSRIII flow cytometer (Becton Dickinson). At least  $2.5 \times 10^5$  events were collected for each analysis and analyzed using FloJo version 8.1.1 software.

**[0261]** *Colony Forming Unit (CFU) Assay and BD Pathway Live Imaging.* After isolation of coelomic and subcoelomic/stromal cells as described above, cells were counted by hemocytometer and limiting dilutions of  $2 \times 10^5$ ,  $1 \times 10^5$ ,  $5 \times 10^4$ ,  $2.5 \times 10^4$ ,  $1 \times 10^4$  and  $5 \times 10^3$  cells were added to 2mL of Murine MesenCult Media according to protocol (StemCell Technologies) and cultured at 37 C, 5% CO<sub>2</sub> for 14 days to obtain an optimal plating number of  $1 \times 10^4$  for subsequent studies. During the course of incubation, the plated cells were routinely observed and imaged for GFP expression and colony formation. Colonies were considered GFP positive if a minimum of 2 contiguous nuclei had visually detectable GFP epifluorescence. At the end of the 14 day incubation period, the percentage of GFP positive colonies was estimated visually using an epifluorescent microscope and then macroscopic colony counts were obtained after Giemsa staining. For live imaging, an identical protocol was used except colonies were incubated and imaged under the BD Pathway live cell confocal imager (Becton Dickinson) using BD Attovision imaging software. Data analysis was performed using ImageJ software (NIH). All experiments were performed in triplicate.

**[0262]** *Statistical Analysis.* In MTT assays, MIS-, doxorubicin-, and paclitaxel-treated and untreated samples were analyzed by using the univariant two-tailed Student *t* test, with  $P \leq 0.05$  conferring statistical significance. All experiments were performed in triplicate. In ovarian somatic stem cell studies, all *p*-values were calculated with the use of two-tailed student's *t*-test. Differences with *p*-values less than 0.05 were considered significant.

#### EXAMPLE 1

**[0263]** *Identification of SPs in Mouse Ovarian Cancer Cell Lines.* To determine whether mouse ovarian cancer cell lines contain candidate cancer stem cells, Hoechst 33342 was used to sort for the SP phenotype. The serous adenocarcinoma-recapitulating MOVCAR 7 and 8 cell lines were developed by using the MIS type II receptor (MISR2) promoter to drive the SV40 T antigen

(19). The endometrioid carcinoma-recapitulating 4306 cell line was developed from conditional LSL-K-ras<sup>G12D/+</sup>/Pten<sup>loxP/loxP</sup> mice in which the ovarian surface epithelium was infected with adenovirus expressing Cre recombinase (20). Flow cytometry demonstrated a very high percentage of Hoechst<sup>Low</sup> SP cells in the MOVCAR 7 and 4306 cell lines (Fig. 1 A and B), whereas SP was not detected in MOVCAR 8. Verapamil, a BCRP1 inhibitor (18), effectively eliminated the SP in both MOVCAR 7 and 4306 cells (Fig. 1 C and D). The average first sort percentage of SP cells was 6.28% ( $n = 6$ ) for MOVCAR 7 and 1.83% ( $n = 4$ ) for 4306 cells, which is elevated relative to the SP found in other somatic and malignant sources (3, 18, 21). Colocalization of Hoechst<sup>Low</sup> and Bcrp1 immunoreactive MOVCAR 7 and 4306 cells confirmed the presence of SP cells (Fig. 1E–H and data not shown). Bcrp1 mRNA was detected by qualitative RT-PCR in SP cells (data not shown). Thus, MOVCAR 7 and 4306 cells possess SPs with Hoechst efflux characteristics reminiscent of those defined in hematopoietic stem cells.

#### EXAMPLE 2

**[0264] *Ex Vivo Growth of SP and NSP Cells.*** Growth characteristics of the SP and NSP cells were consistent with previous findings for cancer stem cells (21). MOVCAR 7 and 4306 cells were sorted by flow cytometry and equal numbers of SP and NSP cells cultured. SP cells from both cell lines formed characteristic compact circular colonies with a cobblestone appearance and survived numerous passages (Fig. 2 A and C;  $n = 9$ ). NSP cells from both cell lines were sparse and failed to proliferate beyond 1–2 weeks (Fig. 2 B and D;  $n = 9$ ). These differences were not a consequence of prolonged Hoechst retention in the NSP cells because propidium iodide was used to gate out all nonviable cells. Serial sorting and reanalysis (total passages = 3) of SP cells demonstrated enrichment of the SP and the presence of NSP cells (Fig. 2 E–J), suggesting asymmetric division occurred during culture (Fig. 2 F, G, I, and J). Thus, SP cells are able to self-renew, be enriched, and produce NSP cells when recovered and serially sorted in culture.

#### EXAMPLE 3

[0265] *SP Cells Are in G<sub>1</sub> Cell Cycle Arrest and Resistant to Doxorubicin in Vitro.* By definition, SP cells should express high levels of BCRP1 and thus be able to efflux the lipophilic dye Hoechst 33342 and some lipophilic anticancer drugs, including those used in the treatment of ovarian cancer (18, 22). The lipophilic anticancer drug doxorubicin is a substrate of the BCRP1 transporter, whereas the lipophilic microtubule inhibitor paclitaxel is not (23). To investigate the functional significance of the Bcrp1 transporter found in MOVCAR 7 SP cells, we tested their response to doxorubicin and paclitaxel, as compared with that observed in the NSP, by methylthiazolotetrazolium (MTT) proliferation assays (Fig. 3). MOVCAR 7 SP cells were only inhibited by 30% after treatment with doxorubicin, whereas the NSP cells showed 81% inhibition (Fig. 3A). In contrast to doxorubicin, MOVCAR 7 SP and NSP cells were almost equally inhibited by the Bcrp1-resistant paclitaxel (Fig. 3B; SP = 85% inhibition; NSP = 83% inhibition). Quiescence is one of the defining characteristics of somatic stem cells (24). Cell cycle analysis of three sorted populations, Hoechst<sup>Low</sup> SP, Hoechst<sup>Mid</sup> NSP, and Hoechst<sup>High</sup> NSP (Fig. 3C), revealed that the Hoechst<sup>Mid</sup> and Hoechst<sup>High</sup> NSP cells had a higher percentage of cells in S phase (Fig. 3D and E), compared with Hoechst<sup>Low</sup> SP (Fig. 3F). In contrast, Hoechst<sup>Low</sup> SP cells demonstrate a predominance of cells in the G<sub>1</sub> phase (Fig. 3F) compared with the Hoechst<sup>Mid</sup> and Hoechst<sup>High</sup> NSP cells (Fig. 3D).

#### EXAMPLE 4

[0266] *In Vivo Growth Characteristics of MOVCAR 7 SP and NSP Cells.* To assess *in vivo* tumorigenicity of MOVCAR 7 SPs and NSPs, viable propidium iodide-negative SP and NSP cells were sorted and injected into the dorsal fat pad of nude mice (Fig. 4A and Table 1, which is published as supporting information on the PNAS web site). Tumors appeared in three of three animals at 10 weeks after injection of  $5.0 \times 10^5$  SP cells, whereas animals injected with an equal number of NSP cells had no detectable tumors (zero of three) at that time (Fig. 4B). Tumors appeared in two of three of the NSP animals only after 14 weeks. Tumors appeared at 7 weeks

in animals injected with  $7.5 \times 10^5$  SP cells, whereas NSP-injected animals had no detectable tumors (zero of three) at that time and only appeared after 10 weeks in two of three animals (Table 1). To investigate whether the appearance of tumors in the NSP could possibly be explained by incomplete sorting, we reanalyzed the sorted populations by using identical gating and found 82.6% SP cell purity (Fig. 4C; NSP contamination = 2.63% or ~13,150 SP cells in a total of  $5 \times 10^5$  cells per animal; 19,750 SP cells in a total of  $7.5 \times 10^5$  cells per animal) and 92.3% NSP cell purity (Fig. 4D; SP contamination = 1.72% or ~8,600 SP cells in  $5 \times 10^5$  cells per animal; 12,900 SP cells in  $7.5 \times 10^5$  cells per animal). In addition, the NSP tumors dissected from animals at euthanization showed verapamil-sensitive SP cells (Fig. 4 E and F), suggesting that SP cells have the potential to initiate earlier tumor growth at lower numbers. In a parallel experiment, preinjection analysis demonstrated an SP fraction equal to 0.21% (~12,600 SP cells per animal) of the  $6 \times 10^6$  unsorted cells per animal injected into 50 nude mice (data not shown). The average time to appearance of these tumors was ~9 weeks; in close agreement with our  $7.5 \times 10^5$  NSPs (~12,900 SP cells) injected animals and corroborating our speculation that a very small population of SP cells has the potential to initiate tumor growth *in vivo*.

**[0267] Table 1.** MOVCAR 7 SP versus NSP tumorigenicity *in vivo*. \* Number of animals with tumors at time point/total number of animal injected.

|  |     | Weeks after injection |     |     |
|--|-----|-----------------------|-----|-----|
|  |     | 7                     | 10  | 14  |
| Experiment no. 1 ( $5 \times 10^5$ cells per animal)   | SP  | *0/3                  | 3/3 | 3/3 |
|  | NSP | 0/3                   | 0/3 | 0/3 |
| Experiment no. 2 ( $7.5 \times 10^5$ cells per animal) | SP  | 3/3                   | 3/3 | 3/3 |
|  | NSP | 0/3                   | 2/3 | 2/3 |

#### EXAMPLE 5

**[0268] *MOVCAR 7 and 4306 SP Cells Respond to MIS in Vitro.*** MIS has been shown to inhibit MOVCAR 7 both *in vitro* and *in vivo* (25). Thus, we investigated whether MIS inhibits MOVCAR 7 and 4306 SP and/or NSP cells *in vitro*. We first confirmed that SP and NSP cells possess an intact MIS signal transduction pathway, previously shown to be required for MIS responsiveness in the embryonic urogenital ridge (26). By using anti-MISRII antibody the inventors observed that MOVCAR 7 and 4306 cells express the MISRII receptor by epifluorescent and confocal microscopy (Fig. 5 B and 5C; 4306 cells not shown). The inventors then confirmed the presence of MISRII, MISRI (Alk 2 and 3), and Smad 1/5/8 mRNA by RT-PCR in sorted SP and NSP cells (SP in Fig. 5D; NSP and 4306 cells are the same but not shown), demonstrating that these cells would likely respond to MIS.

**[0269]** MOVCAR 7 and 4306 SP and NSP cells were sorted, incubated for 24 h, and treated with 10 µg/ml MIS for MTT proliferation assays. MOVCAR 7 SP and NSP cells responded to MIS after initial sorting of the neat population. MOVCAR 7 SP cells were inhibited by 86%, whereas NSP cells were inhibited by 93% compared with vehicle controls (Fig. 5 E). In contrast, only 4306 SP cells showed a significant inhibition of 37% by MIS (Fig. 7). However, because NSP cells could not reliably be maintained in culture for serial sorting, we evaluated the ability of MIS to inhibit the SP alone after enrichment in both cell lines. MOVCAR 7 serial sorting followed by MTT showed 93% inhibition after sort 2 and 94% inhibition after sort 3 (Fig. 5 F and G). Serial sorting of 4306 cells followed by MTT showed 60% inhibition after sort 2 (Fig. 7), and no inhibition after sort 3 was observed (17% inhibition;  $P = 0.054$ ). Thus, MIS inhibits MOVCAR 7 and 4306 SP cells *in vitro*.

#### EXAMPLE 6

**[0270] *Human Ovarian Cancer Cell Lines and Primary Patient Ascites Cells Have SPs.*** To determine the prevalence of SP cells in human ovarian cancer, we evaluated the cell lines OVCAR 3, OVCAR 8, SK-OV-3, and IGROV-1, as well as ascites from six ovarian cancer

patients (see cell line and patient demographics in Table 2. Patient ascites cells were obtained directly from the operating theatre and analyzed within 96 h. The inventors detected verapamil-sensitive SP cells in IGROV-1 (Fig. 6A), OVCAR 3 (data not shown), and SK-OV-3 (21), but not in OVCAR 8 (Fig. 6B). Viable human ascites cells, selected as CD45<sup>+</sup>/CD31<sup>-</sup>, were found to exhibit verapamil-sensitive SP cells in four of six patients (Fig. 6 C and D). Thus, an appreciable number of human ovarian cancer cell lines and primary ovarian cancer ascites cells possess SP cells. The inventors also performed immunofluorescent analysis of IGROV-1 and the ascites cells of patients 215 and 216, and discovered colocalization of BCRP1 with Hoechst<sup>Low</sup> cells in IGROV-1 and the ascites cells, (data not shown), whereas OVCAR-8 did not express Hoechst<sup>Low</sup> or BCRP1-positive cells (data not shown).

**[0271] Table 2.** Demographics and surface markers of human ovarian cancer cell lines and primary ascites. All samples were gated on SP/CD45<sup>+</sup>/CD31<sup>-</sup> population, and all patient cells were from ascites. SP positivity was assessed by flow cytometry and based on >90% elimination of SP with the addition of verapamil. Surface marker positivity was assessed by flow cytometry. Markers were ranked based on percent positive cells: -, <5%; +/-, 6–10%; +, 10–20%; ++, 21–40%; +++, 41–70%; +++++, >70%. Positivity was assessed by FACS. Markers were ranked based on percent positive cells: -, <5%; +/-, 6–10%; +, 10–20%; ++, 21–40%; +++, 41–70%; +++++, >70%.

|                       | Sample # / cell line | Pathology             | Age, yr | SP, %        | ESA  | CD24 | CD44 | c-Kit |
|-----------------------|----------------------|-----------------------|---------|--------------|------|------|------|-------|
| Human cell lines      | OVCAR-3              | Serous adenocarcinoma | 60      | Pos (0.085)  | ++++ | ++++ | -    | -     |
|                       | OVCAR-8              | Serous adenocarcinoma | 60      | Neg          | -    | -    | -    | -     |
|                       | SK-OV-3              | Serous adenocarcinoma | 64      | Pos (0.16)   | +    | -    | +/-  | -     |
|                       | IGROV-1              | Serous adenocarcinoma | 47      | Pos (0.12%)  | ++++ | -    | -    | -     |
| Patient ascites cells | AC-01                | Serous adenocarcinoma | 56      | Neg          | -    | -    | -    | -     |
|                       | TC 203               | Clear cell CA         | 55      | Pos (0.047%) | +/-  | -    | -    | -     |
|                       | TC 212               | Clear cell CA         | 54      | Pos (0.6%)   | +/-  | -    | -    | -     |
|                       | TC 214               | Serous adenocarcinoma | 71      | Neg          | +/-  | -    | -    | -     |

|  |        |                       |    |              |     |   |   |   |
|--|--------|-----------------------|----|--------------|-----|---|---|---|
|  | TC 215 | Serous adenocarcinoma | 71 | Pos (0.047%) | -   | - | - | - |
|  | TC 216 | Serous adenocarcinoma | 66 | Pos (0.69%)  | +++ | - | - | - |

## EXAMPLE 7

**[0272] *Mouse and Human Ovarian Cancer Cell Surface Phenotype.*** To investigate whether ovarian cancer cells express somatic and cancer stem cell surface markers, as well as to identify differential expression between SP and NSP cells, we analyzed mouse and human ovarian cancer cells by flow cytometry. All mouse and human SP cells were gated as negative for CD45 (common leukocyte antigen) and CD31 (platelet endothelial cell adhesion molecule 1/endothelial cells). Compared with NSP cells, the MOVCAR 7 SP cells were enriched in number of cells and intensity of expression of *c-kit*/CD117 (stem cell factor receptor), whereas 4306 and human SP and NSP cells did not express *c-kit*. MOVCAR 7 SP and NSP cells strongly express the tumor metastasis marker CD 44 (hyaluronic acid receptor), whereas 4306 cells and most human ovarian cancer cells do not. MOVCAR 7 and 4306 SP and NSP cells did not express CD24, CD34, CD105, CD133, or Sca-1 (Table 3). Human cell lines and ascites cells showed variable expression of the epithelial cell marker epithelial-specific antigen/Ep-CAM (epithelial specific antigen) and CD24 (Table 2 and Fig. 8). These markers, aside from *c-kit* in MOVCAR 7, did not add to the consistent SP phenotype and Bcrp1 immunostaining we have observed in identifying putative ovarian cancer stem cells in both mouse and human.

**[0273] *Table 3. Cell surface markers on MOVCAR 7 and 4306 SP and NSP cells.*** Positivity was assessed by flow cytometry. Markers were ranked based on percent positive cells: -, <5%; +/-, 6-10%; +, 10-20%; ++, 21-40%; +++, 41-70%; +++++, >70%.

| Cell surface markers | Reactivity                                       | MOVCAR 7 |     | 4306 |     |
|----------------------|--|----------|-----|------|-----|
|                      |  | SP       | NSP | SP   | NSP |
| <b>c-Kit (CD117)</b> | Hematopoietic stem cells, mast cells             | ++       | -   | -    | -   |
| <b>CD24 (BA-1)</b>   | Breast cancer progenitor cells, binds P-selectin | -        | -   | -    | -   |

|  |  |      |      |   |   |
|--|--|------|------|---|---|
| <b>CD34 (mucosalin)</b>                | Hematopoietic stem cell/epidermal stem cells                                 | -    | -    | - | - |
| <b>CD44 (HCAM)</b>                     | Tumor metastasis, WBC adhesion, hyaluronidase                                | ++++ | ++++ | - | - |
| <b>CD45 (leukocyte common antigen)</b> | Pan-leukocyte marker   | -    | -    | - | - |
| <b>CD90 (Thy-1)</b>                    | Thymocytes, myofibroblasts   | -    | ++++ | - | - |
| <b>CD105 (endoglin)</b>                | Endothelial, macrophage activation, TGF- $\beta$ type III receptor, adhesion | -    | ++++ | - | - |
| <b>CD133 (prominin-1)</b>              | Hematopoietic progenitors, neural and endothelial stem cells, retinoblastoma | -    | -    | - | - |
| <b>SCA-1 (Ly6-A/E)</b>                 | Hematopoietic stem cells, mast cells   | -    | -    | - | - |

## EXAMPLE 8

[0274] **Mouse OSE Estrous Cycle Stage Dependent Proliferation.** To identify the presence of stem cells in normal ovary, herein termed “ovarian somatic stem cells” the inventors performed a series of pulse-chase experiments in different transgenic mice strains. Short-term (2 hr) pulse BrdU labeling was used to investigate estrous cycle stage dependent proliferation in the mouse ovarian coelomic epithelium. Animals were grouped as preovulatory (diestrus, proestrus, and early estrus) and postovulatory (late estrus and metestrus) based on vaginal cytology, and analyzed for BrdU incorporation. Preovulatory ovaries demonstrated BrdU incorporation in proliferating granulosa cells, while little coelomic or stromal incorporation was observed (Fig 9A). Postovulatory ovaries demonstrated that the ovarian surface epithelium proliferates in association with antral follicle formation (Fig 9B red arrow) and in early metestrus in association with corpora luteum formation (Fig 9B black arrows). Ovarian coelomic epithelial proliferation terminated in late metestrus and diestrus over newly formed corpora albicans. Quantification of ovarian coelomic epithelial proliferative activity by incorporation of BrdU over the entire coelomic epithelium demonstrated that an average of  $5.2 \pm 3.2\%$  of cells were dividing in the preovulatory group and  $18.9 \pm 1.3\%$  of cells were dividing in the postovulatory group (Fig 9C). Within the post-ovulatory group, the majority of the increased ovarian surface

epithelial proliferation was overlying antral follicles and corpora luteum (Fig 9D), confirming the temporal-spatial relationship of postovulatory proliferation to coelomic epithelial repair.

**[0275] Characterization of BrdU & Rosa-rtTA; tetO-H2Bj-GFP labeling.** To determine if a population of slow cycling LRCs exists in the mouse ovary, the inventors used pulse-chase labeling with BrdU/IdU or tetracycline regulated H2Bj-GFP fusion protein in pre- and postpubertal female mice. Rosa26-rtTA; tetO-H2Bj-GFP mice were engineered as depicted in Fig 10A and as previously described (Brennand et al., 2007). The timeline for embryonic (E0-P42) Rosa26-rtTA; tetO-H2Bj-GFP, adult (6w-10w) Rosa26-rtTA; tetO-H2Bj-GFP, and adult (6w-7w) BrdU pulse-chase experiments is shown in Figure 10B. To validate the ability of Rosa26-rtT; tetO-H2Bj-GFP mice to identify somatic stem cells in a known model system, flow cytometry was used to compare bone marrow GFP label retaining cells to the hematopoietic stem cell phenotype  $\text{Lin}^- \text{cKit}^+ \text{Sca-1}^+$ . Analysis of whole bone marrow from wild type and Rosa26-rtTA; tetO-H2Bj-GFP animals not receiving a doxycycline pulse were used to set the flow cytometry gates. Animals administered doxycycline during the embryonic period demonstrated that  $37.6 \pm 12\%$  (SE, standard error) of whole bone marrow and  $81.36 \pm 7.6\%$  of  $\text{Lin}^- \text{cKit}^+ \text{Sca-1}^+$  cells labeled during the pulse period (Fig 16A). After 2 and 6 month chase periods respectively,  $0.47 \pm 0.22\%$  and  $0.2 \pm 0.10\%$  of WBM and  $9.64 \pm 2.1\%$  and  $2.93 \pm 1.1\%$  of  $\text{Lin}^- \text{cKit}^+ \text{Sca-1}^+$  cells retained GFP label above the gated threshold (Fig 16B). These findings confirm that Rosa26-rtTA; tetO-H2Bj-GFP is an excellent model that can identify somatic label retaining stem cells.

**[0276] Ovarian GFP and BrdU labeling** was evaluated by immunofluorescence and compared with intestine, skin, and brain as positive control tissues (Fig 17, Brennand et al, 2007). PBS injected (no BrdU) and naive (no doxycycline) Rosa26-rtTA; tetO-H2Bj-GFP mice were used as negative controls (not shown). BrdU and H2Bj-GFP demonstrated labeling in the coelomic, subcoelomic/stromal (Fig 17 insets), and hilar areas of the ovary during the pulse. Significant

variability in initial pulse whole ovary labeling was observed within the H2Bj-GFP labeling method and between the H2Bj-GFP and BrdU methods used in this study (Fig 10C; adult pulse H2Bj-GFP =  $82.5 \pm 7.9\%$ , adult pulse BrdU =  $46.9 \pm 8.9\%$ , embryonic pulse H2Bj-GFP =  $26.0 \pm 2.5\%$ ;  $p < 0.05$ ). Such variability within the H2Bj-GFP labeling technique is likely the result of the visually evident lack of granulosa cell labeling in the embryonic pulse (Fig 17) and is not observed when the coelomic/subcoelomic labeling is evaluated by segmenting the granulosa and medullary cells out of the analysis (Fig 10D, detailed below). The difference observed between the BrdU and H2B-GFP pulse labeling methods is likely explained by a shorter labeling period with the BrdU method and potentially the efficiency of delivery/incorporation of the BrdU into dividing progenitor cells. After three months chase there was a significant difference in whole ovary label retention when comparing BrdU to the adult and embryonic pulse H2Bj-GFP labeling methods (Fig 10C,  $p = 0.016$  &  $p = 0.010$ ), but there was no significant difference between the two H2Bj-GFP pulse labeling methods (Fig 10C,  $p = 0.12$ ). Likewise, quantification of coelomic/subcoelomic (defined as the single layer coelomic epithelium plus the 2-4 cell layer thick region immediately below the coelomic epithelium based on visual segmentation) labeling efficiency demonstrated no significant difference between the two H2Bj pulse periods (Fig 10D,  $91\%$  &  $88\%$ ,  $p = 0.43$ ), but a significant difference between the two H2Bj-GFP techniques and BrdU was observed (Fig 10D,  $p = 0.0016$  &  $p = 0.00011$ ). Similarly, no significant difference was noted in label retention after three months chase in the H2Bj-GFP animals (Fig 10D, adult pulse H2Bj-GFP =  $5 \pm 1.1\%$  LRCs, embryonic pulse H2Bj-GFP =  $3.2 \pm 0.2\%$  LRCs,  $p = 0.794$ ) while there remained a significant difference in label retention between the H2Bj animals and the BrdU animals (Fig 10D, BrdU =  $2.2 \pm 0.4\%$  LRCs, vs adult pulse h2Bj-gfp  $p = 0.021$  & vs embryonic pulse H2Bj-GFP  $p = 0.041$ ). The inventors have discovered that both techniques and both pulse periods were able to identify similar sub-populations of LRCs in the adult ovary at the end of the chase period. Furthermore, these cells share label

retaining properties similar to those observed in the bone marrow Lin<sup>-</sup>cKit<sup>+</sup>Sca-1<sup>+</sup> hematopoietic stem cells which serve as a positive control.

#### EXAMPLE 9

[0277] *Identification of ovarian LRCs.* The inventors next evaluated ovaries at various time points in the chase interval of the experiment to determine whether re-epithelialization occurs via progenitor cell proliferation or simple self-duplication. The self-duplication model predicts uniform loss of signal during the chase period while the stem cell asymmetric division model predicts a preferential retention of label in stem/progenitor cells (Fig 11A). After 3 months chase, gross observation of H2Bj-GFP ovaries demonstrated visually bright LRCs congregating near inter-follicular clefts formed by the ovarian vasculature (Fig 11B & 11C; Fig 19: confocal 3D reconstruction, cross section). BrdU/IdU and H2Bj-GFP (embryonic and adult pulse) labeling techniques both identified label-retaining cells (Fig 11D, 11E, 11F, 11G, 11H, 11I) in the coelomic epithelium (CE), subcoelomic/stromal (SC; defined as the CD45<sup>-</sup>/CD31<sup>-</sup> 1-4 cell layer thick region immediately below the coelomic epithelium plus the stromal tissue of the ovary), and perihilar medullary cells (PHM). BrdU/IdU and H2Bj-GFP combination pulse-chase studies demonstrated colocalization of BrdU/IdU and H2Bj-GFP LRCs in most instances throughout the chase period. These results identify a candidate LRC population representative of a putative stem cell population in perivascular coelomic epithelial clefts capable of functioning in repair after ovulation induced coelomic epithelium damage. In addition, the inventors demonstrate at least two other LRC populations within the ovarian stroma that may represent stem/progenitor cell precursors of other somatic cell types in the ovary.

#### EXAMPLE 10

[0278] *Phenotypic characterization of ovarian LRCs in their microenvironment.* To understand better the niche microenvironment responsible for preserving the undifferentiated state and to characterize the surface marker expression of the identified LRC populations, the inventors evaluated a series of known stem, epithelial, mesenchymal, cell-cell adhesion, germ, and ovarian cancer cell markers. These markers and findings are summarized in Table 4 and detailed below.

[0279] *Table 4. Summary of LRC surface marker expression.* CE = Coelomic epithelial label retaining cells; SC = Subcoelomic label retaining cells, PHM = Peri-hilar medullary label retaining cells; “\*” = Hu Ov (human normal ovary) and OvCa (ovarian cancer) expression patterns were obtained from the Human Protein Atlas tissue arrays ([www.proteinatlas.org](http://www.proteinatlas.org)). “-“ = no expression; “+” = positive expression in the ovary; “+/-“ variable expression; “Dec/-“ = decreased or negative expression; NR = not reported in literature.

| Antigen                   | CE | SC  | PHM | Hu Ov* | Ov CA* |
|---------------------------|----|-----|-----|--------|--------|
| CD3 (T3)                  | -  | -   | -   | NR     | NR     |
| CD4 (T4)                  | -  | -   | -   | -      | -      |
| CD11b (Mac-1)             | -  | -   | -   | -      | -      |
| CD19 (B4)                 | -  | -   | -   | NR     | NR     |
| CD23 (Ly-42,B6)           | -  | -   | -   | -      | -      |
| CD25 (IL-2R $\alpha$ )    | -  | -   | -   | -      | -      |
| CD31 (PECAM-1)            | -  | -   | -   | +      | -      |
| CD34 (gp105-120)          | -  | +/- | -   | +      | -      |
| CD44 (Hermes, Pgp-1)      | -  | +/- | +   | -      | +      |
| CD45 (CLA)                | -  | -   | -   | -      | -      |
| CD49b(Pan-NK)             | -  | -   | -   | -      | NR     |
| CD61 (integrin $\beta$ 3) | -  | -   | -   | +      | +      |
| CD62 (E-Selectin)         | -  | -   | -   | -      | -      |
| CD90 (Thy-1)              | -  | +/- | -   | +      | +      |
| CD105 (Endoglin)          | -  | +   | +   | +      | +      |
| CD117 (c-Kit)             | -  | -   | +   | -      | -      |
| CD133 (AC133)             | -  | -   | -   | NR     | NR     |
| CD140b (PDGFRb)           | -  | +   | -   | +      | +      |
| CD309 (Flk-1, VEGFR2)     | -  | -   | -   | -      | -      |
| CD324 (E-Cadherin)        | +  | -   | -   | +      | +      |
| CD326 (EpCam)             | -  | -   | -   | -      | +      |
| Cytokeratin 8 (Troma-1)   | +  | -   | -   | +      | +      |
| Beta-Catenin              | +  | -   | -   | +      | +      |
| $\alpha$ -SMA             | -  | +/- | -   | +      | +      |
| Lineage                   | -  | -   | -   | +      | NR     |

|                    |   |     |   |   |       |
|--------------------|---|-----|---|---|-------|
| <b>NG2</b>         | - | +/- | - | + | +     |
| <b>Gata-4</b>      | + | -   | + | + | NR    |
| <b>Met</b>         | - | +   | + | + | +     |
| <b>Vimentin</b>    | + | +   | + | + | +     |
| <b>SF-1</b>        | - | -   | + | + | -     |
| <b>p16 INK4A</b>   | + | -   | + |   | +     |
| <b>Connexin 43</b> | - | -   | - | + | Dec/- |
| <b>VASA</b>        | - | -   | - | + | -     |
| <b>Oct-4</b>       | - | -   | - | - | NR    |
| <b>Era</b>         | + | +   | + | + | +/-   |
| <b>Collagen IV</b> | + | -   | - | + | +     |
| <b>PTEN</b>        | + | -   | + | + | +     |
| <b>PI3K</b>        | + | -   | - | + | +     |
| <b>Notch-1</b>     | - | -   | - | - | Dec/- |

[0280] *Coelomic LRCs*. Immunofluorescence demonstrated that coelomic LRCs express

cytokeratin 8,  $\beta$ -catenin, dim and E-cadherin (data not shown) (Table 4), and are negative for EpCam (data not shown). In addition, coelomic LRCs were negative for the pan-hematopoietic marker CD45 and the endothelial marker CD31 (Table 4 and data not shown). These cells also labeled for Collagen IV, PTEN, Vimentin, Gata-4, and PI3K (Table 4). Characterization of the coelomic LRC niche microenvironment demonstrated a close association with the immediately adjacent perivascular subcoelomic/stromal LRCs and non-LRCs. The inventors did not observe a surface marker in this study that was unique to coelomic LRCs. Thus, coelomic LRCs express known markers of epithelial cells and their perivascular microenvironment is made up of subcoelomic/stromal LRCs and non-LRCs that express classical stromal markers as detailed below.

[0281] *Subcoelomic/Stromal LRCs*. Subcoelomic/stromal LRCs were discovered predominantly immediately below the coelomic epithelium and adjacent to CD31<sup>+</sup> endothelial cells (data not shown) where they expressed varying degrees of the stromal markers NG2<sup>+/-</sup>, PDGFRb<sup>+</sup>, Thy-1<sup>+/-</sup>, CD44<sup>+/-</sup>, and  $\alpha$ SMA<sup>+/-</sup> (data not shown and Table 4). In addition, these LRCs were negative for cKit receptor, cytokeratin 8,  $\beta$ -Catenin, and E-cadherin (data not shown and Table 4). The inventors observed that the visual epifluorescent intensity of Thy-1 and NG2 increased as the subcoelomic/stromal LRCs and their progeny incorporated into the growing follicle in

association with the developing follicular capillary network. Since cells derived from the bone marrow are known to express these stromal/pericyte/fibroblastic markers, the inventors performed parabiosis and bone marrow transplantation experiments as detailed below in an effort to identify their derivation.

**[0282] Perihilar Medullary LRCs** Immunofluorescence of PHM GFP<sup>+</sup> LRCs revealed that these cells also reside immediately adjacent to CD31<sup>+</sup> endothelial cells in a perivascular niche (Fig 19I), which is bounded by  $\alpha$ -SMA (Table 4). However, in direct contrast to subcoelomic/stromal LRCs, PHM LRCs express the theca cell markers c-Kit, SF-1, and Gata-4 (data not shown). These LRCs with the marker expression profile of these cells were observed to incorporate into the developing theca layer at all chase intervals examined. A detailed surface marker profile is provided in Table 4 and the origin of these cells was determined by parabiosis and irradiation experiments as detailed below. Coelomic LRCs express the epithelial markers Cytokeratin-8,  $\beta$ -Catenin and are E-Cadherin<sup>Dim</sup>/EpCam<sup>-</sup> expression profiles are shown in Table 4. Subcoelomic/stromal LRCs lie immediately adjacent to CD31<sup>+</sup> endothelial cells (data not shown), are variably positive for NG2, PDGFRb, Thy-1, CD44 (C-G),  $\alpha$ -SMA (Table 4), and are negative for cKit (data not shown). The peri-vascular niche microenvironment of coelomic and subcoelomic/stromal LRCs was also studied (data not shown). Perihilar Medullary LRCs also reside in a perivascular niche immediately adjacent to CD31<sup>+</sup> endothelial cells (data not shown) but, in contrast to subcoelomic LRCs, they express the theca cell markers c-Kit, Gata-4, and SF-1 (data not shown) demonstrating a potential population of theca progenitor cells. These findings demonstrate that PHM LRCs may serve as a progenitor cell population for this cell production during follicle maturation.

**[0283]** To complete the niche description, the inventors investigated the relationship of germ cells to the identified LRCs. The inventors observed that VASA (Table 4) positive germ cells and primordial follicles reside within the perivascular coelomic/subcoelomic LRC niche described

in detail above, but did not co-localize with H2Bj-GFP or BrdU at any time during the pulse or the chase. GFP stained germ cells were not found in actin-GFP bone marrow recipient animals or after parabiosis using either an actin-GFP or an ubiquitin-GFP donor (as described herein in Example 11).

#### EXAMPLE 11

##### **[0284] *Parabiosis and Irradiation with $\beta$ -actin GFP bone marrow transplantation.***

Immunofluorescent characterization of the identified LRC populations, as detailed above, led the inventors to investigate whether these populations are exclusively intrinsic within the mouse ovary or are derived from an extrinsic source such as the circulation or bone marrow. The inventors performed 1) parabiosis between isogenic actin-GFP or ubiquitin-GFP mice and wild type littermates (actin-GFP n=6 pairs, ubiquitin GFP n=4 pairs), 2) parabiosis from actin-GFP mice into wild type isogenic recipients treated with cytoxan/busulfan to produce ovarian injury by chemoablation (n=6), and 3) irradiation plus isogenic  $\beta$ -actin GFP bone marrow transplantation (n=4), to investigate whether GFP positive circulation/bone marrow derived cells expressing any of the three LRC marker profiles as defined above, appeared in the non-GFP ovaries. Hematoxylin and eosin staining of ovary sections from all three conditions demonstrated a loss of stromal tissue architecture (data not shown). After irradiation, near complete replacement of the remaining spared ovarian tissue with GFP+/CD45+ circulation/bone marrow derived cells was observed (data not shown). The inventors did not observe incorporation of GFP into the coelomic epithelium or co-localization of actin-GFP with c-Kit positive perihilar medullary cells in any of these models (Figure 12H and data not shown). The inventors also did observe a loss of peri-hilar SF-1<sup>+</sup>/Gata-4<sup>+</sup>/c-Kit<sup>+</sup> cells in both the Cytoxan/Busulfan treated parabiotics and in the irradiated transplant animals without rescue by circulating/bone marrow derived actin-GFP cells. The results demonstrate that these cells are intrinsically replenished/maintained and not constitutively rejuvenated from a bone

marrow/circulating source in response to various modalities of injury or the ovarian cycle. Conversely, GFP<sup>+</sup> cells were observed to co-localize in all three models with the markers that the inventors discovered were characterized as the subcoelomic/stromal LRCs, namely, CD44, PDGFR $\beta$ , NG2, CD105, and Thy-1 to varying degrees suggesting that these cells may be derived from a circulating/bone marrow reservoir (depicted in Figure 12C, 12D, 12F, 12G and data not shown). Thus, the inventors findings demonstrate by phenotypic marker profile that coelomic and PHM LRCs are likely of intrinsic origin while subcoelomic/stromal LRCs are potentially of extrinsic circulatory/bone marrow origin.

#### EXAMPLE 12

**[0285]** *LRCs replicate in response to estrus cycling in vivo.* *In vivo* coelomic label retaining cell response to estrus cycling is necessary to confirm their identity as functional candidate stem/progenitor cells. To assess this response, the inventors used both superphysiologic hCG stimulation and simple estrous cycle staging, in combination with short 2-4h pulses of i.p. injected IdU. Prior to hCG stimulation, two proestrous chase week 12 BrdU mice were sacrificed to determine the level of prestimulation BrdU (Fig 13A). Proestrous chase week 12 BrdU mice were then hyperstimulated (n=10) by injection of 10 Units hCG and sacrificed in late estrous/early metestrous, revealing increased BrdU labeling in the coelomic and subcoelomic niches (Fig 13B). These findings demonstrate that there is increased proliferation within the coelomic and subcolomic niches in response to the estrus cycle.

**[0286]** To confirm these findings and determine if LRCs replicate *in vivo* without artificial superphysiologic hyperstimulation, the inventors performed short 2-4h pulse injections of IdU/BrdU in three-month chase H2Bj-GFP mice to asses for colocalization of BrdU/IduU and H2Bj-GFP LRCs. Pre-ovulatory or post-ovulatory (as defined in short-term BrdU experiments above) Rosa26-rtTA; tetO-H2Bj-GFP week 12 chase mice were timed by vaginal cytology and

injected with IdU 2-4h prior to sacrifice in order to identify actively mitotic cells. Response of H2Bj-GFP LRCs to the estrus cycle was evaluated with a short 2-4h pulse injection of IdU in 3 month chase H2Bj-GFP animals (data not shown). In pre-ovulatory ovaries, IdU was observed only in proliferating granulosa cells (GC) while non-proliferating subcoelomic/stromal LRCs were observed in association with primordial follicles (data not shown). In post-ovulatory animals, IdU was observed to co-localize with coelomic and subcoelomic LRCs (data not shown) demonstrating that these LRCs are functionally responsive to the estrus cycle. Subcoelomic LRCs were observed to co-localize with IdU immediately adjacent to additional proliferating IdU cells that appear to be associating with the developing follicle (data not shown). Coelomic LRCs were observed to co-localize with IdU on either side of the re-epithelializing ovulation wound (data not shown). Preovulatory ovaries demonstrated GFP<sup>+</sup> cuboidal coelomic LRCs and subcoelomic LRCs in their characteristic intrafollicular perivascular niche, but BrdU was only incorporated in granulosa cells during this phase (data not shown). In addition, the inventors observed the close association of subcoelomic LRCs with a developing primordial follicle (data not shown). Postovulatory ovaries demonstrated flattened coelomic and subcoelomic LRCs of varying GFP intensity that appeared in close proximity to both newly formed corpora lutea and in close association with a developing primary follicle (data not shown). Closer inspection revealed that both coelomic and subcoelomic LRCs are mitotically active in response to the estrus cycle as demonstrated by colocalization of IdU and H2Bj-GFP LRCs (data not shown). In addition, the inventors discovered IdU incorporation and co-localization with GFP on either side of the repairing epithelium demonstrating that there is a combination of stem/progenitor replication followed by daughter cell symmetric replication and migration (data not shown). These findings demonstrate that both coelomic and subcoelomic LRCs are responsive to the estrus cycle and

appear to supply daughter cells for reepithelialization and possibly folliculogenesis, respectively.

### EXAMPLE 13

**[0287]** *In vitro isolation and characterization of coelomic LRCs.* A mesenchymal stem cell colony forming unit (CFU) assay was used to select ovarian coelomic epithelial stem cells capable of generating characteristic colonies. Rosa26-rtTA; tetO-H2Bj-GFP coelomic epithelial cells released by collagenase treatment were plated and, after 14 days incubation, the average number of Giemsa stained colonies (Fig 14A) was determined to be  $10 \pm 5$  CFU's per  $1 \times 10^4$  plated cells (n=9) independent of pulse-chase status. These findings indicate there are a constant number of stem/progenitor cells yielding a constant number of colonies after inoculation of  $1 \times 10^4$  coelomic epithelial cells. The percentage of GFP positive colonies (Fig 14B) was visually estimated at about 30% of the colonies independent of pulse-chase status indicating there is a constant number stem/progenitor cells labeled during the pulse and that these cells retain their label and colony forming ability throughout the chase period (Fig 14C). Using the BD Pathway live confocal microscope, the inventors discovered that the H2B-GFP LRCs form spheres that settle and maintain a three-dimensional sphere structure as their symmetrically dividing daughter cells replicate away from the LRC nidus and dilute out the GFP signal, (Fig 14B, 14D and Fig 20). Quantification of GFP signal intensity loss with replication was determined to be exponential and a function of distance from the brightest LRC at all pulse-chase time points (Fig 14D).

**[0288]** To confirm the identity of CFU isolated LRCs as coelomic epithelial cells, the inventors analyzed them for expression of the surface markers identified in tissue sections. Phenotypic analysis of LRC colonies demonstrated that they are positive for the same markers as were observed in tissue sections, such as cytokeratin 8, E-cadherin, vimentin and  $\beta$ -catenin (data not

shown). In addition, the inventors did not observe expression of  $\alpha$ SMA or c-Kit (data not shown) in these cells, confirming that they were not contaminated by subcoelomic or perihilar medullary LRCs, but that the collagenase treatment of the ovary selected predominantly for the coelomic epithelial cells. These findings demonstrate that CFU assay can be used to isolate candidate normal ovarian coelomic stem cells *in vitro* and that the Rosa26-rtTA; tetO-H2Bj-GFP model appears to mark putative progenitor cells *in vivo* and *in vitro*.

#### EXAMPLE 14

[0289] **Enrichment of coelomic epithelial SP cells by H2B-GFP LRCs.** Based on our previous findings that ovarian cancer stem cells can be detected in a verapamil-sensitive Hoechst effluxing SP (Szotek, et al. 2006), the inventors assessed if the normal coelomic epithelium possessed a similar SP and that these SP cells might co-localize with coelomic LRCs. Chase 1 month and 2 month H2Bj-GFP coelomic epithelial cells were isolated, harvested, and subjected to SP analysis (Szotek et al., 2006) as previously described (1 month n=3 animals, 2 month n=3, 3 month n=1). SP analysis clearly identified a verapamil-sensitive side population (Fig 15A, SP =  $2.46 \pm 0.27\%$ -SD, n=6 compared to Fig 15B, +Verapamil % SP =  $0.005 \pm 0.008\%$ -SD, n=6) within the normal coelomic epithelium in adult H2Bj-GFP mice. GFP intensity gates were set using wild type GFP<sup>-</sup> epithelial cells to define the GFP<sup>+</sup> gate as intensity  $\geq 10^2$  and the GFP<sup>bright</sup> LRC gate as an intensity  $\geq 10^3$  (Fig 15C). Evaluation of 2 month chase SP cells for GFP expression demonstrated that  $56.5 \pm 4.1\%$  SD of SP<sup>+</sup> cells are H2Bj-GFP<sup>+</sup> (Fig 15C; n=3) and  $67.7 \pm 8.1\%$  SD (Fig 15D, n=3) of those SP<sup>+</sup>/H2B-GFP<sup>+</sup> are classified as GFP<sup>bright</sup>/LRCs. Thus, the inventors demonstrate in these studies validate that SP can be used as a workable surrogate to identify LRCs with stem cell-like characteristics within the coelomic epithelium of normal mouse ovary and, by extension, in tumor populations.

[0290] The inventors also discovered coelomic epithelial LRCs do not express EpCam. The inventors used immunofluorescence to determine if the reported ovarian cancer cell marker EpCam is expressed on LRCs. The inventors did not observe expression of EpCam on the mouse ovarian surface epithelium but it was clearly expressed on the fallopian tube epithelium (not shown) and the uterine epithelium (data not shown). To confirm the discovery that the subcoelomic/stromal LRCs are likely bone marrow derived and that the coelomic and perihilar-medullary cells are likely not circulatory/bone marrow derived, the inventors tested whether chemo-ablation of the germ cells using Cytoxan/Busulfan or irradiation followed by actin-GFP bone marrow transplantation would stimulate an otherwise extremely rare event to occur. H&E sections demonstrated that the ovarian stroma of the Cy/Bu treated parabiosis mice and the irradiated GFP-bone marrow transplanted mice is significantly altered over that of wild type or non-treated parabiosis mice (data not shown). Surface marker profiling of Cy/Bu treated parabiosis ovaries and irradiated bone marrow transplant ovaries demonstrated co-localization of actin-GFP with the markers used to identify subcoelomic/stromal LRCs confirming that these cells are likely bone marrow derived (data not shown). At no time did we see incorporation of GFP into the coelomic epithelium or co-localization with cytokeratin 8 in the coelomic epithelium; however, the inventors did note loss of cytokeratin 8 expression and gain of aSMA expression in the irradiated mice (data not shown). The inventors did not observe the presence of cKit<sup>+</sup>/Gata-4<sup>+</sup>/SF-1<sup>+</sup> perihilar medullary cells in either model suggesting that these cells are not bone marrow derived and are likely dependent on the presence of germ cells for maintenance of their progenitor pool. The inventors also discovered that the ovarian stroma is almost completely replaced by CD45<sup>+</sup>/Lineage<sup>+</sup> cells and that the vasculature appears atrophic in the irradiated mice.

[0291] The inventors also performed 3D confocal reconstruction of LRC perivascular niche.

Three-dimensional reconstruction of 3 month chase Rosa26-rtTA; tetO-H2B-GFP coelomic and

subcoelomic LRCs within their perivascular niche. Coelomic H2B-GFP LRCs (Green) appear to reside just superficial to the subcoelomic LRCs and the subcoelomic LRCs appear to lie directly in contact with the ovarian vasculature stained with CD31(data not shown).

**[0292]** The hypothesis that rare "embryonic rests" are responsible for malignancy was suggested >100 years ago (24), but recent advances in somatic stem cell identification has rejuvenated research in this area (28-29). The unique asymmetric self-renewal capacities of somatic stem cells make it plausible and probable that mutations in these cells are perpetuated and over time lead to malignancy. Like somatic stem cells, cancer stem cell populations have the properties of self-renewal, heterologous descendent cells, slow cell-cycle times, and, unlike somatic stem cells, enriched tumor formation (8, 24). Herein, the inventors have discovered these properties within a subpopulation of mouse ovarian cancer cells that were isolated by SP sorting. The inventors have discovered MOVCAR7 and 4306 SP cells are able to self-renew and produce heterologous descendent NSP cells in culture, MOVCAR 7 SP cells are predominantly G<sub>1</sub> cell cycle arrested, and the *in vivo* time to appearance of tumors in animals injected with equal numbers of MOVCAR 7 cells may be shorter in those receiving SP cells. The inventors discovered that appearance of tumors in NSP-injected animals occurred at the same time as animals injected with unsorted cells possessing approximately the same number of SP cells. Thus, the inventors have discovered that isolated mouse SP cells possess the properties ascribed to cancer stem cells, and only a low number of these SP cells is required to initiate tumor formation *in vivo*, thus the inventors have discovered a new model for human ovarian cancer.

**[0293]** Ovarian cancer patients initially respond well to surgical cytoreduction and chemotherapy. Chemotherapy alone can yield several logs of tumor cytoreduction but seldom a cure. The majority of patients who respond to primary chemotherapy ultimately develop recurrent, usually drug-resistant, disease that is conceivably due to the ability of ovarian cancer stem cells to escape these drugs. BCRP1, otherwise known as the ABCG2 transporter, confers the ability to

not only define a stem cell-like Hoechst 33342-excluding SP but, perhaps more importantly, the drug resistance-associated efflux of many lipophilic chemotherapeutic agents such as mitoxantrone, daunorubicin, doxorubicin, indolcarbazole, and others (22). Herein, the the inventors demonstrate that candidate mouse ovarian cancer stem cells, defined as Hoechst-effluxing, verapamil-sensitive, and BCRP1<sup>+</sup> SP cells, are more resistant to doxorubicin, confirming these stem cell-like characteristics as a potential mechanism for drug resistance. In addition, the inventors have identified a similar subpopulation of cells in both human ovarian cancer cell lines and primary human ascites cells that could be defined as Hoechst-effluxing, verapamil-sensitive, BCRP1<sup>+</sup> SP cells. The inventors have discovered that BCRP1 and ability to exclude lipophilic molecules can be used as "markers" to detect and isolate patient primary ovarian cancer stem cells for further characterization.

**[0294]** The inventors have discovered that a subpopulation of cells found in the mouse SPs demonstrate some of the properties of cancer stem cells. The inventors have also discovered the expression of the drug-resistance transporter BCRP1 or other multidrug-resistance proteins (30-33) in these cells, which can have a profound impact on selection of individual treatment strategies, clinical outcome, and the design or selection of the next generation of chemotherapeutic agents. For example, MIS inhibits human anchorage-independent Mullerian tumors in soft agarose (34). The inventors have discovered herein that MIS also acts on cancer stem cell-like populations. The inventors demonstrate that MIS inhibits MOVCAR 7 SP cells *in vitro*. The inventors have discovered therefore that suggests that MIS can function as an effective adjuvant to current ovarian cancer chemotherapeutic regimens because of its ability to attack this elusive subpopulation of cancer cells. MIS also inhibits MOVCAR 8 and OVCAR 8 cells (25, 35), indicating that response to MIS is not only dependent on the presence of an SP.

**[0295]** Accumulating evidence suggests that somatic stem cells residing in local niche microenvironments may ultimately undergo mutagenic transformation into cancer stem cells

(Calabrese et al., 2007) and that alternatively, aberrant regulatory signals from the niche microenvironment might also lead to tumorigenesis (Clarke and Fuller, 2006). The inventors herein demonstrate the presence of somatic stem cells in the adult mouse ovary and characterize their niche microenvironment. Using several lines of evidence and experimental approaches, the inventors demonstrate that coelomic LRCs residing in a perivascular niche microenvironment exist in the adult mouse ovary, are functionally responsive to the estrus cycle *in vivo*, and possess many of the functional properties ascribed to somatic stem cells from other tissues, as well as ovarian cancer stem cells (Szotek et al., 2006).

**[0296]** The inventors demonstrate, using both BrdU and Rosa26-rtTA; tetO-H2B-GFP pulse-chase experiments in combination with parabiosis and bone marrow transplant experiments, intrinsically derived coelomic LRCs located in a perivascular niche microenvironment (Fig 11), characterize their surface marker phenotype (Fig 12), and demonstrate that postovulatory coelomic reepithelialization is a stem cell-mediated process (Fig 13 and Fig 18- a model of coelomic epithelial repair). Surface marker characterization performed by the inventors demonstrated that the coelomic LRCs have an epithelial lineage *in vivo* and *in vitro* (cytokeratin-8<sup>+</sup>,  $\beta$ -Catenin<sup>+</sup>, and E-Cadherin<sup>+</sup>), they are also vimentin<sup>+</sup> demonstrating a dual epithelial/mesenchymal potential ascribed to the embryonic and adult coelomic epithelium (Auersperg et al., 1999; Orvis and Behringer, 2007).

**[0297]** Herein, the inventors demonstrate that the ovarian surface epithelium contains a subset of cells that are able to form characteristic colonies in a mesenchymal stem cell CFU assay and that LRCs isolated by this method proliferate in a manner consistent with stem cell asymmetric division (Fig 14 & Fig 20). Finally, the inventors demonstrate that somatic LRCs from the normal ovarian coelomic epithelium enrich for the ovarian cancer stem cell-ascribed functional property of verapamil-sensitive Hoechst 33342 exclusion (SP). However, unlike ovarian cancer cells, which express the surface marker EpCam (Drapkin et al., 2004; Heinzelmann-Schwarz et

al., 2004; Kim et al., 2003; Szotek et al., 2006), coelomic LRCs are negative for EpCam (Fig 18). Parabiosis experiments performed by the inventors also demonstrates that the coelomic epithelial LRCs are not derived from the circulation/bone marrow but are intrinsic to the ovary. Collectively, the inventors have discovered and identified somatic stem cell population within the mouse ovarian coelomic epithelium that, like cancer stem cells, has the characteristics of slow-cycling (label retention) and multi-drug resistance (Hoechst 33342 dye exclusion/SP).

**[0298]** In addition to the characterization of the coelomic epithelial somatic stem cell, its niche microenvironment, and its potential relationship to ovarian cancer progression, the inventors demonstrate at least two other somatic LRCs exist within the ovarian stroma (subcoelomic/stromal LRCs and perihilar medullary LRCs; Fig 11C & 11D) and reside in perivascular niche microenvironments (data not shown).

**[0299]** The inventors demonstrate, based on phenotypic lineage analysis of subcoelomic/stromal ( $cKIT^{-}/\alpha SMA^{\pm}/PDGFRb^{+}/NG2^{\pm}/CD44^{+}/CD105^{+}/CD45^{-}/CD31^{-}$ ) and perihilar medullary ( $cKIT^{+}/SF-1^{+}/GATA-4^{+}/CD44^{+}/CD105^{+}/CD45^{-}/CD31^{-}/\alpha SMA^{-}$ ) LRCs that these two non-coelomic LRC populations are involved in folliculogenesis as described in Fig 18C & 18D. Furthermore, using parabiosis experiments the inventors demonstrate that subcoelomic/stromal LRCs are circulation/bone marrow derived cells that appear to incorporate into the early developing follicular capillary network, while perihilar medullary LRCs are intrinsically derived and appear to incorporate into the maturing follicle as developing theca cells (Fig 12).

**[0300]** The notion that cancer is derived from tissue stem cells is over one-hundred years old, but only recently has this hypothesis been validated (Reya et al., 2001; Sell, 2004) and insight provided into the mechanisms by which mutations may be accumulated, passed on to differentiating daughter cells, and ultimately lead to tumor progression. Herein, the inventors, using mouse models of label retaining cells, demonstrate that there is a sub-population of ovarian coelomic epithelial cells with somatic and cancer stem cell-like characteristics,

including the ovarian cancer property of Hoechst dye efflux (SP). Since many of the same functional properties that define somatic stem cells also define the properties of cancer cells, the inventors have discovered a method to compare somatic ovarian stem cells with cancer ovarian stem cells to elucidate factors that cause a change from the normal somatic ovarian stem cells to ovarian cancer stem cell phenotype. In addition to demonstrating the existence coelomic LRCs, the inventors have also demonstrated a methods to isolate the somatic ovarian stem cells and ovarian cancer stem cells *in vitro* using a CFU assay, which can be used as a method to identify agents which inhibit the proliferation of the ovarian cancer stem cells as compared to the somatic ovarian stem cells.

**[0301]** Furthermore, having equated H2B and BrdU LRCs in pulse chase experiments and subsequently correlated enriched H2B-GFP in the SP population, the inventors have demonstrated that use of the side population (SP) in unmarked cells, such as those from primary human patient biological samples, as a marker to identify a biological sample enriched in an ovarian cancer stem cell population.

**[0302]** As demonstrated herein, the inventors have discovered methods to identify and enrich for somatic ovarian stem cells and ovarian cancer stem cells, which can be used for further study as well as use in assays to identify agents which inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian cancer cells, as well as identify agents which prevent the transformation of somatic ovarian cancer cells to become ovarian cancer stem cells. Ultimately, the inventors have discovered the ovarian stem cell populations underlying ovarian cancer and a method for comparison of these two populations (ovarian cancer stem cells as compared to somatic ovarian cancer cells) that can be used to direct the development of therapies and treatments targeted at the chemotherapeutic elusive stem cell properties that define these populations.

## REFERENCES

[0303] The references cited herein and throughout the application are incorporated herein by reference.

- [0304] 1. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. (2003) *Proc. Natl. Acad. Sci. USA* 100, 3983–3988.
- [0305] 2. Haraguchi, N., Utsunomiya, T., Inoue, H., Tanaka, F., Mimori, K., Barnard, G. F. & Mori, M. (2006) *Stem Cells* (Dayton, Ohio) 24, 506–513.
- [0306] 3. Kondo, T., Setoguchi, T. & Taga, T. (2004) *Proc. Natl. Acad. Sci. USA* 101, 781–786.
- [0307] 4. Wulf, G. G., Wang, R. Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K., Andreeff, M. & Goodell, M. A. (2001) *Blood* 98, 1166–1173.
- [0308] 5. Seigel, G. M., Campbell, L. M., Narayan, M. & Gonzalez-Fernandez, F. (2005) *Mol. Vis.* 11, 729–737.
- [0309] 6. Poste, G. & Greig, R. (1982) *Invasion Metastasis* 2, 137–176.
- [0310] 7. Poste, G., Tzeng, J., Doll, J., Greig, R., Rieman, D. & Zeidman, I. (1982) *Proc. Natl. Acad. Sci. USA* 79, 6574–6578.
- [0311] 8. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. (2001) *Nature* 414, 105–111.
- [0312] 9. Tu, S. M., Lin, S. H. & Logothetis, C. J. (2002) *Lancet Oncol.* 3, 508–513.
- [0313] 10. Li, L. & Xie, T. (2005) *Annu. Rev. Cell Dev. Biol.* 21, 605–631.
- [0314] 11. Bukovsky, A., Caudle, M. R., Svetlikova, M. & Upadhyaya, N. B. (2004) *Reprod. Biol. Endocrinol.* 2, 20.
- [0315] 12. Scully, R. E. (1970) *Hum. Pathol.* 1, 73–98.
- [0316] 13. Young, R. H. (2005) *Mod. Pathol.* 18 2, S3–S17.
- [0317] 14. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J. & Thun, M. J. (2005) *CA Cancer J. Clin.* 55, 10–30.
- [0318] 15. Cannistra, S. A. (1993) *N. Engl. J. Med.* 329, 1550–1559.

- [0319] 16. Parker, S. L., Tong, T., Bolden, S. & Wingo, P. A. (1997) *CA Cancer J. Clin.* 47, 5–27.
- [0320] 17. Gottesman, M. M., Fojo, T. & Bates, S. E. (2002) *Nat. Rev. Cancer* 2, 48–58.
- [0321] 18. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. (1996) *J. Exp. Med.* 183, 1797–1806.
- [0322] 19. Connolly, D. C., Bao, R., Nikitin, A. Y., Stephens, K. C., Poole, T. W., Hua, X., Harris, S. S., Vanderhyden, B. C. & Hamilton, T. C. (2003) *Cancer Res.* 63, 1389–1397.
- [0323] 20. Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D. & Jacks, T. (2005) *Nat. Med.* 11, 63–70.
- [0324] 21. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A. & Brenner, M. K. (2004) *Proc. Natl. Acad. Sci. USA* 101, 14228–14233.
- [0325] 22. Doyle, L. A. & Ross, D. D. (2003) *Oncogene* 22, 7340–7358.
- [0326] 23. Gottesman, M. M. & Pastan, I. (1993) *Annu. Rev. Biochem.* 62, 385–427.
- [0327] 24. Sell, S. (2004) *Crit. Rev. Oncol. Hematol.* 51, 1–28.
- [0328] 25. Pieretti-Vanmarcke, R., Donahoe, P. K., Szotek, P., Manganaro, T., Lorenzen, M. K., Lorenzen, J., Connolly, D. C., Halpern, E. F. & MacLaughlin, D. T. (2006) *Clin. Cancer Res.* 12, 1593–1598.
- [0329] 26. Zhan, Y., Fujino, A., MacLaughlin, D., Manganaro, T., Szotek, P., Arango, N., Teixeira, J. & Donahoe, P. (2006) *Development (Cambridge, U.K.)* 133, 2359–2369.
- [0330] 27. Behbod, F. & Rosen, J. M. (2005) *Carcinogenesis* 26, 703–711.
- [0331] 28. Gale, R. P. & Butturini, A. (1992) *Leukemia* 6, Suppl. 1, 80–85.
- [0332] 29. Makino, S. (1956) *Ann. N. Y. Acad. Sci.* 63, 818–830.
- [0333] 30. Duan, Z., Brakora, K. A. & Seiden, M. V. (2004) *Mol. Cancer Ther.* 3, 833–838.
- [0334] 31. Duan, Z., Lamendola, D. E., Yusuf, R. Z., Penson, R. T., Preffer, F. I. & Seiden, M. V. (2002) *Anticancer Res.* 22, 1933–1941.

- [0335] 32. Penson, R. T., Oliva, E., Skates, S. J., Glyptis, T., Fuller, A. F. Jr., Goodman, A. & Seiden, M. V. (2004) *Gynecol. Oncol.* 93, 98–106.
- [0336] 33. Seiden, M. V., Swenerton, K. D., Matulonis, U., Campos, S., Rose, P., Batist, G., Ete, E., Garg, V., Fuller, A., Harding, M. W. & Charpentier, D. (2002) *Gynecol. Oncol.* 86, 302–310.
- [0337] 34. Fuller, A. F. Jr., Krane, I. M., Budzik, G. P. & Donahoe, P. K. (1985) *Gynecol. Oncol.* 22, 135–148.
- [0338] 35. Ha, T. U., Segev, D. L., Barbie, D., Masiakos, P. T., Tran, T. T., Dombkowski, D., Glander, M., Clarke, T. R., Lorenzo, H. K., Donahoe, P. K. & Maheswaran, S. (2000) *J. Biol. Chem.* 275, 37101–37109.
- [0339] 36. Preffer, F. I., Dombkowski, D., Sykes, M., Scadden, D. & Yang, Y. G. (2002) *Stem Cells (Dayton, Ohio)* 20, 417–427.
- [0340] 37. Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J. Jr., Ozols, R. F., Fojo, A. T. & Hamilton, T. C. (1990) *Int. J. Cancer* 45, 416–422.
- [0341] 38. Denizot, F. & Lang, R. (1986) *J. Immunol. Methods* 89, 271–277.
- [0342] 39. Lorenzo, H. K., Teixeira, J., Pahlavan, N., Laurich, V. M., Donahoe, P. K. & MacLaughlin, D. T. (2002) *J. Chromatogr. B Biomed. Sci. Appl.* 766, 89–98.
- [0343] 40. Hudson, P. L., Dougas, I., Donahoe, P. K., Cate, R. L., Epstein, J., Pepinsky, R. B. & MacLaughlin, D. T. (1990) *J. Clin. Endocrinol. Metab.* 70, 16–22.
- [0344] 41. Donahoe, P. K., Ito, Y., Marfatia, S. & Hendren, W. H. (1976) *Biol. Reprod.* 15, 329–334.
- [0345] 42. Donahoe, P. K., Ito, Y. & Hendren, W. H. (1977) *J. Surg. Res.* 23, 141–148.
- [0346] Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 100, 3983-3988.

- [0347] Albert, M.R., Foster, R.A., and Vogel, J.C. (2001). Murine epidermal label-retaining cells isolated by flow cytometry do not express the stem cell markers CD34, Sca-1, or Flk-1. *J Invest Dermatol* 117, 943-948.
- [0348] Alvarez-Buylla, A., and Lim, D.A. (2004). For the long run: maintaining germinal niches in the adult brain. *Neuron* 41, 683-686.
- [0349] Arango, N.A., Szotek, P.P., Manganaro, T.F., Oliva, E., Donahoe, P.K., and Teixeira, J. (2005). Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. *Dev Biol* 288, 276-283.
- [0350] Auersperg, N., Pan, J., Grove, B.D., Peterson, T., Fisher, J., Maines-Bandiera, S., Somasiri, A., and Roskelley, C.D. (1999). E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. *Proc Natl Acad Sci U S A* 96, 6249-6254.
- [0351] Beard, C., Hochedlinger, K., Plath, K., Wutz, A., and Jaenisch, R. (2006). Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. *Genesis* 44, 23-28.
- [0352] Behbod, F., and Rosen, J.M. (2005). Will cancer stem cells provide new therapeutic targets? *Carcinogenesis* 26, 703-711.
- [0353] Berns, A. (2005). Stem cells for lung cancer? *Cell* 121, 811-813.
- [0354] Bhatt, R.I., Brown, M.D., Hart, C.A., Gilmore, P., Ramani, V.A., George, N.J., and Clarke, N.W. (2003). Novel method for the isolation and characterisation of the putative prostatic stem cell. *Cytometry A* 54, 89-99.
- [0355] Bjersing, L., and Cajander, S. (1974). Ovulation and the mechanism of follicle rupture. V. Ultrastructure of tunica albuginea and theca externa of rabbit graafian follicles prior to induced ovulation. *Cell Tissue Res* 153, 15-30.
- [0356] Bjersing, L., and Cajander, S. (1975). Ovulation and the role of the ovarian surface epithelium. *Experientia* 31, 605-608.

- [0357] Blanpain, C., Lowry, W.E., Geoghegan, A., Polak, L., and Fuchs, E. (2004). Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. *Cell* 118, 635-648.
- [0358] Braun, K.M., and Watt, F.M. (2004). Epidermal label-retaining cells: background and recent applications. *J Investig Dermatol Symp Proc* 9, 196-201.
- [0359] Brennand, K., Huangfu, D., and Melton, D. (2007). All beta Cells Contribute Equally to Islet Growth and Maintenance. *PLoS Biol* 5, e163.
- [0360] Bukovsky, A., Caudle, M.R., Svetlikova, M., and Upadhyaya, N.B. (2004). Origin of germ cells and formation of new primary follicles in adult human ovaries. *Reprod Biol Endocrinol* 2, 20.
- [0361] Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., Oh, E.Y., Gaber, M.W., Finklestein, D., Allen, M., *et al.* (2007). A perivascular niche for brain tumor stem cells. *Cancer cell* 11, 69-82.
- [0362] Cheng, W., Liu, J., Yoshida, H., Rosen, D., and Naora, H. (2005). Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. *Nat Med* 11, 531-537.
- [0363] Clarke, M.F., and Fuller, M. (2006). Stem cells and cancer: two faces of eve. *Cell* 124, 1111-1115.
- [0364] Clow, O.L., Hurst, P.R., and Fleming, J.S. (2002). Changes in the mouse ovarian surface epithelium with age and ovulation number. *Mol Cell Endocrinol* 191, 105-111.
- [0365] Drapkin, R., Crum, C.P., and Hecht, J.L. (2004). Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. *Human pathology* 35, 1014-1021.
- [0366] Eggan, K., Jurga, S., Gosden, R., Min, I.M., and Wagers, A.J. (2006). Ovulated oocytes in adult mice derive from non-circulating germ cells. *Nature* 441, 1109-1114.

- [0367] Fuchs, E., Tumber, T., and Guasch, G. (2004). Socializing with the neighbors: stem cells and their niche. *Cell* 116, 769-778.
- [0368] Goodell, M.A., Brose, K., Paradis, G., Conner, A.S., and Mulligan, R.C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med* 183, 1797-1806.
- [0369] Haraguchi, N., Utsunomiya, T., Inoue, H., Tanaka, F., Mimori, K., Barnard, G.F., and Mori, M. (2005). Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System. *Stem Cells*, 2005-0282.
- [0370] Heinzelmann-Schwarz, V.A., Gardiner-Garden, M., Henshall, S.M., Scurry, J., Scolyer, R.A., Davies, M.J., Heinzelmann, M., Kalish, L.H., Bali, A., Kench, J.G., *et al.* (2004). Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. *Clin Cancer Res* 10, 4427-4436.
- [0371] Imitola, J., Comabella, M., Chandraker, A.K., Dangond, F., Sayegh, M.H., Snyder, E.Y., and Khoury, S.J. (2004). Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. *Am J Pathol* 164, 1615-1625.
- [0372] Johnson, J., Bagley, J., Skaznik-Wikiel, M., Lee, H.J., Adams, G.B., Niikura, Y., Tschudy, K.S., Tilly, J.C., Cortes, M.L., Forkert, R., *et al.* (2005). Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. *Cell* 122, 303-315.
- [0373] Jonker, J.W., Freeman, J., Bolscher, E., Musters, S., Alvi, A.J., Tittley, I., Schinkel, A.H., and Dale, T.C. (2005). Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. *Stem Cells* 23, 1059-1065.
- [0374] Kenney, N.J., Smith, G.H., Lawrence, E., Barrett, J.C., and Salomon, D.S. (2001). Identification of Stem Cell Units in the Terminal End Bud and Duct of the Mouse Mammary Gland. *J Biomed Biotechnol* 1, 133-143.

- [0375] Kim, J.H., Herlyn, D., Wong, K.K., Park, D.C., Schorge, J.O., Lu, K.H., Skates, S.J., Cramer, D.W., Berkowitz, R.S., and Mok, S.C. (2003). Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. *Clin Cancer Res* 9, 4782-4791.
- [0376] Kondo, M., Wagers, A.J., Manz, M.G., Prohaska, S.S., Scherer, D.C., Beilhack, G.F., Shizuru, J.A., and Weissman, I.L. (2003). Biology of hematopoietic stem cells and progenitors: implications for clinical application. *Annu Rev Immunol* 21, 759-806.
- [0377] Leedham, S.J., Brittan, M., McDonald, S.A., and Wright, N.A. (2005). Intestinal stem cells. *J Cell Mol Med* 9, 11-24.
- [0378] Li, L., and Xie, T. (2005). Stem Cell Niche: Structure and Function. *Annu Rev Cell Dev Biol*.
- [0379] Liu, X., Driskell, R.R., and Engelhardt, J.F. (2004). Airway glandular development and stem cells. *Curr Top Dev Biol* 64, 33-56.
- [0380] Lowry, W.E., Blanpain, C., Nowak, J.A., Guasch, G., Lewis, L., and Fuchs, E. (2005). Defining the impact of beta-catenin/Tcf transactivation on epithelial stem cells. *Genes Dev* 19, 1596-1611.
- [0381] Mills, J.C., and Gordon, J.I. (2001). The intestinal stem cell niche: there grows the neighborhood. *Proc Natl Acad Sci U S A* 98, 12334-12336.
- [0382] Morris, R.J., Fischer, S.M., and Slaga, T.J. (1986). Evidence that a slowly cycling subpopulation of adult murine epidermal cells retains carcinogen. *Cancer Res* 46, 3061-3066.
- [0383] Morris, R.J., and Potten, C.S. (1994). Slowly cycling (label-retaining) epidermal cells behave like clonogenic stem cells in vitro. *Cell Prolif* 27, 279-289.
- [0384] Morris, R.J., and Potten, C.S. (1999). Highly persistent label-retaining cells in the hair follicles of mice and their fate following induction of anagen. *J Invest Dermatol* 112, 470-475.
- [0385] Morrison, S.J., Uchida, N., and Weissman, I.L. (1995). The biology of hematopoietic stem cells. *Annu Rev Cell Dev Biol* 11, 35-71.

- [0386] Morrison, S.J., and Weissman, I.L. (1994). The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. *Immunity* *1*, 661-673.
- [0387] Murdoch, W.J., Townsend, R.S., and McDonnell, A.C. (2001). Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: prospective regulatory mechanisms of repair/survival and apoptosis. *Biol Reprod* *65*, 1417-1424.
- [0388] Oliver, J.A., Maarouf, O., Cheema, F.H., Martens, T.P., and Al-Awqati, Q. (2004). The renal papilla is a niche for adult kidney stem cells. *J Clin Invest* *114*, 795-804.
- [0389] Orlic, D., Fischer, R., Nishikawa, S., Nienhuis, A.W., and Bodine, D.M. (1993). Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. *Blood* *82*, 762-770.
- [0390] Orvis, G.D., and Behringer, R.R. (2007). Cellular mechanisms of Mullerian duct formation in the mouse. *Dev Biol* *306*, 493-504.
- [0391] Patrawala, L., Calhoun, T., Schneider-Broussard, R., Zhou, J., Claypool, K., and Tang, D.G. (2005). Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, whereas ABCG2+ and ABCG2- Cancer Cells Are Similarly Tumorigenic. *Cancer Res* *65*, 6207-6219.
- [0392] Preffer, F.I., Dombkowski, D., Sykes, M., Scadden, D., and Yang, Y.G. (2002). Lineage-negative side-population (SP) cells with restricted hematopoietic capacity circulate in normal human adult blood: immunophenotypic and functional characterization. *Stem Cells* *20*, 417-427.
- [0393] Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells, cancer, and cancer stem cells. *Nature* *414*, 105-111.
- [0394] Sell, S. (2004). Stem cell origin of cancer and differentiation therapy. *Crit Rev Oncol Hematol* *51*, 1-28.
- [0395] Smalley, M.J., and Clarke, R.B. (2005). The mammary gland "side population": a putative stem/progenitor cell marker? *J Mammary Gland Biol Neoplasia* *10*, 37-47.

- [0396] Smalley, M.J., Titley, I., and Ashworth, A. (2005). An improved definition of mouse mammary epithelial side population cells. *Cytotherapy* 7, 497-508.
- [0397] Spradling, A., Drummond-Barbosa, D., and Kai, T. (2001). Stem cells find their niche. *Nature* 414, 98-104.
- [0398] Szotek, P.P., Chang, H.L., Zhang, L., Preffer, F., Dombkowski, D., Donahoe, P.K., and Teixeira, J. (2007). Adult Mouse Myometrial Label-Retaining Cells Divide in Response to Gonadotropin Stimulation. *Stem Cells*.
- [0399] Szotek, P.P., Pieretti-Vanmarcke, R., Masiakos, P.T., Dinulescu, D.M., Connolly, D., Foster, R., Dombkowski, D., Preffer, F., Maclaughlin, D.T., and Donahoe, P.K. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. *Proc Natl Acad Sci U S A* 103, 11154-11159.
- [0400] Tan, O.L., and Fleming, J.S. (2004). Proliferating cell nuclear antigen immunoreactivity in the ovarian surface epithelium of mice of varying ages and total lifetime ovulation number following ovulation. *Biol Reprod* 71, 1501-1507.
- [0401] Tsujimura, A., Koikawa, Y., Salm, S., Takao, T., Coetzee, S., Moscatelli, D., Shapiro, E., Lepor, H., Sun, T.T., and Wilson, E.L. (2002). Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. *J Cell Biol* 157, 1257-1265.
- [0402] Tumber, T., Guasch, G., Greco, V., Blanpain, C., Lowry, W.E., Rendl, M., and Fuchs, E. (2004). Defining the epithelial stem cell niche in skin. *Science* 303, 359-363.
- [0403] Vidrich, A., Buzan, J.M., and Cohn, S.M. (2003). Intestinal stem cells and mucosal gut development. *Curr Opin Gastroenterol* 19, 583-590.
- [0404] Wagers, A.J., Sherwood, R.I., Christensen, J.L., and Weissman, I.L. (2002). Little evidence for developmental plasticity of adult hematopoietic stem cells. *Science* 297, 2256-2259.
- [0405] Watt, F.M., and Hogan, B.L. (2000). Out of Eden: stem cells and their niches. *Science* 287, 1427-1430.

- [0406] Welm, B., Behbod, F., Goodell, M.A., and Rosen, J.M. (2003). Isolation and characterization of functional mammary gland stem cells. *Cell Prolif 36 Suppl 1*, 17-32.
- [0407] Welm, B.E., Tepera, S.B., Venezia, T., Graubert, T.A., Rosen, J.M., and Goodell, M.A. (2002). Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. *Dev Biol 245*, 42-56.
- [0408] Williams, E.D., Lowes, A.P., Williams, D., and Williams, G.T. (1992). A stem cell niche theory of intestinal crypt maintenance based on a study of somatic mutation in colonic mucosa. *Am J Pathol 141*, 773-776.
- [0409] Wong, M.H. (2004). Regulation of intestinal stem cells. *J Investig Dermatol Symp Proc 9*, 224-228.
- [0410] Wright, D.E., Wagers, A.J., Gulati, A.P., Johnson, F.L., and Weissman, I.L. (2001). Physiological migration of hematopoietic stem and progenitor cells. *Science 294*, 1933-1936.
- [0411] Wu, W.Y., and Morris, R.J. (2005). In vivo labeling and analysis of epidermal stem cells. *Methods Mol Biol 289*, 73-78.
- [0412] Wulf, G.G., Wang, R.Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M.K., Andreeff, M., and Goodell, M.A. (2001). A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. *Blood 98*, 1166-1173.
- [0413] Zhan, Y., Fujino, A., MacLaughlin, D.T., Manganaro, T.F., Szotek, P.P., Arango, N.A., Teixeira, J., and Donahoe, P.K. (2006). Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression. *Development 133*, 2359-2369.

[0414] SEQUENCES

**SEQ ID NO: 15:** nucleic acid sequence of human MIS mRNA (Accession ID; NM\_000479.3 GeneID:157266297)

```
1 gcatgttgac acatcaggcc cagctctatc actggggagg gagataggct gccagggaca
61 gaaagggctc tttgagaagg ccaactctgcc tggagtgggg gcgcccggca ctgtccccc
121 aggtcgcggc agaggagata ggggtctgtc ctgcacaaac accccacctt ccaactcggt
181 cacttaaggc aggcagccca gcccttgga gcacccacga tgcgggacct gcctctcacc
```

```

241 agcctggccc tagtgctgtc tgccttgggg gctctgctgg ggactgagge cctcagagca
301 gaggagccag ctgtgggcac cagtggcctc atcttccgag aagacttggga ctggcctcca
361 ggcagcccac aagagcctct gtgcctggtg gcactgggcg gggacagcaa tggcagcagc
421 tccccctgc ggggtggtggg ggctctaagc gcctatgagc aggccttccct gggggccgtg
481 cagagggccc gctggggccc ccgagacctg gccaccttcg gggctcgcaa caccggtgac
541 aggcaggctg ccttgccctc tctacggcgg ctgggggctt ggctgcgga ccctgggggg
601 cagcgcctgg tggctctaca cctggaggaa gtgacctggg agccaacacc ctcgctgagg
661 ttccaggagc ccccgcttgg aggagctggc cccccagagc tggcgctgct ggtgctgtac
721 cctgggcctg gccctgaggt cactgtgacg agggctgggc tgccgggtgc ccagagcctc
781 tgccccctcc gagacacccg ctacctggtg ttagcgggtg accgcctgc gggggcctgg
841 cgcggtccg ggctggcctt gacctgcag ccccgcgag aggaactccg gctgagtacc
901 gcccggctgc aggcactgct gttcggcgac gaccaccgct gcttcacacg gatgaccccg
961 gccctgctcc tgctgccgcg gtccgagccc gcgcccgtgc ctgcgacag ccagctggac
1021 accgtgccct tcccgccgcc caggccatcc gcggaactcg aggagtcgcc acccagcgca
1081 gacccttcc tggagacgct cacgcgctg gtgcgggcg tgccgggtccc cccggcccgg
1141 gcctccgcg cgcgctggc cctggatccg gacgctggc ccggcttccc gcagggccta
1201 gtcaacctgt cggacccccg ggcgctggag cgctactcg acggcgagga gccgctgctg
1261 ctgctgctga ggcccactgc ggccaccacc ggggatcctg cccccctgca cgacccacg
1321 tcggcgccgt gggccacggc cctggcgcgc cgcgtggctg ctgaactgca agcggcggtt
1381 gccgagctgc gaagcctccc gggctgctc ccggccacag ccccgctgct ggcgcgctg
1441 ctgcgctct gcccaggtgg ccccgcggc ctcgcgatc ccctgcgagc gctgctgctc
1501 ctgaaggcgc tgcaggcct gcgctggag tggcgcgggc gggatccgcg cgggcccggg
1561 cgggcacagc gcagcgcggg ggccaccgcc gccgacgggc cgtgcgctg gcgagctc
1621 agcgtagacc tcccgccga gcgctccgta ctcatcccc agacctacca ggccaacaat
1681 tgccaggggc tgtgcgctg gcctcagtc gaccgcaacc cgcgctacgg caaccagtg
1741 gtgctgctgc tgaagatgca ggcccgtgg gccgcctgg cgcgcccacc ctgctgctg
1801 cccaccgct acgcgggcaa gctgctcatc agcctgtcgg aggagcgcac cagcgcgac
1861 cacgtgccc acatggtgg caccgagtg ggtgcccgt gaccctgcg ccgcgcgac
1921 tctgccccg agggctccga cgcgcccag ctgcgcccc tccccatatt tattcgacc
1981 ccaagcatcg cccaataaa gaccagcaag caaccggcaa aaaaaaaaa aaaaaaaaa
2041 aaaaaaaaa aaaaaaaaa aaaaa

```

**SEQ ID NO: 16: amino acid sequence of human MIS protein**

```

MRDLPLTSLALVLSALGALLGTEALRAEPAVGTSGLIIFREDLD
WPPGSPQEPLCLVALGGDSNGSSSPLRVVVALSAYEQAFILGAVQRRARWGPRLATFGV
CNTGDRQAALPSLRRLGAWLRDPGGQRLVVLHLEEVTWEP TSLRFQEP PP GGAGPPE
LALLVLYPGPGPEVTVTRAGLPGAQSLCPSRDTRYLVLA VDRPAGAWRGSLALTLQP
RGEDSRLSTARLQALLFGDDHRCFTTRMTPALLLLRSEPA PLPAHQLDTPFP PPRP
SAELESPPSADPFLETLTRLVRLRVPPPARASAPRLALDP DALAGFPQGLVNLSDPA
ALERLLDGEELLLLLLRPTAATTGDPAPLHDPT SAPWATALARRVAE LQAAAAELRS
LPGLPPATAPLLARLLALCPGGPGGLDPLRALLLLKALQGLR VEWGRDPRGPGRAQ
RSAGATAADGPCALRELSVDLRAERSVLIPETYQANNCQGV CGWPQSDRNPRYGNHVV
LLLKMQARGAALARPPCCVPTAYAGKLLISLSEERISAHHV PNMVATECGCR

```

**SEQ ID NO: 17: nucleic acid sequence of human MIS Receptor II (MISR II)**

```

1 atctgaagaa agatttggcc aggggcagct gtgctggctt atgctcttct ccttctgctg
61 ctgccatcct ccagcaagat gctagggctt ttggggcttt gggcattact tcccacagct
121 gtggaagcac ccccaaacag gcgaacctgt gtgttctttg aggcccttgg agtgcgggga
181 agcaciaaaga cactgggaga gctgctagat acaggcacag agtccccag agctatccgc
241 tgccctctaca gccgctgctg ctttgggatc tggaacctga cccaagaccg ggcacaggtg
301 gaaatgcaag gatgccgaga cagtgatgag ccaggctgtg agtccctcca ctgtgacca
361 agtccccgag cccaccccag ccctggctcc actctcttca cctgctcctg tggcactgac
421 ttctgcaatg ccaattacag coactgctc cctccaggga gccctgggac tcttggctcc
481 caggggtccc aggtgcccc aggtgagtcc atctggatgg cactggtgct gctggggctg
541 ttctcctccc tcttctgctg gctgggcagc atcatcttgg ccctgctaca gcgaaagaac
601 tacagagtg gaggtgagcc agtgccagag ccaaggccag actcaggcag ggactggagt
661 gtggagctgc aggagctgcc tgagctgtgt ttctcccagg taatccggga aggaggtcat

```

```

721 gcagtggttt gggccgggca gctgcaagga aaactggttg ccatcaagge cttcccaccg
781 aggtctgtgg ctcagttcca agctgagaga gcattgtacg aacttccagg cctacagcac
841 gaccacattg tccgatttat cactgccagc cggggggggtc ctggccgcct gctctctggg
901 cccctgctgg tactggaact gcatcccaag ggctccctgt gccactactt gaccagtac
961 accagtgact ggggaagttc cctgcggatg gcaactgtccc tggcccaggg cctggcattt
1021 ctccatgagg agcgctggca gaatggccaa tataaaccag gtattgccc aagagatctg
1081 agcagccaga atgtgtcat tcgggaagat ggatcgtgtg ccattggaga cctgggcctt
1141 gccttgggtg tccctggcct cactcagccc cctgctgga cccctactca accacaaggc
1201 ccagctgcca tcatggaagc tggcaccag aggtacatgg caccagagct cttggacaag
1261 actctggacc tacaggattg gggcatggcc ctccgacgag ctgatattta ctctttggct
1321 ctgctcctgt gggagatact gagccgctgc ccagatttga ggctgacag cagtccacca
1381 cccttccaac tggcctatga ggcagaactg ggcaataacc ctacctga tgagctatgg
1441 gccttggcag tgcaggagag gaggcgtccc tacatcccat ccacctggcg ctgctttgcc
1501 acagaccctg atgggctgag ggagctccta gaagactgtt gggatgcaga cccagaagca
1561 cggctgacag ctgagtgtgt acagcagcgc ctggctgctt tggcccattc tcaagagagc
1621 caccctttc cagagagctg tccacgtggc tgcccacctc tctgcccaga agactgtact
1681 tcaattcctg cccctaccat cctcccctgt aggcctcagc ggagtgcctg ccacttcagc
1741 gttcagcaag gcccttgttc caggaatcct cagcctgctt gtaccctttc tctgtgtaa
1801 atatgcagtt tatgtgtcat caatgtacat gccaacataa atatggcgat tgtat
    
```

**SEQ ID NO: 18:** amino acid sequence of human MIS Receptor II (MISRII)

```

MLGSLGLWALLPTAVEAPPNRRTCVFFFEAPGVRGSTKTLGELLD
TGTELPRAIRCLYSRCCFGIWNLTQDRAQVEMQGCRRDSDEPGCESLHCDSPRAHPSP
GSTLFTCSCGTDFCNANYSHLPPPGSPGTPGSQGPQAAPGESIWMALVLLGLFLLLLLL
LLGSIILALLQRKNYRVRGEPVPEPRPDSGRDWSVELQELPELFCFSQVIREGGHAVVW
AGQLQGLVAIKAFPPRSVAQFQAERALYELPGLQHDHIVRFITASRGGPGRLLSGPL
LVLELHPKGLSLCHYLTYTSDWGSLSLRLMALSQAQGLAFLHEERWQNGQYKPGIAHRDL
SSQNVLIREDGSCAIGDLGLALVLPGLTQPPAWTPTQPPQGPAAIMEAGTQRYMAPELL
DKTLDLQDWGMALRRADIYSLALLLWEILSRCPDLRPDSSPPPFQLAYEAEIENPTPS
DELWALAVQERRRPIYIPSTWRCFATDPDGLRELLEDWCWDADPEARLTAECVQORLAAL
AHPQESHFPFESCPRGCPPLCPEDCTSIPAPTILPCRPQRSACHFSVQQGPCSRNPQP
ACTLSPV
    
```

**SEQ ID NO: 19:** nucleic acid sequence for human BCRP1

```

1 gtcagcgtg cctgagctcg tcccctggat gtccgggtct ccccaggcgg ccaccgcgg
61 gctcccatcg tgacctccag ccgcagcgc tcccacgcc gcccgcgcg gaggggagcg
121 ctcgggcgcg ccgggtgtgg ttgggggaa gggttgtgcc gcgcggggc tgcgtgctgt
181 gccactcaa aaggttccgg gcgcgcagga gggaagaggc agtgcccgc actcccactg
241 agattgagag acgcggcaag gaggcagcct gtggaggaac tgggtaggat ttaggaacgc
301 accgtgcaca tgcttgggtg tcttgttaag tggaaactgc tgctttagag tttgtttggg
361 aggtccgggt gactcatccc aacatttaca tccttaattg ttaaagcgt gcctccgagc
421 gcacgcaccc tgagatcctg agcctttggt taagaccgag ctctattaag ctgaaaagat
481 aaaaactctc cagatgtctt ccagtaatgt cgaagtttt atcccagtgt cacaaggaaa
541 caccaatggc ttccccgcga cagcttccaa tgacctgaag gcatttactg aaggagctgt
601 gttaagtttt cataacatct gctatcgagt aaaactgaag agtggtttc taccttgtcg
661 aaaaccagtt gagaaagaaa tattatcgaa tatcaatgg atcatgaaac ctggtctcaa
721 cgccatcctg ggaccacag gtggaggcaa atcttcgtta ttagatgtct tagctgcaag
781 gaaagatcca agtggattat ctggagatgt tctgataaat ggagaccgc gacctgcaa
841 tttcaaatgt aattcaggtt acgtggtaca agatgatgtt gtgatgggca ctctgacggt
901 gagagaaaac ttacagttct cagcagctct tcggcttga acaactatga cgaatcatga
961 aaaaaacgaa cggattaaca gggtcattca agagttaggt ctggataaag tggcagactc
1021 caaggttgga actcagttta tccgtggtgt gtctggagga gaaagaaaa ggactagtat
1081 aggaatggag cttatcactg atccttccat cttgttcttg gatgagccta caactggctt
1141 agactcaagc acagcaaatg ctgtcctttt gtcctgaaa aggatgtcta agcagggagc
1201 aacaatcatc ttctccattc atcagcctcg atattccatc ttcaagttgt ttgatagcct
1261 caccttattg gcctcaggaa gacttatgtt ccacgggctt gctcaggagg ccttgggata
1321 ctttgaatca gctggttatc actgtgaggc ctataataac cctgcagact tcttcttggg
1381 catcattaat ggagattcca ctgctgtggc attaaacaga gaagaagact ttaaagccac
    
```

1441 agagatcata gagccttcca agcaggataa gccactcata gaaaaattag cggagattta  
 1501 tgtcaactcc tccttctaca aagagacaaa agctgaatta catcaacttt cggggggtga  
 1561 gaagaagaag aagatcacag tcttcaagga gatcagctac accacctcct tctgtcatca  
 1621 actcagatgg gtttccaagc gttcattcaa aaacttgctg ggtaatcccc aggcctctat  
 1681 agctcagatc attgtcacag tctgactggg actggttata ggtgccattt actttgggct  
 1741 aaaaaatgat tctactggaa tccagaacag agctgggggt ctcttcttcc tgacgaccaa  
 1801 ccagtgtttc agcagtgttt cagccgtgga actccttctg gttagagaaga agctcttcat  
 1861 acatgaatac atcagcggat actacagagt gtcatcttat ttccttggaa aactgttatc  
 1921 tgatttatta cccatgagga tgttaccaag tattatattt acctgtatag tgtacttcat  
 1981 gttaggattg aagccaaagg cagatgcctt cttcgttatg atgtttacc ttatgatggt  
 2041 ggcttattca gccagttcca tggcactggc catagcagca ggtcagagtg tggtttctgt  
 2101 agcaacactt ctcatgacca tctgttttgt gtttatgatg atttttcag gtccttgggt  
 2161 caatctcaca accattgcat cttggctgtc atggcttcag tacttcagca tccacagata  
 2221 tggatttacg gctttgcagc ataatgaatt tttgggacaa aacttctgcc caggactcaa  
 2281 tgcaacagga aacaatcctt gtaactatgc aacatgtact ggcgagaat atttgtaaa  
 2341 gcagggcatc gatctctcac cctggggcct gtggaagaat cacgtggcct tggcttgtat  
 2401 gattgttatt ttcctcacia ttgcctacct gaaattgtta tttcttaaaa aatattctta  
 2461 aatttcccct taattcagta tgatttatcc tcacataaaa aagaagcact ttgattgaag  
 2521 tattcaatca agtttttttg ttgttttctg ttcccttgcc atcacactgt tgcacagcag  
 2581 caattgtttt aaagagatac atttttagaa atcacaacaa actgaattaa acatgaaaga  
 2641 acccaagaca tcatgtatcg catattagtt aatctcctca gacagtaacc atggggaaga  
 2701 aatctggctc aatttattaa tctaaaaaag gagaattgaa ttctggaaac tctgacaag  
 2761 ttattactgt ctctggcatt tgtttctca tctttaaatt gaataggtag gttagtagcc  
 2821 cttcagtcct aatactttat gatgctatgg tttgccatta ttaataaat gacaaatgta  
 2881 ttaatgctat actggaaaatg taaaattgaa aatatgttgg aaaaaagatt ctgtcttata  
 2941 gggtaaaaaa agccaccgtg atagaaaaaa aatctttttg ataagcacat taaagttaat  
 3001 agaacttact gatattcctg tctagtggta taatatctca ggaatcttgg ctgagggttt  
 3061 ggaactgtgg gtagagtaga gggccaggag tccagtaata gaattcttgc accatttctg  
 3121 gaacattcta gctctgggag gtcacgtaac cttcttgggg tagttcagtg gtttagtgggt  
 3181 ttataatcca ggtgtgcgtc agaatcatct gaggaacttt gctaaaaatc aaaaatctgg  
 3241 cctaagtagc tccagatcta ccttcataaa ggaatctgac cactcctgga tttggtaatt  
 3301 tccaagttct gaaaatttta cttaggattt aataactatt aacatctgtc cctacatagg  
 3361 ttttcttcc tacttatata ccttatgttc tcttcattct aaccttcac agtaataggg  
 3421 aaatgtttta attttatttt tttagttgaa gggtaatgta ccaaaaaata tagttcagtg  
 3481 aattaaaatg aacacacatg tgcaaccatc aattcaggtc aagaaataga agattgtagc  
 3541 acacaaaagc ctactcagcc attctcccag tcaactctc ctccctacc cctgggttat  
 3601 ttttgaaatg aacttggatg tatttccctc tgttgctgtt atgagaacat tgctacagcc  
 3661 aagtgttggtg tttctgtgtg catagttgta tacttaatta tctccccact ttttaataaa  
 3721 cttttaattt ggaaataatt ttagattgac agaaaagtg caaagatagt gaggaaagtt  
 3781 cctgtctact ctttgctcag cttcccttaa tgtaacatt ttatatagca agatgcattt  
 3841 gtcaaagcta acaagttaac attggtacaa tcaactgtta ttaaactgca cacaatattc  
 3901 agatttcacc acttttccac taatattctt tcattgttct aggattcaat tcaggagacc  
 3961 acatttcac tagccctctt ttttaaaagt aaatacttt cagcacttac aggagttaac  
 4021 tgagctgggg catcatggtg tatagacgcc ctgacactgg tcatcttggga attcatttag  
 4081 tttgtcagtg ggtgccctga cattctgtca caacatcaat ttgggaacat ggcattatata  
 4141 ttttatcttt gaactttttt ctttttggat gacatttgat taatgctca tcttgggaaca  
 4201 cattatcttt tttcttgggt atgtgatcag gaagattaat cagtttttcc gttcttgggt  
 4261 ataattcctg cttttcacat acctgtccct tacagttctc tatatatacc cttcccttat  
 4321 tacacagaga gaaatatcta tctatacttt ttacacaaaa tatacttcaa aagaacaaaa  
 4381 acagccacaa ttattaactt tttaaataaa tgagaattta attatatcct aaaaaaaaaa  
 4441 aaaaa

**SEQ ID NO: 20:** Amino acid sequence for BCRP1 (Accession No: NP\_004818)

MSSSNVEVFIPVSGQNTNGFPATASNDLKAFTEGAVLSFHNICY  
 RVKLLKSGFLPCRKPVEKEILSNINGIMKPLNAILGPTGGGKSSLLDVLAAARKDPSGL  
 SGDVLINGAPRPFANFKNSGYVVQDDVVMGTLTVRENLFQSAALRLATTMTNHEKNER  
 INRVIQELGLDKVADSKVGTQFIRGVSGGERKRTSIGMELITDPSILFLDEPTGLDS  
 STANAVLLLLKRMSKQGRITIFS IHQPRYSIFKLFDSLTLASGRIMFHGPAQEALGY  
 FESAGYHCEAYNNPADFFLDIINGDSTAVALNREEDFKATEIIEPSKQDKPLIEKLAE

IYVNSSFYKETKAELHQLSGGEKKKKITVFKEISYTTSFCHQLRWVSKRSFKNLLGNP  
QASIAQIIIVTVVLGLVIGAIYFGLKNDSTGIQNRAGVLFFLTNQCFSVSAVELFVV  
EKKLFIEHEYISGYRVSSYFLGKLLSDLLPMRMLPSIIFTCIVYFMLGLKPKADAFFV  
MMFTLMMVAYSASSMALAIAAGQSVVSVATLLMTICFVFMIFSGLLVNLTTIASWLS  
WLQYFSIPRYGFTALQHNEFLGQNFPCPLNATGNNPCNYATCTGEEYLVKQGIDLSPW  
GLWKNHVALACMIVIFLTIAYLKLLFLKKYS

## CLAIMS:

1. A method for enriching for a population of ovarian cancer stem cells, the method comprising contacting a population comprising ovarian cells with agents reactive for BCRP1 and separating cells positive for the agent reactive for BCRP1 from cells non-reactive to agents for BCRP1.
2. A method for enriching for a population of ovarian cancer stem cells, the method comprising contacting a population comprising ovarian cells with a lipophilic molecule and separating cells that do not incorporate the lipophilic molecule from the cells which do incorporate the lipophilic molecule, wherein the cells that do not incorporate the lipophilic molecule are ovarian cancer stem cells.
3. A method of claim 1, further comprising the method of claim 2.
4. The method of claims 1 or 2, wherein separation is done using florescence cell sorting (FACS); fluometry, flow cytometry, microscopy techniques.
5. The method of claims 1 or 2, wherein the population of ovarian cells is in a biological sample.
6. The method of claims 1 or 2, wherein the biological sample is a tissue sample.
7. The method of claim 5, wherein the tissue sample is a cancer cell or a tumor cell.
8. The method of claim 6, wherein the tissue sample is a biopsy tissue sample.
9. The method of claims 1 or 2, wherein the ovarian cells are ovarian cancer cells.
10. The method of claim 8, wherein the ovarian cancer cells are selected from the group comprising ovarian cancer cells, ovarian cancer cells, vulvar epidermal carcinoma cells, cervical carcinoma cells, endometrial adenocarcinoma cells and ovarian adenocarcinoma cells.
11. The method of claim 5, wherein the tissue sample is obtained from a subject.
12. The method of claim 10, wherein the subject is a mammal.
13. The method of claim 11, wherein the subject is a human.

14. The method of claims 1 or 2, wherein the population of ovarian cells is a population of primary ascite cells.
15. The method of claims 1 or 2, wherein the population of ovarian cells is a population of ovarian cancer cell line cells.
16. The method of claim 14, wherein the ovarian cancer cell line is a human ovarian cancer cell line.
17. The method of claim 15, wherein the human ovarian cancer line is selected from IGROV-1, SK-OV3, OVCAR-3.
18. The method of claim 14, wherein the ovarian cancer cell line is a rodent ovarian cancer cell line.
19. The method of claim 17, wherein the rodent ovarian cancer line is selected from MOVCAR7 or 4306 cells.
20. The method of claim 2, wherein the lipophilic molecule is Hoechst 33342.
21. The method of claim 1, wherein the agent is a nucleic acid agent, protein or fragment thereof.
22. The method of claim 20, wherein the agent is a labeled with a detectable marker.
23. The method of claim 20, wherein the protein is an antibody or antibody fragment.
24. The method of claim 22, wherein the antibody is anti-BCRP1 antibody.
25. The method of claim 1 or 2, wherein the ovarian cancer stem cell is further characterized to be have multi-drug resistance sensitivity.
26. The method of claim 25, wherein the multi-drug resistance sensitivity is sensitivity to a BCRP1 inhibitor.
27. The method of claim 26, wherein the BCRP1 inhibitor is a nucleic acid, small molecule, protein, aptamer, or nucleic acid analogue or fragments thereof.
28. The method of claim 26, wherein the BCRP1 inhibitor is verapamil

29. A method to identify a population of ovarian cancer stem cells in a biological sample, comprising measuring the biological sample for at least one of: (i) BCRP1 expression, or (ii) ability to efflux a lipophilic dye, wherein the biological sample comprises ovarian cells and wherein positively for at least one of (i) and/or (ii) in the biological sample identifies a population of ovarian cancer stem cells.
30. The method of claim 29, further comprising measuring the biological sample for multi-drug resistance, wherein the biological sample comprises ovarian cells if the biological sample does not have multi-drug resistance.
31. The method of claim 29, wherein the ovarian cells are ovarian cancer cells.
32. The method of claim 29, further comprising selecting for the cell positive for at least one of (i), (ii) or (iii).
33. The method of claim 29, wherein the multi-drug resistance sensitivity is sensitivity to a BCRP1 inhibitor.
34. The method of claim 29, wherein the BCRP1 inhibitor is a nucleic acid, small molecule, protein, aptamer, or nucleic acid analogue or fragments thereof.
35. The method of claim 29, wherein the BCRP1 inhibitor is verapamil
36. The method of claim 29, wherein the lipophilic dye is Hoechst 33342.
37. The method of claim 29, wherein the biological sample is a tissue sample.
38. A method for preventing and/or treating ovarian cancer in a subject, comprising:
  - (a) selecting a subject having ovarian cancer from a population of subjects having ovarian cancer, wherein the subject selected has ovarian cancer comprising ovarian cancer stem cells, and wherein the presence of ovarian cancer stem cells is identified in the subject according to claims 1, 2 or 29, and

- (b) administering to the subject selected in step (i) an effective amount of MIS or a homologue or variant or derivative thereof and/or a effective amount of an agent that inhibits BCRP1 or a homologue or variant or derivative thereof.
39. A method for treating a subject with ovarian cancer the method comprising:
- (a) identifying the presence of ovarian cancer stem cells in a biological sample obtained from the subject according to claims 1, 2 or 29; and
- (b) administering to the subject an effective amount of MIS or a homologue or variant or derivative thereof.
40. A method for treating a subject with ovarian cancer the method comprising:
- (a) identifying the presence of ovarian cancer stem cells in a biological sample obtained from the subject according to claims 1, 2 or 29; and
- (b) administering to the subject an effective amount of an agent that inhibits BCRP1 or a homologue or variant or derivative thereof.
41. The method of claim 39, further comprising the method of claim 40.
42. The method of claims 39 or 40, further comprising administering to the subject one or more additional therapies.
43. The method of claim 42, wherein the additional therapies are selected from the group consisting of chemotherapy, radiotherapy, thermotherapy, immunotherapy, hormone therapy, laser therapy and surgery.
44. The method of claim 43, wherein chemotherapy is an agent that inhibits BCRP1.
45. The method of claims 40 or 44, wherein the agent that inhibits BCRP1 is a nucleic acid, small molecule, protein, aptamer, or nucleic acid analogue or fragments thereof.

46. The method of claim 45, wherein the BCRP1 inhibitor is verapamil or a functional derivative, analogue or variant thereof.
47. The method of claim 43, wherein chemotherapy is selected from paclitaxel, cisplatin, doxorubicin.
48. The method of claim 39, wherein the MIS is a functional derivative, analogue or variant thereof.
49. The method of claim 48, wherein a functional derivative of MIS is a pyrazoloanthrone or derivative or analogue thereof.
50. The method of claim 39, wherein the MIS is recombinant human MIS.
51. The method of claim 39, wherein administration of MIS is administered more than once.
52. The method of claim 50, wherein MIS or derivative thereof is administered before, after or at the same time as the additional therapy.
53. The method of claim 39, wherein the MIS further comprises a targeting moiety.
54. The method of claims 39 or 40, wherein administering is intravenous, intradermal, intramuscular, intraarterial, intralesional, percutaneous, subcutaneous, intratumoral, or by aerosol.
55. The method of claims 39 or 40, wherein administration is prophylactic administration.
56. The method of claims 39 or 40, wherein administration is therapeutic administration.
57. The method of claims 39 or 40, wherein the subject is a mammal.
58. The method of claim 57, wherein the mammal is a human.
59. The method of claims 39 or 40, wherein the subject has undergone one or more cancer therapies selected from a group consisting of surgery, chemotherapy, radiotherapy, thermotherapy, immunotherapy, hormone therapy and laser therapy.
60. The method of claim 39, wherein the effective amount of MIS is an effective amount of a pharmaceutical composition comprising MIS or a variant or derivative thereof.

61. The method of claim 40, wherein the effective amount of an agent that inhibits BCRP1 is an effective amount of a pharmaceutical composition comprising an inhibitor of BCRP1.
62. The method of claims 60 or 61, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
63. The method of claim 61, wherein the pharmaceutical composition further comprises a chemotherapeutic agent or an inhibitor of BCRP1.
64. The method of claims 39 or 40, wherein the ovarian cancer is recurrent ovarian cancer.
65. A method to determine if a subject is at risk of having a recurrent ovarian cancer, the method comprising assessing the presence of ovarian cancer stem cells according to claim 6, wherein if the biological sample is identified to comprise ovarian cancer stem cells, the subject is at risk of having a metastasis or recurrent ovarian cancer.
66. A method for enriching for a population of somatic ovarian stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to cytokeratin-8,  $\beta$ -catenin and E-cadherin and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are likely to be somatic ovarian stem cells.
67. The method of claim 66, further comprising contacting a population of cells comprising ovarian cells with agents reactive to EpCam and separating reactive positive cells from non-reactive cells, wherein the non-reactive cells are somatic ovarian stem cells.
68. The method of claim 66, further comprising contacting a population of cells comprising ovarian cells with agents reactive to EpCam and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are ovarian cancer stem cells.
69. The methods of claims 66 or 67, wherein the somatic ovarian stem cells are somatic coelomic ovarian stem cells.
70. A method for enriching for a population of somatic ovarian stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to

cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD44, CD105 and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are likely to be somatic ovarian stem cells.


71. The method of claim 70, further comprising contacting a population of cells comprising ovarian cells with agents reactive to CD45 or CD 31 and separating reactive positive cells from non-reactive cells, wherein the non-reactive cells are somatic stem cells.
72. The methods of claims 70 or 71, wherein the somatic ovarian stem cells are somatic subcoelomic or stromal ovarian stem cells.
73. A method for enriching for a population of somatic ovarian stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to cKIT, SF-1, GATA-4, CD44, CD105 and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are likely to be somatic ovarian stem cells.
74. The method of claim 73, further comprising contacting a population of cells comprising ovarian cells with agents reactive to CD45 or CD 31 or  $\alpha$ SMA and separating reactive positive cells from non-reactive cells, wherein the non-reactive cells are somatic stem cells.
75. The methods of claims 73 or 74, wherein the somatic ovarian stem cells are somatic periphilar medullary ovarian stem cells.
76. A method for enriching for a population of ovarian cancer stem cells, the method comprising contacting a population of cells comprising ovarian cells with agents reactive to EpCam, cytokeratin-8,  $\beta$ -catenin and E-cadherin and separating reactive positive cells from non-reactive cells, wherein the reactive positive cells are likely to be ovarian cancer stem cells.
77. A method to identify agents that reduce the self-renewal capacity of an ovarian cancer stem cell, comprising contacting an ovarian cancer stem cell as identified according to claims 1 to 3, with an agent, and measuring the proliferation of the ovarian cancer cell, whereby an agent that decreases the proliferation as compared to a reference agent or absence of an agent identifies an agent that inhibits the self-renewal capacity of the ovarian cancer stem cell.

78. The method of claim 66, further comprising contacting a somatic ovarian stem cell with an agent, and measuring the proliferation of the somatic ovarian cell, and comparing the rate of proliferation of the somatic ovarian stem cell in the presence of the agent with the rate of proliferation of an ovarian cancer stem cell in the presence of the same agent, whereby if the agent decreases the rate of proliferation of the ovarian cancer stem cells as compared to the rate of proliferation of somatic ovarian stem cells identifies the agent inhibits the self-renewal capacity of the ovarian cancer stem cell.
79. A method for identifying agents which kill or decrease the rate of proliferation of ovarian cancer stem cells, the method comprising:
- (a) culturing a population of ovarian cancer stem cells as identified according to claims 1 to 3 or claim 76 ;
  - (b) culturing a population of somatic ovarian stem cells as identified according to claims 66 to 75;
  - (c) adding to the media of the population of ovarian cancer stem cells one or more agents and adding to the media of the population of somatic ovarian stem cells one or more of the same agents;
  - (d) measuring the rate of proliferation of the population of ovarian cancer stem cells and measuring the rate of proliferation of the population of somatic ovarian stem cells;
  - (e) comparing the rate of proliferation of the population of ovarian cancer stem cells with rate of proliferation of the population of somatic ovarian stem cells,
- wherein an agent which decreases the rate of proliferation of the ovarian cancer stem cells as compared to the rate of proliferation of somatic ovarian stem cells identifies an agent that kills or decreases the rate of proliferation of an ovarian cancer stem cell.


80. The method of claim 79, wherein the population of somatic ovarian stem cell is a coelomic ovarian stem cell population.
81. The method of claims 77 or 79, wherein the agent is a nucleic acid, nucleic acid analogue, small molecule, protein, peptiomimetic, antibody, peptide, aptamer, ribozyme, and variants and fragments thereof.
82. The method of claims 66 or 68, wherein the proliferation assay is the methythiazoletetrazolium (MTT) proliferation assay.
83. The method of claims 66 or 68, wherein the proliferation assay is the colony forming unit (CFU) assay.
84. A method of treating a subject affected with cancer, the method comprising assessing the presence of ovarian cancer stem cells in a biological sample obtained from the subject, wherein a clinician reviews the results and if the results indicate the presence of ovarian cancer stem cells in the biological sample, the clinician directs the subject to be treated with an effective amount of a pharmaceutical composition comprising MIS or a homologue or variant or derivative thereof, and/or an BCRP1 inhibitor.
85. The method of claim 84, wherein the biological sample is a tissue sample.
86. The method of claim 85, wherein the tissue sample is a cancer cell or a tumor cell.
87. The method of claim 85, wherein the tissue sample is a biopsy tissue sample.
88. The method of claim 84, wherein the tissue sample comprises ovarian cancer cells, vulvar epidermal carcinoma cells, cervical carcinoma cells, endometrial adenocarcinoma cells and ovarian adenocarcinoma cells.
89. The method of claim 84, wherein the tissue sample comprises ascite cells.
90. The method of claims 66, 67, 68, 70, 71, 73, 74 and 76, wherein the agent is a nucleic acid or a protein or a fragment thereof.

91. The method of claim 90, wherein the agent is reactive to the expression product of the nucleic acids encoded by genes cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4.
92. The method of claims 66, 67, 68, 70, 71, 73, 74 and 76, wherein the agent is reactive to a nucleic acid encoding the genes selected from the group consisting of: cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4.
93. The method of claim 90, wherein the nucleic acid is selected from the group consisting of RNA, messenger RNA, or genomic DNA.
94. The method of claim 90, wherein the protein is an antibody or antibody fragment thereof.
95. The method of claim 90, wherein the agent is a small molecule or aptamer or antibody fragment thereof.
96. A kit to identify and/or enrich for a population of ovarian cancer stem cells in a biological sample, the kit comprising agents reactive to EpCam, cytokeratin-8,  $\beta$ -catenin and E-cadherin.
97. The kit of claim 96, further comprising an agent reactive to BCRP1 and/or MIS.
98. A kit to identify and/or enrich for a population of somatic coelomic ovarian stem cells in a biological sample, the kit comprising agents reactive to EpCam, cytokeratin-8,  $\beta$ -catenin and E-cadherin.
99. A kit to identify and/or enrich for a population of somatic subcoelomic/stromal ovarian stem cells in a biological sample, the kit comprising agents reactive to cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD44, CD105.
100. The kit of claim 99, further comprising an agent reactive to CD45 and/or an agent reactive to CD31.


101. A kit to identify and/or enrich for a population of somatic periphilar medullary ovarian stem cells in a biological sample, the kit comprising agents reactive to cKIT, SF-1, GATA-4, CD44, CD105.
102. The kit of claim 101, further comprising an agent reactive to CD 45 and/or CD31 and/or  $\alpha$ SMA.
103. A kit to identify and/or enrich for a population of identifying ovarian stem cells in a biological sample, the kit comprising at least 3 agents reactive to cytokeratin-8,  $\beta$ -catenin and E-cadherin, EpCam, cKIT,  $\alpha$ SMA, PDGFRb, NG2, CD31, CD44, CD105, SF-1 or GATA-4, MIS or BCRP1.
104. The kits of claims 96, 97, 98, 99, 100, 101, 102 or 103, wherein the agent is a nucleic acid or a protein or a fragment thereof.
105. The kit of claim 104, wherein the protein is an antibody, anitmer or fragment thereof.
106. The kits of claims 96, 97, 98, 99, 100, 101, 102 or 103, wherein the kit is an ELISA.
107. The kits of claim 96, 97, 98, 99, 100, 101, 102 or 103, wherein the kit is protein chip.
108. The kits of claim 96, 97, 98, 99, 100, 101, 102 or 103, wherein the kit is a microarray chip or nucleic acid binding chip.
109. The kits of claim 96, 97, 98, 99, 100, 101, 102 or 103, wherein the kits are used for isolation of the ovarian stem cell of interest.




**FIG. 1B**




**FIG. 1D**




**FIG. 1A**




**FIG. 1C**




**FIG. 1F**




**FIG. 1H**



**FIG. 1E**



**FIG. 1G**




NSP

**FIG. 2B**



NSP

**FIG. 2D**




SP

**FIG. 2A**




SP


**FIG. 2C**




**FIG. 2G**




**FIG. 2J**




**FIG. 2F**



**FIG. 2I**




**FIG. 2E**




**FIG. 2H**


5/38




**FIG. 3B**




**FIG. 3A**




**FIG. 3C**




**FIG. 3D**




**FIG. 3E**




**FIG. 3F**




**FIG. 4A**




**FIG. 4B**




**FIG. 4D**




**FIG. 4F**




**FIG. 4C**




**FIG. 4E**




**FIG. 5B**



**FIG. 5A**




**FIG. 5D**




**FIG. 5C**


10/38




**FIG. 5G**




**FIG. 5F**




**FIG. 5E**




**FIG. 6D**




**FIG. 6C**




**FIG. 6B**




**FIG. 6A**




**FIG. 6H**




**FIG. 6G**




**FIG. 6F**




**FIG. 6E**





**FIG. 7B**



**FIG. 7A**









**FIG. 9B**




**FIG. 9A**




**FIG. 9D**



**FIG. 9C**



**FIG. 10B**



**FIG. 10A**




FIG. 10C







FIG. 10D







**FIG. 11B**




**FIG. 11C**




**FIG. 11D**




**FIG. 11F**




**FIG. 11H**




**FIG. 11E**




**FIG. 11G**




**FIG. 111**




**FIG. 12A** **FIG. 12B**




**FIG. 12E**




**FIG. 12D**




**FIG. 12C**




**FIG. 12H**




**FIG. 12G**




**FIG. 12F**




**FIG. 13B**




**FIG. 13A**




**FIG. 14A**




**FIG. 14B**




**FIG. 14C**




**FIG. 14D**




**FIG. 15B**




**FIG. 15A**




**FIG. 15D**




**FIG. 15C**




**FIG. 16B**



**FIG. 16A**



**FIG. 17C**



**FIG. 17B**



**FIG. 17A**




FIG. 17F




FIG. 17I




FIG. 17E




FIG. 17H




FIG. 17D







FIG. 17G




**FIG. 18B**




**FIG. 18A**



**FIG. 18D**



**FIG. 18C**



*FIG. 19*



**FIG. 20**